

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2004, 09:16:10 ; Search time 1464 Seconds
(without alignments)
2664.531 Million cell updates/sec

Title: US-09-806-701-15_COPY_991_1080

Perfect score: 90

Sequence: 1 gaacggatgctctgca.....gaacgtggaacactagag 90

Scoring table: IDENTITY_NUC

Gapop 10_0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

1: gb_ba.*

2: gb_hgt.*

3: gb_in.*

4: gb_om.*

5: gb_ov.*

6: gb_pat.*

7: gb_ph.*

8: gb_pl.*

9: gb_pr.*

10: gb_ro.*

11: gb_sts.*

12: gb_sy.*

13: gb_un.*

14: gb_vi.*

15: em_ba.*

16: em_fun.*

17: em_hum.*

18: em_in.*

19: em_mu.*

20: em_om.*

21: em_or.*

22: em_ov.*

23: em_pat.*

24: em_ph.*

25: em_pl.*

26: em_ro.*

27: em_sts.*

28: em_un.*

29: em_vi.*

30: em_htg_hum.*

31: em_htg_inv.*

32: em_htg_other.*

33: em_htg_mus.*

34: em_htg_pln.*

35: em_htg_rod.*

36: em_htg_mam.*

37: em_htg_vrt.*

38: em_sy.*

39: em_htgo_hum.*

40: em_htgo_mus.*

41: em_htgo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	90	100.0	771	6	AX053659	Sequence
2	90	100.0	1055	6	AR099307	Sequence
3	90	100.0	1659	6	AX024046	Sequence
4	90	100.0	2268	6	AR067807	Sequence
5	90	100.0	2268	6	AR084022	Sequence
6	90	100.0	2268	6	AR153351	Sequence
7	90	100.0	2268	6	AR153423	Sequence
8	90	100.0	2268	6	AR153426	Sequence
9	90	100.0	2268	6	AR253906	Sequence
10	90	100.0	2268	6	AR318491	Sequence
11	90	100.0	2268	6	BD062396	Sequence
12	90	100.0	2268	6	BD062399	Sequence
13	90	100.0	2268	6	AF029684	Sequence
14	90	100.0	2271	6	AR162236	Sequence
15	90	100.0	2271	6	AR342527	Sequence
16	90	100.0	2271	6	BD009912	Sequence
17	90	100.0	2271	6	AF031416	Sequence
18	90	100.0	2783	9	AK091297	Sequence
19	90	100.0	2818	6	AX880268	Sequence
20	90	100.0	2818	6	BD158288	Sequence
21	90	100.0	2818	9	AK023193	Sequence
22	90	100.0	2931	6	AR156758	Sequence
23	90	100.0	2931	6	BD082222	Sequence
24	90	100.0	3018	6	AX024044	Sequence
25	90	100.0	3024	6	AX024040	Sequence
26	90	100.0	3058	9	AF080158	Sequence
27	90	100.0	3785	9	HSM808312	Sequence
28	90	100.0	3966	6	AK099305	Sequence
29	86	95.6	2404	9	AK097828	Sequence
30	86	95.6	163298	9	AK107885	Sequence
31	86	95.6	186433	2	AF271407	Sequence
32	86	95.6	186573	9	AC083973	Sequence
33	77.2	85.8	3038	10	AF115282	Sequence
34	74	82.2	2274	10	AF026524	Sequence
35	74	82.2	3572	10	BC037723	Sequence
36	74	82.2	4039	10	AF088910	Sequence
37	73.2	81.3	274786	2	AC109661	Sequence
38	70	77.8	225065	10	AC121835	Sequence
39	68.2	75.8	3490	4	BTM414556	Sequence
40	36.2	40.2	3442	4	BTM414555	Sequence
41	35.6	39.6	1874	6	AR258658	Sequence
42	35.6	39.6	2025	6	AR102061	Sequence
43	35.6	39.6	2056	10	BC018243	Sequence
44	35.6	39.6	3314	6	AR258657	Sequence
45	35.6	39.6	3466	6	AX306151	Sequence

ALIGNMENTS

RESULT 1	AX053659	Sequence	425 from Patent WO0073801.	771 bp	DNA	linear	PAT 13-JAN-2001
LOCUS	AX053659	Sequence	425 from Patent WO0073801.	771 bp	DNA	linear	PAT 13-JAN-2001
DEFINITION	AX053659	Sequence	425 from Patent WO0073801.	771 bp	DNA	linear	PAT 13-JAN-2001
ACCESSION	AX053659	Sequence	425 from Patent WO0073801.	771 bp	DNA	linear	PAT 13-JAN-2001
VERSION	AX053659.1	GI:12227978					
KEYWORDS							
SOURCE							
ORGANISM							
		Homo sapiens (human)					
		Homo sapiens					
		Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;					
		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE							
AUTHORS							
TITLE							
		Obata, Y.					
		Breast, gastric and prostate cancer associated antigens and uses					
		therefor					

JOURNAL Patent: WO 0073801-A 425 07-DEC-2000; (US)
LUDWIG INSTITUTE FOR CANCER RESEARCH (US)
FEATURES
source
Location/Qualifiers
1. .771
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 771;
Best Local Similarity 100.0%; Pred. No. 1.5e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
Db 112 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 171
QY 61 AAGCAGGGGGGAACGCTGACGACCTAGAG 90
Db 172 AAGCAGGGGGGAACGCTGACGACCTAGAG 201
RESULT 2
AR099307
LOCUS AR099307 1055 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 3 from patent US 6077701.
ACCESSION AR099307
VERSION AR099307.1 GI:12809073
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1055)
AUTHORS Chu, K. and Pot, D.
TITLE Ikk beta. regulates transcription factors
JOURNAL Patent: US 6077701-A 3 20-JUN-2000;
FEATURES
source
1. .1055
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 1055;
Best Local Similarity 100.0%; Pred. No. 1.4e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
Db 322 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 381
QY 61 AAGCAGGGGGGAACGCTGACGACCTAGAG 90
Db 382 AAGCAGGGGGGAACGCTGACGACCTAGAG 411
RESULT 3
AX024046
LOCUS AX024046 1659 bp DNA linear PAT 15-SEP-2000
DEFINITION Sequence 15 from Patent WO0023091.
ACCESSION AX024046
VERSION AX024046.1 GI:10184361
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Scudder, K.M., Thastrup, O., Bjoern, S.P., Terry, B.R. and Arkhammar, P.O.
TITLE Specific therapeutic interventions obtained by interference with redistribution and/or targeting
JOURNAL Patent: WO 0023091-A 15 27-APR-2000;
SCUDDER KURT MARSHALL (DK) ; BIOIMAGE A S (DK) ; THASTRUP OLE (DK)
; BJOERN SARA PETERSEN (DK) ; TERRY BERNARD ROBERT (DK) ; ARKHAMMAR

PER O G (SE)
Location/Qualifiers
1. .1659
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
1. .1659
/note="unnamed protein product; fusion between Aequorea victoria and human"
/codon_start=1
/transl_table=11
/protein_id="CAC08904.1"
/db_xref="GI:10184362"
/db_xref="REMTREMBL:CAC08904"
/translation="MVSKGSELFVGVVPIILVELGDVNGHKFSVSGEGEGDATYKLT
LKFTCTTKPKLPVWPMTLVTLITLYGVQCFSRYPDMKHQDFFKSAPEGIYVERIIFFK
DDGNVKTAEVKFEFGDTLVNRILKIDFKEDGNILGHLEYNYNHNVYIMADQKN
GIKYNFKIRNIEDGSVOLADHYOQNTPIGDGPVLLPDNHYLSQSALSKDNKRDH
MVLLEFVTAAGITLGMDELYKSLRSRAQASTMNLILNNSCLSKMKNVSLMSQOLK
AKLDFFTSIQIDLEKYSQTEFGITSDKLLLAWEQAVALGRENVEKLVLRMM
ALQTDIVDLQSPMGRKGGTLDLEQARELYRRLRKRPRDQRTGDSQEMVRLILQ
AIQSFKKRVITYTQLSKTVYCKOKALELLPKVEVSLMNEDEKTVVRLQKROKEL
WNLKIAKSVRGVPVSGSPDSMNASRLSQQLMSQPSTASNSLPEPAKKGSELVAEA
HNLCITLLENAIQDVTREQDQSFALDMSWLQTEEREHSCLQAS"
ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 1659;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
Db 991 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1050
QY 61 AAGCAGGGGGGAACGCTGACGACCTAGAG 90
Db 1051 AAGCAGGGGGGAACGCTGACGACCTAGAG 1080
RESULT 4
AR067807
LOCUS AR067807 2268 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5851812.
ACCESSION AR067807
VERSION AR067807.1 GI:5999029
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2268)
AUTHORS Goeddel, D.V. and Woronicz, J.
TITLE IKK-beta. proteins, nucleic acids and methods
JOURNAL Patent: US 5851812-A 1 22-DEC-1998;
FEATURES
source
1. .2268
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.2e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662
QY 61 AAGCAGGGGGGAACGCTGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGACGACCTAGAG 1692
RESULT 5

ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 2268)
AUTHORS	Rothe,M., Cao,Z. and Regnier,C.
TITLE	IKK- alpha. proteins, nucleic acids and methods
JOURNAL	Patent: US 6235512-A 1 22-MAY-2001;
FEATURES	Location/Qualifiers
source	1..2268
ORIGIN	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity	100.0%; Pred. No. 1.2e-14;
Matches	90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db	1503 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
QY	61 AAGCAGGGGGGAACGCTGACACCTAGAG 90
Db	1663 AAGCAGGGGGGAACGCTGACACCTAGAG 1692
RESULT 8	
AR153426	
LOCUS	AR153426 2268 bp DNA linear PAT 08-AUG-2001
DEFINITION	Sequence 1 from patent US 6235513.
ACCESSION	AR153426
VERSION	AR153426.1 GI:15120958
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 2268)
TITLE	Rothe,M., Cao,Z. and Regnier,C.
JOURNAL	Patent: US 6235513-A 1 22-MAY-2001;
FEATURES	Location/Qualifiers
source	1..2268
ORIGIN	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity	100.0%; Pred. No. 1.2e-14;
Matches	90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db	1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
QY	61 AAGCAGGGGGGAACGCTGACACCTAGAG 90
Db	1663 AAGCAGGGGGGAACGCTGACACCTAGAG 1692
RESULT 9	
AR253906	
LOCUS	AR253906 2268 bp mRNA linear PAT 20-DEC-2002
DEFINITION	Sequence 1 from patent US 6479266.
ACCESSION	AR253906
VERSION	AR253906.1 GI:27302384
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 2268)
TITLE	Rothe,M., Cao,Z. and Regnier,C.
JOURNAL	Patent: US 6479266-A 1 12-NOV-2002;
FEATURES	Location/Qualifiers

Fri Sep 24 12:51:52 2004

us-09-806-701-15_copy_991_1080.rge

```
source
1. .2268
/organism="unknown"
/mol_type="mrna"

ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.2e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 10
AX318491 2268 bp DNA linear PAT 14-DEC-2001
LOCUS
DEFINITION
Sequence 1 from Patent WO0183554.
ACCESSION AX318491
VERSION AX318491.1 GI:17900949
KEYWORDS
synthetic construct
synthetic construct
artificial sequences.
ORGANISM
SOURCE
REFERENCE
1
AUTHORS May, M. J., Ghosh, S., Findeis, M. A. and Phillips, K.
TITLE Anti-inflammatory compounds and uses thereof
JOURNAL Patent: WO 0183554-A 1 08-NOV-2001;
PRAECIS Pharmaceuticals Incorporated (US) ; YALE UNIVERSITY (US)
FEATURES
source
1. .2268
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32830"
/notes="wild-type IKK ( NBD"

ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.2e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 11
BD062396 2268 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION
IKK-alpha proteins, nucleic acids and methods.
ACCESSION BD062396
VERSION BD062396.1 GI:22607999
KEYWORDS JP 2001510346-A/1.
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 2268)
AUTHORS Rothe, M., Cao, Z. and Regnier, C.
TITLE IKK-alpha proteins, nucleic acids and methods
JOURNAL Patent: JP 2001510346-A 1 31-JUL-2001;
TULARIK INC
COMMENT PN JP 2001510346-A/1
PD 31-JUL-2001
PF 01-JUL-1998 JP 1999507372

source
1. .2268
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 100.0%; Score 90; DB 6; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.2e-14;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGGCTCTCGACACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 13
AF029684
```

AF029684	2268 bp	mRNA	linear	PRI 15-NOV-1997
LOCUS				
DEFINITION	Homo sapiens IKB kinase-beta (IKK-beta)	mRNA	partial cds.	
ACCESSION	AF029684			
VERSION	AF029684.1	GI:2599557		
KEYWORDS				
SOURCE	Homo sapiens (human)			
ORGANISM				
REFERENCE				
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
TITLE	Woronicz,J.D., Gao,X., Cao,Z., Rothe,M. and Goeddel,D.V.			
JOURNAL	IKKAPAB kinase-beta: NF-kappaB activation and complex formation			
MEDLINE	Science 278 (5339), 866-869 (1997)			
PUBMED	98008814			
FEATURES				
source	2 (bases 1 to 2268)			
ORIGIN	Woronicz,J.D., Gao,X., Cao,Z., Rothe,M. and Goeddel,D.V.			
DEFINITION	Direct Submission			
ACCESSION	Submitted (09-OCT-1997) Biology, Tularik, Inc., Two Corporate			
VERSION	Drive, S. San Francisco, CA 94080, USA			
KEYWORDS	Location/Qualifiers			
SOURCE	1..2268			
ORIGIN	/organism="Homo sapiens"			
DEFINITION	/mol_type="mRNA"			
ACCESSION	/db_xref="taxon:9606"			
VERSION	/cell_line="Jurkat"			
KEYWORDS	/cell_type="T cell"			
SOURCE	1..2268			
ORIGIN	/gene="IKK-beta"			
DEFINITION	1..2268			
ACCESSION	/gene="IKK-beta"			
VERSION	/codon_start=1			
KEYWORDS	/product="IKK kinase-beta"			
SOURCE	/protein_id="AAC51860.1"			
ORIGIN	/db_xref="GI:2599558"			
DEFINITION	/translation="MSWPSLTTQTTCGAWEMKERLGTGGVIRVHNOETGEIAIK			
ACCESSION	QCRQLSPNRRWCLIEIIMRLTHPNVVAARDVPEGMONLAPNDPLLAWEYCGG			
VERSION	ILRKYLQNPENCGLRREGAILTLSDIASALRYLHNRNIHRDLKPENIVLQGGQRL			
KEYWORDS	IKKI IDLVAKELDQGLSCTSVGTLOYLAPLLEQQKYTVVDVWSFGTLAFECITG			
SOURCE	FRPFLPWQPVQWHSKVRQKSEVDIVSEDLNQTVPFSSLPYNNLNSVLAERLEKW			
ORIGIN	LQMLMWHPRQGTDTYTPNGCFKALDDILNLKLVLHNLMTGTIHTYPTVEDSLQ			
DEFINITION	SLKARIQDTGPIPEDEQLLEAGLALI PDKATQCSIDGKLNHGTITDMLDVLFDN			
ACCESSION	SKITVYQISPRPQSVESVCIQEPKRNLAFFQLRWQVWHSITLKEDCNRLQQG			
VERSION	ORAAAMNLRNNSCLSKMNSMSQQLKALDFPKTSIQIDLEKYSQTEFGITSD			
KEYWORDS	KILLAWREMEQAVELCGRENEVKLIVERMVALQTDIVDLQSPMRKQGGTDLDEEQ			
SOURCE	ARELYRLREKPRQTEGDSQEMVRLLOAIQSPFEKVRVYITQLSKTVCKQKALE			
ORIGIN	LIPKVEVSLMNEDEKTVRLOEKRKQELWNLKIAKSKVRGSPVSGPDSMNASRLS			
DEFINITION	QPGQMSQPSATSNLSLPEPAKSEELVAEHNLTLENAIQDTVREQDSFTALDWS			
ACCESSION	WLQTEEEHSCLEQAS"			
VERSION				
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	Query Match	100.0%; Score 90; DB 9; Length 2268;		
ACCESSION	Best Local Similarity	100.0%; Pred. No. 1.2e-14;		
VERSION	Matches	90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 60			
ACCESSION				
VERSION	Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 1662			
KEYWORDS				
SOURCE	QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90			
ORIGIN				
DEFINITION	Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692			
ACCESSION				
VERSION				
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	Query Match	100.0%; Score 90; DB 6; Length 2271;		
ACCESSION	Best Local Similarity	100.0%; Pred. No. 1.2e-14;		
VERSION	Matches	90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 60			
ACCESSION				
VERSION	Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 1662			
KEYWORDS				
SOURCE	QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90			
ORIGIN				
DEFINITION	Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692			
ACCESSION				
VERSION				
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	Query Match	100.0%; Score 90; DB 6; Length 2271;		
ACCESSION	Best Local Similarity	100.0%; Pred. No. 1.2e-14;		
VERSION	Matches	90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
KEYWORDS				
SOURCE				
ORIGIN				
DEFINITION	QY 1 GAACGGAT			

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2004, 08:42:00 ; Search time 330 Seconds
(without alignments)
1158.599 Million cell updates/sec

Title: US-09-806-701-15_COPY_991_1080

Perfect score: 90

Sequence: 1 gaacggatggtgctctgca.....gaacgtgacgacctagatag 90

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_29Jan04:*

- 1: Geneseqn1980s:*
- 2: Geneseqn1990s:*
- 3: Geneseqn2000s:*
- 4: Geneseqn2001as:*
- 5: Geneseqn2001bs:*
- 6: Geneseqn2002s:*
- 7: Geneseqn2003as:*
- 8: Geneseqn2003bs:*
- 9: Geneseqn2003cs:*
- 10: Geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	90	100.0	506	8	ACH37132 Human end
2	90	100.0	771	4	Aaf22846 Human pro
3	90	100.0	1055	2	Aax89677 C-termina
4	90	100.0	1558	4	Aah33389 Human col
5	90	100.0	1659	3	Aa14961 DNA encod
6	90	100.0	2268	2	Aax08919 Human I k
7	90	100.0	2268	2	Aaz31590 Human inh
8	90	100.0	2268	2	Aav84689 Human IKK
9	90	100.0	2268	2	Aax98271 cDNA enco
10	90	100.0	2268	2	Aax79304 Human IKK
11	90	100.0	2268	3	Aac81425 Human I-k
12	90	100.0	2268	6	Ab96316 Human IKK
13	90	100.0	2268	7	Abx11974 Human IKK
14	90	100.0	2268	8	ACD66625 Human inh
15	90	100.0	2271	2	Aax722842 DNA encod
16	90	100.0	2818	4	Aah16296 Human cDN
17	90	100.0	2931	2	Aav32970 Human I-k
18	90	100.0	2998	3	Aaf21148 Human low
19	90	100.0	3018	3	Aa14960 DNA encod
20	90	100.0	3024	3	Aa14958 DNA encod
21	90	100.0	3058	3	AA14958 Human ade
22	90	100.0	3058	7	AA35026 Human nuc
23	90	100.0	3965	2	Aax89675 Full leng

24	90	100.0	8631	3	AAA35028	Human ade
25	90	100.0	8631	3	Aaf21150	Human low
26	90	100.0	8631	7	ABZ96844	Human nuc
27	81.6	90.7	400	7	ACD92547	Human col
28	77.2	85.8	3038	8	ACD66707	Rat inhib
29	74	82.2	554	9	ADD34950	Mouse inh
30	74	82.2	2274	8	ACD66672	Mouse inh
31	35.6	39.6	1874	7	ABX94013	Mouse I k
32	35.6	39.6	1875	8	ADA26740	Mouse I k
33	35.6	39.6	2025	3	AAA08830	cDNA IKKa
34	35.6	39.6	3314	7	ABX94012	Murine I
35	35.6	39.6	3314	8	ADA26739	Mouse I k
36	35.6	39.6	3466	6	AB199798	cDNA IKKa
37	35.6	39.6	3466	7	ACC58547	Mouse I k
38	34.6	38.4	2146	2	AAx08917	Mouse IKK
39	34.6	38.4	2146	3	AAc81422	Human ser
40	34.6	38.4	2146	7	ABX11976	Conserved
41	34.6	38.4	2238	2	AAx08918	Human IKK
42	34.6	38.4	2238	2	AAV84690	Human IKK
43	34.6	38.4	2238	2	AAx98272	cDNA enco
44	34.6	38.4	2238	2	AAx79305	Human IKK
45	34.6	38.4	2238	3	AAc81424	Human I-k

ALIGNMENTS

RESULT 1
ACH37132
ID ACH37132 standard; cDNA; 506 BP.
XX
AC ACH37132;
XX
DT 13-OCT-2003 (first entry)
XX
DE Human endothelial cell cDNA #5265.
XX
KW Human; ss; sequencing by hybridisation; SBH; expressed sequence tag; EST;
KW genome mapping; biodiversity; genetic disorder.
XX
OS Homo sapiens.
XX
FN US2003073623-A1.
XX
PD 17-APR-2003.
XX
PF 30-JUL-2001; 2001US-00918995.
XX
PR 30-JUL-2001; 2001US-00918995.
XX
PA (DRMA/) DRMANAC R T.
PA (LABA/) LABAT I.
PA (STAC/) STACHE-CRAIN B.
PA (DICK/) DICKSON M C.
PA (JONE/) JONES L W.
PI Drmanac RT, Labat I, Stache-Crain B, Dickson MC, Jones LW;
XX WPI; 2003-615964/58.
XX
DR New polynucleotide sequences obtained from various cDNA libraries, useful
XX as hybridization probes, as oligomers for PCR, for chromosome and gene
XX mapping, in the recombinant production of protein, or in generating
XX antisense DNA or RNA.
XX
PS Claim 1; SEQ ID NO 24344; 44pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising any one of
XX 38043 cDNA sequences, appearing as ACH12789-ACH50831, whose sequence was
XX determined by the technique of SBH (sequencing by hybridisation). Also
XX included is a purified polypeptide comprising a sequence corresponding to
XX a reading frame of the novel polynucleotide. The nucleic acid sequences
XX are useful in diagnostics as expressed sequence tags (EST) for

CC identifying expressed genes or for physical mapping of the human genome,
 CC in forensics, in assessing biodiversity, or in identifying mutations
 CC responsible for genetic disorders and other traits. The nucleotide
 CC sequences are also useful as hybridisation probes, as oligomers for PCR,
 CC for chromosome and gene mapping, in the recombinant production of
 CC protein, or in generating antibodies specific for it. The present sequence
 CC is useful for generating antibodies specific for it. The present sequence
 CC is one of the 38043 isolated cDNA/EST sequences. Note: The sequence data
 CC for this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html?DocID=20030073623
 XX
 SQ Sequence 506 BP; 144 A; 96 C; 167 G; 95 T; 0 U; 4 Other;
 Query Match 100.0%; Score 90; DB 8; Length 506;
 Best Local Similarity 100.0%; Pred. No. 1.2e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTTGTGGACTTACAGAGAGCCCATGGGCGG 60
 Db 64 GAACGGATGATGGCTCTGCAGACCGACATTTGTGGACTTACAGAGAGCCCATGGGCGG 123
 QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 Db 124 AAGCAGGGGGGAACGCTGGACGACCTAGAG 153
 RESULT 2
 AAF22846
 ID AAF22846 standard; cDNA; 771 BP.
 XX
 AC AAF22846;
 XX
 DT 26-MAR-2001 (first entry)
 XX
 DE Human prostate cancer associated antigen nucleotide sequence SEQ ID:425.
 XX
 KW Human; breast cancer; gastric cancer; prostate cancer; diagnosis;
 KW cancer associated antigen; cytostatic; cancer vaccine; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200073801-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 26-MAY-2000; 2000WO-US014749.
 XX
 PR 28-MAY-1999; 99US-0136526P.
 PR 10-SEP-1999; 99US-0153454P.
 XX
 PA (LUDW-) LUDWIG INST CANCER RES.
 XX
 PI Obata Y;
 XX
 DR WPI; 2001-025274/03.
 XX
 PT Nucleic acids encoding breast, gastric and prostate cancer associated
 PT antigen precursors, useful for diagnosing and treating a condition
 PT characterized by expression of an abnormal amount of a protein, e.g.
 PT cancer.
 XX
 PS Claim 50; Page 413; 799pp; English.
 XX
 AA AAF22422 to AAF22626; AAF22627 to AAF22773 and AAF22774 to AAF23014
 CC represent nucleotide sequences encoding human breast, gastric and
 CC prostate cancer associated antigen precursors (CAAP) respectively.
 CC AAB63232 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970
 CC represent human breast, gastric and prostate CAAP protein sequence
 CC respectively. CAAPs have cytostatic activity and can be used in the
 CC production of cancer vaccines. The human CAAP proteins, peptides, nucleic
 CC acids or anti-CAAP antibodies are useful for diagnosing and treating a
 CC condition characterised by expression of an abnormal amount of a protein,
 CC

CC e.g. cancer
 XX Sequence 771 BP; 213 A; 176 C; 210 G; 157 T; 0 U; 15 Other;
 SQ
 Query Match 100.0%; Score 90; DB 4; Length 771;
 Best Local Similarity 100.0%; Pred. No. 1.3e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTTGTGGACTTACAGAGAGCCCATGGGCGG 60
 Db 112 GAACGGATGATGGCTCTGCAGACCGACATTTGTGGACTTACAGAGAGCCCATGGGCGG 171
 QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 Db 172 AAGCAGGGGGGAACGCTGGACGACCTAGAG 201
 RESULT 3
 AAX89677
 ID AAX89677 standard; DNA; 1055 BP.
 XX
 AC AAX89677;
 XX
 DT 28-SEP-1999 (first entry)
 XX
 DE C-terminal HLH domain of IKKbeta.
 XX
 KW inflammatory disease; kinase; NFKappaB; transcription factor; IKKbeta;
 KW IKK; phosphorylation; drug development; C-terminal; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9934000-A1.
 XX
 PD 08-JUL-1999.
 XX
 PF 30-DEC-1998; 98WO-US027917.
 XX
 PR 30-DEC-1997; 97US-0068954P.
 PR 18-DEC-1998; 98US-00215131.
 XX
 PA (CHIR) CHIRON CORP.
 XX
 PI Chu K, Pot D;
 XX
 DR WPI; 1999-430247/36.
 XX
 PT New I-kappa-B kinase polynucleotides and polypeptides.
 XX
 PS Claim 1; Page 40; 40pp; English.
 XX
 CC Sequence AAX89675 represents the full length DNA sequence of IKKbeta,
 CC while sequence AAX89676 and AAX89677, encode for the N-terminal kinase
 CC domain and C-terminal HLH domain of IKKbeta respectively. The proteins
 CC may be alternatively spliced forms of IKKbeta. The IKK beta enzyme binds
 CC to and phosphorylates I-kappa-B protein. The IKKbeta polypeptides and
 CC fragments can be used to raise antibodies, which can then be used in
 CC immunochemical assays, to detect the presence of mutations in the
 CC IKKappa gene which result in altered expression of the protein, to
 CC detect wild type IKKappa in tissue samples. IKKappa polynucleotides are
 CC a source of probes and primers, and can be used to produce recombinant
 CC protein. The polynucleotides are also a source of antisense sequences,
 CC which can be used to decrease expression of the IKKappa gene. The
 CC protein can be used to screen for test compounds for use as inflammation
 CC inhibitors (claimed). IKK proteins are critical targets for anti-
 CC inflammatory drug development
 XX
 SQ Sequence 1055 BP; 300 A; 248 C; 300 G; 207 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 2; Length 1055;
 Best Local Similarity 100.0%; Pred. No. 1.4e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
QY 1 GAACGGATGATGGCTCTGACAGCCGACATTGTGGACTTACAGAGGAGCCCATGGGCGG 60
   |||||||
Db 322 GAACGGATGATGGCTCTGACAGCCGACATTGTGGACTTACAGAGGAGCCCATGGGCGG 381
   |||||||

QY 61 AAGCAGGGGGGAACGCTGGAGCACTAGAG 90
   |||||||
Db 382 AAGCAGGGGGGAACGCTGGAGCACTAGAG 411
   |||||||

RESULT 4
AAH33389
ID AAH33389 standard; cDNA; 1558 BP.
XX
AC AAH33389;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen encoding cDNA SEQ ID NO:445.
XX
DE Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma; chromosome 8; ss.
XX
OS Homo sapiens.
XX
FN WO2001229220-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.
XX
PR 29-SEP-1999; 99US-0157137P.
PR 03-NOV-1999; 99US-0163280P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX WPI; 2001-235357/24.
DR P-PSDB; AAG73958.
XX
XX
XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
XX useful for preventing, diagnosing and/or treating colorectal cancers.
XX
XX Claim 1; Page 2542; 9803pp; English.
XX
XX AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
XX cancer-associated nucleic acid molecules (N) and proteins (P), where the
XX proteins are collectively known as colon cancer antigens. The colon
XX cancer antigens have cytostatic activity and can be used in gene therapy
XX and vaccine production. N and P may be used in the prevention, diagnosis
XX and treatment of diseases associated with inappropriate p expression. For
XX example, N and P may be used to treat disorders associated with decreased
XX expression by rectifying mutations or deletions in a patient's genome
XX that affect the activity of P by expressing inactive proteins or to
XX supplement the patients own production of P. Additionally, N may be used
XX to produce the colon cancer-associated ps, by inserting the nucleic acids
XX into a host cell and culturing the cell to express the proteins. N and P
XX can be used in the prevention, diagnosis and treatment of colorectal
XX carcinomas and cancers. AAH37196 to AAH37204 and AAG77789 represent
XX sequences used in the exemplification of the present invention. N.B.
XX Pages 666 to 682 and page 7053 of the sequence listing were missing at
XX time of publication, meaning no sequences are present for SEQ ID NO:1027
XX to 1052, 7921 and 7922
XX
SQ Sequence 1558 BP; 445 A; 372 C; 427 G; 302 T; 0 U; 12 Other;
Query Match 100.0%; Score 90; DB 4; Length 1558;
Best Local Similarity 100.0%; Pred. No. 1.5e-19;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGACAGCCGACATTGTGGACTTACAGAGGAGCCCATGGGCGG 60
   |||||||
Db 817 GAACGGATGATGGCTCTGACAGCCGACATTGTGGACTTACAGAGGAGCCCATGGGCGG 876
   |||||||
```

```
QY 61 AAGCAGGGGGGAACGCTGGAGCACTAGAG 90
   |||||||
Db 877 AAGCAGGGGGGAACGCTGGAGCACTAGAG 906
   |||||||

RESULT 5
AAA14961
ID AAA14961 standard; DNA; 1659 BP.
XX
AC AAA14961;
XX
DT 21-AUG-2000 (first entry)
XX
DE DNA encoding a GFP-I-kappaB kinase-LZ domain fusion protein.
XX
XX I-kappaB kinase; cyclic nucleotide phosphodiesterase; cyclic AMP;
KW cyclic GMP; PDE3; PDE7; PDE8; PDE4 splice variant; PDE4D;
KW inflammatory disease; chronic inflammation; airway disease; asthma;
KW chronic bronchial hyper-reactivity; joint disorder; rheumatoid arthritis;
KW pelvispondylitis; bowel disease; ulcerative colitis; Crohn's disease;
KW autoimmune disease; diabetes mellitus type I; Hashimoto's thyroiditis;
KW systemic lupus erythematosus; myasthenia gravis; Grave's disease;
KW immune thrombocytopenic purpura; acute respiratory distress syndrome;
KW septic shock; depression; PDE1; PDE2; PDE6; PDE9; PDE10; jet lag;
KW PDE5 splice variant; tension; erectile dysfunction; circadian rhythm;
KW green fluorescent protein; GFP; ss.
XX
XX Synthetic.
OS Homo sapiens.
OS Aequorea victoria.
XX
XX Key Location/Qualifiers
XX CDS 1..1659
XX /*tag= a
XX
XX WO200023091-A2.
XX
XX 27-APR-2000.
XX
XX 15-OCT-1999; 99WO-DK000567.
XX
XX 15-OCT-1998; 98DK-00001321.
XX 15-OCT-1998; 98DK-00001322.
XX 15-OCT-1998; 98DK-00001323.
XX
XX (BIOI-) BIOIMAGE AS.
XX
XX Arkhammar POG, Terry BR, Scudder KM, Bjorn SP, Thastrup O;
XX WPI; 2000-399281/34.
XX P-PSDB; AAY84883.
XX
XX Modulating the activity of I-kappaB kinases or cyclic nucleotide
XX phosphodiesterases for the treatment of inflammatory disorders.
XX autoimmune disorders (e.g. diabetes and Crohn's disease) and depression.
XX
XX Example 3; Page 125-127; 128pp; English.
XX
XX The specification describes a method for modulating the specific
XX effectiveness of I-kappaB kinases or cyclic nucleotide phosphodiesterases
XX which have the ability to cleave cyclic AMP and/or GMP. This involves
XX modulating the specific effectiveness of the cyclic nucleotide
XX phosphodiesterase or I-kappaB kinase by modulating the spatial
XX distribution within cells of the animal. If the cyclic nucleotide
XX phosphodiesterase used is a PDE3, PDE7, PDE8 or a splice variant of PDE4
XX (such as PDE4D), the method is used to treat inflammatory diseases such
XX as chronic inflammation (especially airway diseases such as asthma and
XX disorders such as rheumatoid arthritis and pelvispondylitis and bowel
XX diseases such as ulcerative colitis and Crohn's disease), autoimmune
XX diseases associated with inflammation (such as diabetes mellitus type I,
XX systemic lupus erythematosus, myasthenia gravis, Hashimoto's
```

CC thyroiditis, Grave's disease and immune thrombocytopenic purpura),
CC dysregulations of the immune system (such as acute respiratory distress
CC syndrome (ARDS) and septic shock) and/or depression. Alternatively, if
CC the cyclic nucleotide phosphodiesterase is PDE1, PDE2, PDE6, PDE9, PDE10
CC or a splice variant of PDE5, the method is used to treat hypo- or
CC hypertension, erectile dysfunction, circadian rhythm resetting or jet-
CC lag. The present sequence encodes a fusion protein of green fluorescent
CC protein (GFP) and I-kappaB kinase and the LZ domain, which is used in the
CC course of the invention
XX
SQ Sequence 1659 BP; 437 A; 461 C; 486 G; 275 T; 0 U; 0 Other;
Query Match 100.0%; Score 90; DB 3; Length 1659;
Best Local Similarity 100.0%; Pred. No. 1.6e-19; Indels 0; Gaps 0;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGGACATTTGGACTTACAGAGGAGCCCATGGGCCCG 60
DB 991 GAACGGATGATGGCTCTGCAGACCGGACATTTGGACTTACAGAGGAGCCCATGGGCCCG 1050
QY 61 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 90
DB 1051 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 1080
RESULT 6
AAZ08919
ID AAZ08919 standard; cDNA; 2268 BP.
AC AAZ08919;
XX
XX 27-APR-1999 (first entry)
XX Human I kappa B kinase coding sequence.
DE
KW I-kappa-B kinase; IKK-alpha; gene expression; modulation; suppression;
KW activation; tumour necrosis factor; TNF; interleukin-1; IL-1;
KW TNF receptor associated factor; TRAF; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..2268
FT /tag= a
FT /label= I_kappa_B_kinase
FT
PN WO9901541-A1.
XX
XX 14-JAN-1999.
XX
XX 01-JUL-1998; 98WO-US013782.
XX
XX 01-JUL-1997; 97US-00887115.
XX 10-JUL-1997; 97US-00890854.
XX
XX (TULA-) TULARIK INC.
XX
XX Rothe M, Cao Z, Regnier C;
PI
XX WPI; 1999-106044/09.
XX P-PSDB; AAW96158.
XX
XX Newly isolated human kinase IkappaB Kinase (IKK-a) polypeptides - useful
XX in screening for agents that modulate the interaction of an IKK
XX polypeptide to a binding target and for modulating signal transduction
XX involving IkappaB in a cell.
XX
XX Disclosure; Page 20; 32pp; English.
XX
XX I-kappa-B, deletion mutants of it retaining I-kappa-B kinase activity and
XX I-kappa-B polypeptides (comprising a six residue domain of I-kappa-B
XX containing one of Ser32 and Ser36, and a candidate agent) can be used to
XX screen for agents that modulate the interaction of an IKK polypeptide to

CC a binding target. The modulation of the kinase activity of IKK-alpha
CC (AAW96157) forms a method for modulating signal transduction involving I-
CC kappa-B in a cell. The IKK-alpha polypeptides are useful for generating
CC oligonucleotide primers and probes for use in the isolation of natural
CC IKK-alpha-encoding nucleic acids. The nucleic acids are useful as
CC translatable transcripts, hybridization probes, polymerase chain reaction
CC (PCR) probes and primers. Their diagnostic applications include IKK-alpha
CC hybridization probes for identifying wild-type and mutant IKK-alpha
CC alleles in clinical and laboratory samples. Therapeutic application
CC includes the use of IKK-alpha nucleic acids for modulating cellular
CC expression or intracellular concentration/availability of active IKK-
CC alpha. Catalytically inactive IKK-alpha mutants suppress NF-kappa-B
CC activation induced by tissue necrosis factor (TNF), interleukin-1 (IL-1)
CC stimulation, TNF receptor-associated factor (TRAF) and NF-kappa-B-
CC inducing kinase (NIK) overexpression
XX
SQ Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
Query Match 100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.7e-19;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGGACATTTGGACTTACAGAGGAGCCCATGGGCCCG 60
DB 1603 GAACGGATGATGGCTCTGCAGACCGGACATTTGGACTTACAGAGGAGCCCATGGGCCCG 1662
QY 61 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 90
DB 1663 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 1692
RESULT 7
AAZ31590
ID AAZ31590 standard; DNA; 2268 BP.
XX
XX AAZ31590;
XX
XX 13-JAN-2000 (first entry)
XX
XX Human inhibitor-kappa B kinase-beta coding sequence.
XX
XX Inhibitor-kappa B kinase-beta; IKB-beta; human; T-cell leukaemia; asthma;
KW inflammatory response; inflammatory disease; juvenile diabetes mellitus;
KW Graves' disease; rheumatoid arthritis; allograft rejection; diagnosis;
KW inflammatory bowel disease; multiple sclerosis; contact dermatitis;
KW rhinitis; allergy; hyperproliferative disorder; tumour; therapy; ss.
XX
OS Homo sapiens.
XX
XX US5977341-A.
XX
XX 02-NOV-1999.
XX
XX 20-NOV-1998; 98US-00197008.
XX
XX 20-NOV-1998; 98US-00197008.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowser LM;
PI
XX WPI; 1999-619715/53.
XX P-PSDB; AAW43247.
XX
XX Antisense oligonucleotides inhibiting human Inhibitor-kappa B Kinase-
XX beta, useful for treating conditions such as inflammation, asthma,
XX diabetes, allograft rejection, allergies, hyperproliferative disorders or
XX tumors.
XX
XX Claim 1; Col 41-48; 32pp; English.
XX
XX This sequence encodes the human inhibitor-kappa B kinase-beta. The
XX invention relates to an antisense oligonucleotide (I) 8 to 30 nucleotides

CC in length inhibiting the expression of human Inhibitor-kappa B kinase-beta (IKK-beta). (I) inhibits the expression of human IKK-beta which plays a role in the development of T-cell leukaemia and in the activation of inflammatory responses. (I) is therefore useful for treating inflammatory diseases or disorders with an inflammatory component such as asthma, juvenile diabetes mellitus, Graves' disease, rheumatoid arthritis, contact dermatitis, inflammatory bowel disease, multiple sclerosis, scleroderma, rhinitis and various allergies, or hyperproliferative disorders such as leukaemias and other tumours. (I) may also be used for detection of the above disorders.

XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 2; Length 2268;
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
 Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
 QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 8
 AAV84689
 ID AAV84689 standard; cDNA; 2268 BP.
 XX
 AC AAV84689;
 XX
 DT 03-MAR-1999 (first entry)
 XX
 DE Human IKK-beta polypeptide encoding cDNA.

IKK-beta; IkappaB kinase; inhibitor; NF-kappaB; nuclear factor-kappaB; nuclear translocation; NF-kappaB-inducing kinase; NIK; recombinant; human; ds.

XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT CDS 1..2268
 FT /*tag= a
 FT /product= "IKK-beta polypeptide"
 FT /note= "the stop codon is not indicated"

XX US5851812-A.
 XX
 XX 22-DEC-1998.
 XX
 XX 10-JUL-1997; 97US-00890853.
 XX
 XX 01-JUL-1997; 97US-00887114.
 XX
 XX (TULA-) TULARIK INC.
 XX
 XX Woronicz J, Goeddel DV;
 XX
 XX WPI; 1999-080407/07.
 XX
 XX P-PSDB; AAW86163.
 XX
 XX DNA encoding IKK-beta polypeptides - useful for producing recombinant polypeptides.
 XX
 XX Claim 3; Col 11-14; 13pp; English.

CC This cDNA encodes a IKK-beta (IkappaB kinase) polypeptide. The IkappaB (inhibitor of nuclear factor (NF)-kappaB nuclear translocation) kinase is a NF-kappaB-inducing kinase (NIK)-interacting protein. A host cell containing a recombinant nucleic acid encoding the IKK-beta polypeptide can be used for the recombinant production of the polypeptide

XX
 SQ Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 2; Length 2268;
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
 Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
 QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 9
 AAX98271
 ID AAX98271 standard; cDNA; 2268 BP.

XX
 AC AAX98271;
 XX
 DT 20-MAR-2003 (revised)
 DT 01-OCT-1999 (first entry)
 XX
 DE cDNA encoding human kinase I-kappa-B kinase (IKK-beta).
 XX
 KW Nuclear factor kappa-B inducing kinase; NIK; NIK-interacting protein; human; I-kappa-B kinase; IKK-beta; IKK-beta disorder; ds.
 XX
 OS Homo sapiens.

XX Key Location/Qualifiers
 FT CDS 1..2268
 FT /*tag= a
 FT /note= "no termination codon given"

XX US5939302-A.

XX 17-AUG-1999.

XX 17-JUN-1998; 98US-00099124.

XX 01-JUL-1997; 97US-00887114.

XX 10-JUL-1997; 97US-00890853.

XX (TULA-) TULARIK INC.

XX Woronicz J, Goeddel DV;

XX WPI; 1999-468406/39.

XX P-PSDB; AAY24051.

XX Polypeptides comprising a novel I-kappa-B Kinase useful as hybridization probes.

XX Claim 4; Col 11-14; 13pp; English.

XX The present sequence encodes a human I-kappa-B kinase (IKK-beta). The protein is a nuclear factor kappa-B inducing kinase (NIK) interacting protein. The IKK-beta nucleic acids, polypeptides, and/or antibodies may be useful as hybridization primers or probes, translatable transcripts, diagnostic probes (e.g. for identifying the presence of IKK-beta in a sample), to detect mutant IKK-beta alleles, in the diagnosis and therapy of IKK-beta disorders, and in the identification of compounds or agents that are able to modulate IKK-beta function. (Updated on 20-MAR-2003 to correct PF field.)

XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 2; Length 2268;
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 DB 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 DB 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 10
 AAX79304
 ID AAX79304 standard; cDNA; 2268 BP.
 AC AAX79304;
 XX
 DT 31-AUG-1999 (first entry)
 XX
 DE Human IKK-beta coding sequence.
 XX
 KW Human; IKK-beta; I-Kappa B-Kinase; inhibitory protein; diagnosis; NF-kB;
 KW Nuclear Factor Kappa B; interaction; binding target; ds.
 XX
 OS Homo sapiens.
 XX
 FN US5916760-A.
 XX
 PD 29-JUN-1999.
 XX
 PF 17-JUN-1998; 98US-00099125.
 XX
 PR 01-JUL-1997; 97US-00887114.
 PR 10-JUL-1997; 97US-00890853.
 XX
 PA (TULA-) TULARIK INC.
 XX
 PI Goeddel DV, Woronicz J;
 XX
 DR P-PSDB; AAY14515.
 XX
 PT Screening for agents which modulate the interaction of IKK-beta
 PT polypeptides and their binding targets.
 XX
 PS Claim 4; Col 11-14; 14pp; English.
 XX
 CC This sequence represents the coding region for human IKK-beta, a novel
 CC IKK Kinase (I-Kappa B-Kinase, one of a family of inhibitory proteins
 CC which interact with Nuclear Factor Kappa B (NF-kB)). The invention
 CC relates to a method of screening for agents which modulate the
 CC interaction of human IKK-beta polypeptides and their binding targets.
 CC Agents which modulate the IKK-beta binding are useful in a variety of
 CC diagnostic and therapeutic applications where the disease is associated
 CC with improper utilization of a pathway involving IKK-beta proteins (e.g.
 CC NF-kB activation and IKK-beta-dependent transcriptional activation)
 XX
 XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 2; Length 2268;
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 DB 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 DB 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 11
 AAC81425

ID AAC81425 standard; cDNA; 2268 BP.
 XX AAC81425;
 XX
 DT 23-FEB-2001 (first entry)
 XX
 DE Human I-kappa-B kinase beta-subunit (IKK-beta) cDNA.
 XX
 KW Human; I-kappa-B kinase; IKK; antisense therapy; gene therapy;
 KW cytokine expression inhibition; NF-kappa-B activation inhibition;
 KW nuclear factor-kappa-B; rheumatoid arthritis; immune disorder; cancer;
 KW IKK-beta; beta-subunit; ss.
 XX
 OS Homo sapiens.
 XX
 FN JP2000253884-A.
 XX
 PD 19-SEP-2000.
 XX
 PF 10-MAR-1999; 99JP-00063291.
 PR 10-MAR-1999; 99JP-00063291.
 XX
 PA (TOAG) TOA GOSEI CHEM IND LTD.
 XX
 DR WPI; 2000-658813/64.
 XX
 PT Antisense nucleic acid compound complementary to the subunit of IkappaB,
 PT used to treat rheumatic arthritis, immune diseases and cancer.
 XX
 PS Claim 3; Page 13-14; 20pp; Japanese.
 XX
 CC The invention relates to an antisense oligonucleotide targetted to a gene
 CC encoding a subunit of I-kappa-B kinase (IKK) which inhibits its
 CC expression, and thereby inhibits expression of a cytokine such as IL-6
 CC (interleukin-6). I-kappa-B kinase activates NF-kappa-B (nuclear factor-
 CC kappa-B) which acts as a transcriptional regulator of cytokine genes. The
 CC antisense oligonucleotide can be used in gene therapy to treat rheumatoid
 CC arthritis, immune disorders and cancers. Sequences AAC81422-C81426 are
 CC cDNAs derived from genes whose expression may be inhibited using an
 CC antisense oligonucleotide of the invention. The present sequence
 CC represents a human IKK-beta subunit cDNA
 XX
 XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
 Query Match 100.0%; Score 90; DB 3; Length 2268;
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 DB 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
 DB 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 12
 ABA96316
 ID ABA96316 standard; DNA; 2268 BP.
 XX ABA96316;
 XX
 DT 20-MAR-2002 (first entry)
 XX
 DE Human IKKbeta encoding polynucleotide GenBank No AR067807.
 XX
 KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
 KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
 KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
 KW antiallergic; membrane translocation domain; NEMO binding domain; human;
 KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;

KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
 KW autoimmune disorder; multiple sclerosis; transplant rejection;
 KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
 KW ataxia telangiectasia; allergy; anaphylaxis; eczema; arthritis; gene; ds.

OS Homo sapiens.

XX Key Location/Qualifiers
 XX FH 2203..2235
 XX CDS /*tag= a
 XX /*product= "IKKbeta peptide"

XX WO200183554-A2.

XX 08-NOV-2001.

XX 02-MAY-2001; 2001WO-US014346.

XX 02-MAY-2000; 2000US-0201261P.

XX 22-AUG-2000; 2000US-00643260.

XX (PRAE-) PRAECIS PHARM INC.

XX (UYVA) UNIV YALE.

XX May MJ, Ghosh S, Findeis MA, Phillips K;

XX WPI; 2002-121889/16.

XX P-PSDB; AAM48506.

XX Novel antiinflammatory compound comprising membrane translocation domain
 fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
 activation, and for treating asthma, lung inflammation, psoriasis.

XX Disclosure; Page; 88pp; English.

XX The invention relates to an antiinflammatory compound (especially
 AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
 AAM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
 residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
 antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
 antirheumatic, antiarthritic, osteoprotective, antibacterial,
 immunosuppressive, dermatological, neuroprotective, nootropic,
 antiatherosclerotic, virucide and anti-allergic activity. The compounds
 act as selective inhibitors of cytokine-mediated NFkappaB activation by
 blocking interaction of IkkappaB kinase beta (IKKbeta) at the NEMO binding
 domain that results in inhibition of IKKbeta kinase activation and
 subsequent decreased phosphorylation of IkkappaB. The compounds are useful
 for treating inflammatory disorders, e.g. asthma, lung inflammation or
 cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
 bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
 lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
 transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
 viral infections; and ataxia telangiectasia. The compounds are also
 useful for treating pro-inflammatory responses such as allergies,
 urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
 sunburn, aging and arthritis. Note: The present sequence is not given in
 the printed specification but is that of human IKKbeta encoding
 polynucleotide derived from the sequence given at GenBank Number AR067807

XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;

Query Match 100.0%; Score 90; DB 6; Length 2268;

Best Local Similarity 100.0%; Pred. No. 1.7e-19;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60

Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGACGCTGGACGACCTAGAG 90

Db 1663 AAGCAGGGGGACGCTGGACGACCTAGAG 1692

RESULT 13

ABX11974

ID ABX11974 standard; cDNA; 2268 BP.

XX AC ABX11974;

XX 08-MAY-2003 (first entry)

XX Human IKK-alpha related cDNA.

XX Human; gene; ss; inhibitor of nuclear factor kappa-B kinase alpha;

XX IKK-alpha; conserved helix-loop-helix ubiquitous kinase; CHUK; IKK-alpha;

XX nuclear factor kappa B; NF-kappaB; cell regulation; IKK; phosphorylation;

XX IkappaB; signal transduction disorder; genetic defect;

XX autoimmune disease; neuroprotective; immunostimulant.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 1..2268

XX /*tag= a

XX /*product= "IKK-alpha related polypeptide"

XX US6479266-B1.

XX 12-NOV-2002.

XX 02-JUL-1998; 98US-00109986.

XX 01-JUL-1997; 97US-00887115.

XX 10-JUL-1997; 97US-00890854.

XX (TULA-) TULARIK INC.

XX Rothe M, Cao Z, Regnier C;

XX WPI; 2003-298112/29.

XX P-PSDB; ABG75804.

XX New isolated IKK polypeptide involved in transcription factor activation,

XX useful for diagnosing and treating disorders with aberrant activity of

XX the IKK polypeptide, such as signal transduction disorders and genetic

XX defects.

XX Disclosure; Col 13-16; 15pp; English.

XX The invention discloses methods and compositions relating to isolated

XX inhibitor of nuclear factor kappa-B kinase alpha (IKK-alpha), also known

XX as the conserved helix-loop-helix ubiquitous kinase (CHUK), polypeptides.

XX IKK-alpha polypeptides regulate nuclear factor kappa B (NF-kappaB)

XX activation and hence regulate cell function. Also disclosed are methods

XX for screening for an agent which modulates the interaction of an IKK

XX polypeptide to a binding target and for screening for an agent which

XX modulates the ability of an IKK polypeptide to specifically phosphorylate

XX an IkappaB polypeptide. The methods and compositions of the present

XX invention are useful for the diagnosis and treatment of disorders

XX associated with the aberrant activity of the IKK polypeptide, such as

XX signal transduction disorders, genetic defects and autoimmune diseases.

XX The sequence presented is the human IKK-alpha related cDNA

XX Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;

Query Match 100.0%; Score 90; DB 7; Length 2268;

Best Local Similarity 100.0%; Pred. No. 1.7e-19;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60

Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGACGCTGGACGACCTAGAG 90

Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAG 1692

RESULT 14
ACD66625
ID ACD66625 standard; cDNA; 2268 BP.
XX
AC ACD66625;
XX
DT 16-SEP-2003 (first entry)
XX
DE Human inhibitor-kappa B kinase-beta DNA sequence.
XX
KW Human; inhibitor-kappa B kinase-beta; anorectic; antidiabetic;
KW antiinflammatory; cytosstatic; gene therapy; antisense compound; obesity;
KW diabetes type II; inflammatory disorder; cancer; leukaemia; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003050270-A1.
XX
PD 13-MAR-2003.
XX
PF 24-MAY-2002; 2002US-00156610.
XX
PR 20-NOV-1998; 98US-00197008.
PR 28-JUL-1999; 99WO-US016959.
PR 30-AUG-2001; 2001US-00856246.
XX
PA (MONI//) MONIA B P.
PA (COWS//) COWSERT L M.
PA (KOLL//) KOLLER E.
XX
PI Monia BP, Cowsert LM, Koller E;
XX
XX WPI: 2003-512357/48.
DR P-PSDB; ABO32508.
XX
PT New antisense compound, useful for preparing a composition for treating
PT obesity, diabetes type II, inflammatory disorder or cancer e.g.,
PT leukemia.
XX
PS Example 13; Page 29-31; 49pp; English.
XX
CC The invention describes a new antisense compound, which is 8-30
CC nucleobases in length targeted to a nucleic acid molecule encoding
CC inhibitor-kappa B Kinase-beta that specifically hybridises with and
CC inhibits the expression of inhibitor-kappa B Kinase-beta. The compound is
CC useful for preparing a composition for treating obesity, diabetes type
CC II, inflammatory disorder or cancer e.g., leukaemia. This sequence
CC represents human inhibitor-kappa B kinase-beta DNA
XX
SQ Sequence 2268 BP; 603 A; 569 C; 661 G; 435 T; 0 U; 0 Other;
Query Match 100.0%; Score 90; DB 8; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.7e-19;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
QY 61 AAGCAGGGGGGAACGCTGGACGACCTAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAG 1692

RESULT 15
AAV22842
ID AAV22842 standard; DNA; 2271 BP.
XX
AC AAV22842;
XX

DT 24-JUL-1998 (first entry)
XX
DE DNA encoding inhibitory subunit I-kappa-B signalosome kinase 2.
XX
KW Inhibitory subunit; I-kappa-B-beta; nuclear factor kappa-B;
KW NF-kappa-B/Rel dimer; inhibitory activity; phosphorylation;
KW stimulus-inducible I-kappa-B kinase; IKK; signalosome; I-kappa-B-alpha;
KW identification; stimulate; signal transduction; the NF-kappa-B cascade;
KW therapeutic composition; inflammatory; neurodegenerative; disease;
KW autoimmune disease; cancer; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..2271
FT /*tag= a
XX
XX WO9808955-A1.
XX
XX 05-MAR-1998.
XX
XX 26-AUG-1997; 97WO-US015003.
XX
XX 26-AUG-1996; 96US-00697393.
XX
XX 13-AUG-1997; 97US-00910820.
XX
XX (SIGN-) SIGNAL PHARM INC.
XX
XX Mercurio F, Zhu H, Barbosa M, Li G, Murray BW;
XX
XX WPI: 1998-179440/16.
XX
XX P-PSDB; AAW56328.
XX
PT New isolated stimulus-inducible I-kappa-B kinase signalosome - useful for
PT developing products for treating, e.g. inflammatory neuro-degenerative
PT and auto-immune diseases.
XX
XX Disclosure; Page 58-60; 115pp; English.
XX
XX The present sequence encodes an inhibitory subunit I-kappa-B kinase (IKK)
XX 2. IKK kinases, when incorporated into an IKK signalosome, are capable of
XX phosphorylating inhibitory subunit I-kappa-B-alpha, at serine residues 32
XX and 36. I-kappa-B-alpha retains nuclear factor (NF) kappa-B in the
XX cytoplasm. I-kappa-B proteins contain 5-7 ankyrin-like repeats which are
XX required for association with the NF-kappa-B/Rel dimer and for inhibitory
XX activity. A stimulus-inducible IKK "signalosome" is described that is
XX capable of specifically phosphorylating I-kappa-B-alpha at residues S32
XX and S36, without the addition of exogenous cofactors. The proteins of the
XX invention can be used to identify agents that inhibit or stimulate signal
XX transduction via the NF-kappa-B cascade. Therapeutic compositions
XX comprising such agents may be used for treating a patient afflicted with
XX a disorder associated with the activation of an IKK signalosome. The
XX agents may be used to treat, e.g. inflammatory, neurodegenerative
XX diseases and autoimmune diseases, cancer and viral infections. The
XX antibodies may be used in a kit for detecting IKK signalosome activity in
XX a sample
XX
SQ Sequence 2271 BP; 604 A; 569 C; 661 G; 437 T; 0 U; 0 Other;
Query Match 100.0%; Score 90; DB 2; Length 2271;
Best Local Similarity 100.0%; Pred. No. 1.7e-19;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
QY 61 AAGCAGGGGGGAACGCTGGACGACCTAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAG 1692

Search completed: September 23, 2004, 19:55:55

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2004, 14:33:31 ; Search time 2490 Seconds
(without alignments)
1079.356 Million cell updates/sec

Title: US-09-806-701-15_COPY_991_1080

Perfect score: 90
Sequence: 1 gaacggtatgctctgca.....gaacgtggacacactagag 90

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: em_estba.*

2: em_esthum.*

3: em_estin.*

4: em_estmu.*

5: em_estov.*

6: em_estpl.*

7: em_estro.*

8: em_hci.*

9: gb_est1.*

10: gb_est2.*

11: gb_hci.*

12: gb_est3.*

13: gb_est4.*

14: gb_est5.*

15: em_estfun.*

16: em_estom.*

17: em_gss_hum.*

18: em_gss_inv.*

19: em_gss_pln.*

20: em_gss_vrt.*

21: em_gss_fun.*

22: em_gss_mam.*

23: em_gss_mus.*

24: em_gss_pro.*

25: em_gss_rod.*

26: em_gss_phg.*

27: em_gss_vrl.*

28: gb_gss1.*

29: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	90	100.0	588	12	BG336659 602405777
2	90	100.0	589	12	BG107446 602277558
3	90	100.0	727	10	BE384533 601277926
4	90	100.0	745	12	BI084392 602869515

5	90	100.0	868	14	CD251031
6	90	100.0	944	13	BU857051
7	90	100.0	974	13	BQ669894
c 8	90	100.0	1201	9	AL542182
c 9	88.4	98.2	878	13	BQ877352
c 10	86.8	96.4	557	10	BF590924
c 11	86	95.6	402	10	BE077902
c 12	86	95.6	501	28	AQ827088
c 13	86	95.6	864	14	CD299893
c 14	81.6	90.7	400	9	AI906358
c 15	79	87.8	401	10	AW997999
c 16	78	86.7	736	14	CA429223
c 17	78	86.7	789	10	BE734952
c 18	77.2	85.8	558	12	BI296436
c 19	77.2	85.8	558	12	BI296613
c 20	77.2	85.8	565	12	BI291377
c 21	77.2	85.8	714	14	CF113406
c 22	76.4	84.9	946	13	BU558245
c 23	74	82.2	575	12	BG087220
c 24	74	82.2	738	14	CF537632
c 25	74	82.2	741	10	BE310997
c 26	74	82.2	765	14	CD805176
c 27	74	82.2	943	13	BU511732
c 28	74	82.2	2193	11	BC004772
c 29	71	78.9	302	10	BF916026
c 30	69.8	77.6	465	10	AW656805
c 31	69.6	77.3	559	9	AA128064
c 32	69.2	76.9	732	13	BY764258
c 33	68.2	75.8	390	12	BI976355
c 34	68.2	75.8	506	10	BF602600
c 35	68	75.6	393	9	AI906367
c 36	67.4	74.9	300	10	BF915824
c 37	66.2	73.6	718	10	BE687229
c 38	62.4	69.3	949	12	BG476715
c 39	62	68.9	342	10	BF834440
c 40	55.4	61.6	703	13	BU475878
c 41	54.6	60.7	622	12	BM489568
c 42	54.6	60.7	690	13	BU372250
c 43	54.6	60.7	780	13	BU373892
c 44	47.8	53.1	958	14	CA981256
c 45	43	47.8	616	10	AW955375

ALIGNMENTS

RESULT 1	BG336659	588 bp	linear	EST 27-FEB-2001
LOCUS	602405777F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:4543218 5',			
DEFINITION	mRNA sequence.			
ACCESSION	BG336659			
VERSION	BG336659.1			
KEYWORDS	EST.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
REFERENCE	1 (bases 1 to 588)			
AUTHORS	NIH-MGC http://mgc.nci.nih.gov/ .			
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)			
JOURNAL	Unpublished (1999)			
COMMENT	Contact: Robert Strausberg, Ph.D. Email: cgapbs-remail.nih.gov Tissue Procurement: ATCC CDNA Library Preparation: Ling Hong/Rubin Laboratory CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Incyte Genomics, Inc. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Plate: LLCM1224 row: j column: 19 High quality sequence stop: 588.			

FEATURES
source

Location/Qualifiers
1. .589
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4543218"
/tissue_type="choriocarcinoma"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 21"
/note="Organ: Placenta; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 100.0%; Score 90; DB 12; Length 589;
Best Local Similarity 100.0%; Pred. No. 7.2e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
|||||
Db 459 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 518
|||||

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
|||||
Db 519 AAGCAGGGGGAACGCTGGACGACCTAGAG 548
|||||

RESULT 2
BG107446 589 bp mRNA linear EST 30-JAN-2001
LOCUS 602277558F1 NIH_MGC_86 Homo sapiens cDNA clone IMAGE:4365254 5',
DEFINITION mRNA sequence.
ACCESSION BG107446
VERSION BG107446.1 GI:12601292
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 589)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Plate: LLAM10014 row: c column: 15
High quality sequence stop: 419.

FEATURES
source
1. .589
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4365254"
/tissue_type="osteosarcoma, cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 86"
/note="Organ: bone; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally; oligo-dT primed. Average insert size 1.533 kb. Library enriched for full-length clones and constructed by Life Technologies. Note: this is a NIH_MGC Library."

ORIGIN

Query Match 100.0%; Score 90; DB 12; Length 589;
Best Local Similarity 100.0%; Pred. No. 7.2e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
|||||
Db 42 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 101
|||||

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
|||||
Db 102 AAGCAGGGGGAACGCTGGACGACCTAGAG 131
|||||

RESULT 3
BE384533 727 bp mRNA linear EST 21-JUL-2000
LOCUS 601277926F1 NIH_MGC_20 Homo sapiens cDNA clone IMAGE:3618751 5',
DEFINITION mRNA sequence.
ACCESSION BE384533
VERSION BE384533.1 GI:9329898
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 727)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: ATCC/DCTD/BTP
CDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
Plate: LLCW288 row: c column: 08
High quality sequence stop: 614.

FEATURES
source
1. .727
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:3618751"
/tissue_type="melanotic melanoma"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 20"
/note="Organ: skin; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

ORIGIN

Query Match 100.0%; Score 90; DB 10; Length 727;
Best Local Similarity 100.0%; Pred. No. 7.8e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
|||||
Db 356 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 415
|||||

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
|||||
Db 416 AAGCAGGGGGAACGCTGGACGACCTAGAG 445
|||||

```
RESULT 4
BI084392      745 bp  mRNA  linear  EST 20-JUN-2001
LOCUS        602869515F1 NIH_MGC_102 Homo sapiens cDNA clone IMAGE:5014442 5',
DEFINITION   mRNA sequence.
ACCESSION    BI084392
VERSION      BI084392.1 GI:14502722
KEYWORDS     EST.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 745)
AUTHORS      NIH-MGC http://mgc.nci.nih.gov/.
TITLE        National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL      Unpublished (1999)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgapbs-r@mail.nih.gov
              Tissue Procurement: ATCC
              CDNA Library Preparation: CLONETECH Laboratories, Inc.
              CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
              DNA Sequencing by: Incyte Genomics, Inc.
              Clone distribution: MGC clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL at:
              http://image.llnl.gov
              Plate: LLCM1821 row: m column: 03
              High quality sequence stop: 744.
              Location/Qualifiers
                source          1..745
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="IMAGE:5014442"
                /tissue_type="epidermoid carcinoma, cell line"
                /lab_host="DH10B (phage-resistant)"
                /clone_lib="NIH_MGC_102"
                /note="Organ: salivary gland; Vector: pOTB7; Site_1: XhoI;
                Site_2: EcoRI; cDNA made by oligo-dT priming.
                Directionally cloned into EcoRI/XhoI sites using the
                following 5' adaptor: GGCAGAG(G). Library constructed
                by Ling Hong in the laboratory of Gerald M. Rubin
                (University of California, Berkeley) using ZAP-cDNA
                synthesis kit (Stratagene) and Superscript II RT (Life
                Technologies). Note: this is a NIH_MGC Library."

ORIGIN
Query Match      100.0%; Score 90; DB 12; Length 745;
Best Local Similarity 100.0%; Pred. No. 7.8e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCACACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
    |||
Db 180 GAACGGATGATGGCTCTGCACACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 239
    |||

Qy 61 AAGCAGGGGGGAACGCTGGAGCCTAGAG 90
    |||
Db 240 AAGCAGGGGGGAACGCTGGAGCCTAGAG 269

RESULT 5
CD251031      868 bp  mRNA  linear  EST 22-MAY-2003
LOCUS        AGENCOURT_14214315 NIH_MGC_179 Homo sapiens cDNA clone
DEFINITION   IMAGE:30385244 5', mRNA sequence.
ACCESSION    CD251031
VERSION      CD251031.1 GI:31011497
KEYWORDS     EST.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 868)
AUTHORS      NIH-MGC http://mgc.nci.nih.gov/.
```

```
TITLE        National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL      Unpublished (1999)
COMMENT      Contact: Daniela S. Gerhard, Ph.D.
              Office of Cancer Genomics
              National Cancer Institute / NIH
              Bldg. 31 Rm10A07 Bethesda, MD 20892
              Email: cgapbs-r@mail.nih.gov
              Tissue Procurement: Dr. Michael Brownstein
              CDNA Library Preparation: Invitrogen Corp
              CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
              DNA Sequencing by: Agencourt Bioscience Corporation
              Clone distribution: MGC clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL at:
              http://image.llnl.gov
              Plate: NDAM451 row: p column: 21
              High quality sequence stop: 687.
              Location/Qualifiers
                source          1..868
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="IMAGE:30385244"
                /tissue_type="Pituitary"
                /lab_host="DH10B-Ton A ( T1 and T5 phage resistances)"
                /clone_lib="NIH_MGC_179"
                /note="Organ: brain; Vector: pCMV-SPORT6.1; Site_1: EcoRV
                (destroyed); Site_2: NotI; Library is oligo-dT primed and
                directionally cloned (EcoRV site is destroyed upon
                cloning). Average insert size 1.1 kb. Library was
                constructed by (Invitrogen). Note: this is a NIH_MGC
                Library."

ORIGIN
Query Match      100.0%; Score 90; DB 14; Length 868;
Best Local Similarity 100.0%; Pred. No. 8.3e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCACACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
    |||
Db 101 GAACGGATGATGGCTCTGCACACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 160
    |||

Qy 61 AAGCAGGGGGGAACGCTGGAGCCTAGAG 90
    |||
Db 161 AAGCAGGGGGGAACGCTGGAGCCTAGAG 190

RESULT 6
BU857051      944 bp  mRNA  linear  EST 16-OCT-2002
LOCUS        AGENCOURT_10480781 NIH_MGC_107 Homo sapiens cDNA clone
DEFINITION   IMAGE:6646854 5', mRNA sequence.
ACCESSION    BU857051
VERSION      BU857051.1 GI:24042041
KEYWORDS     EST.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 944)
AUTHORS      NIH-MGC http://mgc.nci.nih.gov/.
TITLE        National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL      Unpublished (1999)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgapbs-r@mail.nih.gov
              Tissue Procurement: ATCC
              CDNA Library Preparation: Rubin Laboratory
              CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
              DNA Sequencing by: Agencourt Bioscience Corporation
              Clone distribution: MGC clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL at:
              http://image.llnl.gov
              Plate: LLCM2886 row: f column: 06
              High quality sequence stop: 718.
```

FEATURES
source

Location/Qualifiers
1. 944
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6646854"
/tissue_type="adenocarcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 107"
/note="Organ: breast; Vector: pOTB7; Site_1: EcoRI; Site_2: XhoI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."

ORIGIN

Query Match 100.0%; Score 90; DB 13; Length 944;
Best Local Similarity 100.0%; Pred. No. 8.5e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 60
|||||
Db 213 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 272
QY 61 AAGCAGGGGGGACGCTGGACGACCTAGAG 90
|||||
Db 273 AAGCAGGGGGGACGCTGGACGACCTAGAG 302

RESULT 7
BQ659894
LOCUS

DEFINITION BQ659894 974 bp mRNA linear EST 15-JUL-2002
AGENCY: 8184827 NIH_MGC_102 Homo sapiens cDNA clone IMAGE:6257524
5', mRNA sequence.
ACCESSION BQ659894
VERSION BQ659894.1 GI:21780728
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 974)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLCM2411 row: p column: 05
High quality sequence stop: 527.

FEATURES
source

Location/Qualifiers
1. 974
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6257524"
/tissue_type="epidermoid carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 102"
/note="Organ: salivary gland; Vector: pOTB7; Site_1: XhoI; Site_2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin

ORIGIN

Query Match 100.0%; Score 90; DB 13; Length 974;
Best Local Similarity 100.0%; Pred. No. 8.6e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 60
|||||
Db 178 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 237
QY 61 AAGCAGGGGGGACGCTGGACGACCTAGAG 90
|||||
Db 238 AAGCAGGGGGGACGCTGGACGACCTAGAG 267

RESULT 8
AL542182/c

LOCUS AL542182 1201 bp mRNA linear EST 12-MAY-2003
DEFINITION AL542182 Homo sapiens PLACENTA Homo sapiens cDNA clone CS0DE008YM17
3-PRIME, mRNA sequence.
ACCESSION AL542182
VERSION AL542182.2 GI:30547081
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 15, 2001 this sequence version replaced gi:12873974.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 4655.r For more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DE008AG09NP1&cluster=4655.r. Contact :
Peng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DE008AG09NP1.

FEATURES
source

Location/Qualifiers
1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DE008YM17"
/tissue_type="PLACENTA"
/note="Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

ORIGIN

Query Match 100.0%; Score 90; DB 9; Length 1201;
Best Local Similarity 100.0%; Pred. No. 9.2e-15;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 60
|||||
Db 658 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCCG 599
QY 61 AAGCAGGGGGGACGCTGGACGACCTAGAG 90
|||||
Db 598 AAGCAGGGGGGACGCTGGACGACCTAGAG 569

(University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."

```

RESULT 9
BO877352
LOCUS
DEFINITION BO877352 878 bp mRNA linear EST 16-AUG-2002
5', mRNA sequence.
AGENCOURT_8072483 NIH_MGC_110 Homo sapiens cDNA clone IMAGE:6084011
BO877352
VERSION BO877352.1 GI:22269360
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 878)
TITLE NIH-MGC http://mgc.nci.nih.gov/.
JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLCW2315 row: b column: 12
High quality sequence stop: 621.
FEATURES
location/Qualifiers
1..878
source
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6084011"
/tissue_type="ductal carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_110"
/notes="Organ: pancreas; Vector: pOTF7; Site:1: XhoI;
Site 2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Library constructed by
Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC Library."
ORIGIN
Query Match 98.2%; Score 88.4; DB 13; Length 878;
Best Local Similarity 98.9%; Pred. No. 2.3e-14;
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GAACGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCCATGGGCCGG 60
Db 551 GAACGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCCATGGGCCGG 610
QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 611 AAGCAGGGGGGAACGCTGGACGACCTAAAG 640
RESULT 10
BF590924/c
LOCUS
DEFINITION BF590924 557 bp mRNA linear EST 12-DEC-2000
7b46b08.x1 NCI_CGAP Col6 Homo sapiens cDNA clone IMAGE:3318999 3',
similar to TR:075327 075327 1KB KINASE BETA SUBUNIT. [1] ;, mRNA
sequence.
BF590924
VERSION BF590924.1 GI:11683248
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 402)
TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 557)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: Ilan Kirsch, M.D., Michael R. Emmert-Buck,
M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL, send email to:
info@image.llnl.gov
Seq primer: -400P from Gibco
High quality sequence stop: 402.
FEATURES
location/Qualifiers
1..557
source
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:3318999"
/tissue_type="colon tumor, RER+"
/lab_host="DH10B"
/clone_lib="NCI_CGAP Col6"
/notes="Organ: colon; Vector: pT7T3D-Pac (Pharmacia) with a
modified polylinker; Site_1: Not I; Site_2: Eco RI;
Plasmid DNA from the normalized library NCI_CGAP Col6 was
prepared, and ss circles were made in vitro. Following HAP
purification, this DNA was used as tracer in a subtractive
hybridization reaction. The driver was PCR-amplified cDNAs
from a pool of 5,000 clones made from the same library
(cloneIDs 1057416-1061255, and 1144584-1145351)
Subtraction by Bento Soares and M. Fatima Ronaldo. "
ORIGIN
Query Match 96.4%; Score 86.8; DB 10; Length 557;
Best Local Similarity 97.8%; Pred. No. 5.5e-14;
Matches 88; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 GAACGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCCATGGGCCGG 60
Db 332 GAACGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCCATGGGCCGG 273
QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 272 AAGCAGGGGGGAACGCTGGCTCGACCTAGAG 243
RESULT 11
BE077902
LOCUS
DEFINITION BE077902 402 bp mRNA linear EST 09-JUN-2000
CW1-BT0614-110300-142-c10 BT0614 Homo sapiens cDNA, mRNA sequence.
BE077902
ACCESSION BE077902
VERSION BE077902.1 GI:8429180
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 402)
TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663

```

PUBMED
COMMENT

10737800
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/ILICR Human Cancer Genome
Project. This entry can be seen in the following URL
(<http://www.ludwig.org.br/scripts/gethtml2.pl?tl=6t2-CM1-BT0614-110>
300-142-cl0&t3=2000-03-11&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 8
High quality sequence stop: 402.

FEATURES
source

1..402
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone_lib="BT0614"
/note="Organ: breast; Vector: puc18; Site 1: SmaI; Site 2:
SmaI; A mini-library was made by cloning products derived
from ORESTES PCR (U.S. Letters Patent application No.
196,716 - Ludwig Institute for Cancer Research) profiles
into the pUC 18 vector. Reverse transcription of tissue
mRNA and cDNA amplification were performed under low
stringency conditions."

ORIGIN

Query Match 95.6%; Score 86; DB 10; Length 402;
Best Local Similarity 100.0%; Pred. No. 8.2e-14;
Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 109 GAACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGCGCG 168

QY 61 AAGCAGGGGGAGCGCTGGACGACCT 86
Db 169 AAGCAGGGGGAGCGCTGGACGACCT 194

RESULT 12
AQ827088/c

LOCUS
DEFINITION
HS_5291_B1_H08_T7A_RPCI-11 Human Male BAC Library Homo sapiens
Genomic clone Plate=867 Col=15 Row=P, genomic survey sequence.
ACCESSION
AQ827088
VERSION
AQ827088.1 GI:5793150
KEYWORDS
GSS.
SOURCE
Homo sapiens (human)
ORGANISM

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Mahairas, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
Hood, L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
10449764

COMMENT

Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu

Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering/bac.htm>)
or from Research Genetics (<http://www.hsc.washington.edu>). BAC end Web Server:
<http://www.hsc.washington.edu>
Plate: 867 row: P column: 15
Seq primer: T7
Class: BAC ends
High quality sequence stop: 501.

FEATURES
source

1..501
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone_lib="Plate=867 Col=15 Row=P"
/sex="male"
/clone_lib="RPCI-11 Human Male BAC Library"
/note="Vector: pBACe3.6; Site 1: EcoRI; Site 2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRI Methyase. Size selected DNA was cloned into the
pBACe3.6 vector at EcoRI sites"

ORIGIN

Query Match 95.6%; Score 86; DB 28; Length 501;
Best Local Similarity 100.0%; Pred. No. 8.9e-14;
Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 329 GAACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGCGCG 270

QY 61 AAGCAGGGGGAGCGCTGGACGACCT 86
Db 269 AAGCAGGGGGAGCGCTGGACGACCT 244

RESULT 13
CD299893

LOCUS
DEFINITION
AGENCOURT_14251668 NIH MGC 180 Homo sapiens cDNA clone
IMAGE:30388043 5', mRNA sequence.
ACCESSION
CD299893
VERSION
CD299893.1 GI:31079688
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 864)
NIH-MGC <http://mgc.nci.nih.gov/>.
National Institutes of Health, Mammalian Gene Collection (MGC)
Contact: Daniela S. Gerhard, Ph.D.
Office of Cancer Genomics
National Cancer Institute / NIH
Bldg. 31 Rm10A07 Bethesda, MD 20892
Email: cgabs-r@mail.nih.gov
Tissue Procurement: Dr. Michael Brownstein
cDNA Library Preparation: Invitrogen Corp
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
Plate: NDAM459 row: e column: 12
High quality sequence stop: 566.

FEATURES
source

1..864
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

/clone="IMAGE:30388043"
 /lab_host="DH10B-Ton A (T1 and T5 phage resistances)"
 /clone_lib="NIH MGC 180"
 /note="Organ: Testis; Vector: pCMV-SPORT6.1; Site 1: NotI;
 Site 2: EcoRV (destroyed); Library is oligo-dT primed and
 directionally cloned (EcoRV site is destroyed upon
 cloning). Average insert size 1.68 kb. Library was
 constructed by (Invitrogen). Note: this is a NIH_MGC
 Library."

ORIGIN

Query Match 95.6%; Score 86; DB 14; Length 864;
 Best Local Similarity 100.0%; Pred. No. 1.1e-13;
 Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGATGATGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 |||||
 Db 221 GAACGATGATGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGGCGG 280
 |||||

QY 61 AAGCAGGGGGGAACGCTGGACGACCT 86
 Db 281 AAGCAGGGGGGAACGCTGGACGACCT 306

RESULT 14

AI906358 400 bp mRNA linear EST 30-MAR-2000
 LOCUS RC-BT108-040399-031 BT108 Homo sapiens cDNA, mRNA sequence.
 DEFINITION
 ACCESSION AI906358
 VERSION AI906358.1 GI:6496745
 KEYWORDS EST.
 SOURCE Homo sapiens (human)

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

AUTHORS
 Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
 Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
 Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
 Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V.,
 O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
 Simpson,A.J.
 Shotgun sequencing of the human transcriptome with ORF expressed

TITLE

sequence tags
 Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
 20202663
 10737800

JOURNAL

MEDLINE

PUBMED

COMMENT
 Contact: Simpson A.J.G.
 Laboratory of Cancer Genetics
 Ludwig Institute for Cancer Research
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
 Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome
 Project. This entry can be seen in the following URL
 (http://www.ludwig.org.br/seq/gethtml.pl?t1=RC&t2=RC-BT108-031.html
 &t3=040399&t4=1)

Seq primer: puc 18 forward.

FEATURES

source

1. 400
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /sex="female"
 /dev_stage="Adult"
 /clone_lib="BT108"

/note="Organ: breast; Vector: puc18; Site 1: SmaI; Site 2:
 SmaI; A mini-library was made by cloning products derived
 from ORESTES PCR (U.S. Letters Patent application No.
 196,716 - Ludwig Institute for Cancer Research) profiles
 into the pUC 18 vector. Reverse transcription of tissue

ORIGIN

Query Match 90.7%; Score 81.6; DB 9; Length 400;
 Best Local Similarity 95.5%; Pred. No. 1.4e-12;
 Matches 84; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 ACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGGCGGAA 62
 |||||
 Db 1 ACGGATGATGGCTCTGCAGACGACATTGTGGACTTACAGAGAGCCCATGGGCGGAA 60
 |||||

QY 63 GCAGGGGGGAACGCTGGACGACCTAGAG 90
 Db 61 GCAGGGGGGAACGCTGGACGACCTAGAG 88

RESULT 15

AW997999 401 bp mRNA linear EST 05-JUN-2000
 LOCUS RCL-BN0056-230200-021-b11 BN0056 Homo sapiens cDNA, mRNA sequence.
 DEFINITION
 ACCESSION AW997999
 VERSION AW997999.1 GI:8258233
 KEYWORDS EST.
 SOURCE Homo sapiens (human)

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

AUTHORS
 1. (bases 1 to 401)
 Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
 Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
 Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
 Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V.,
 O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
 Simpson,A.J.
 Shotgun sequencing of the human transcriptome with ORF expressed

TITLE

sequence tags
 Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
 20202663
 10737800

JOURNAL

MEDLINE

PUBMED

COMMENT
 Contact: Simpson A.J.G.
 Laboratory of Cancer Genetics
 Ludwig Institute for Cancer Research
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
 Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome
 Project. This entry can be seen in the following URL
 (http://www.ludwig.org.br/scripts/gethtml2.pl?ti=&t2=RCL-BN0056-230
 200-021-b11&t3=2000-02-23&t4=1)

Seq primer: puc 18 forward

High quality sequence start: 15

High quality sequence stop: 401.

FEATURES

source

Location/Qualifiers
 1. 401
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /dev_stage="Adult"
 /clone_lib="BN0056"

/note="Organ: breast normal; Vector: puc18; Site 1: SmaI;
 Site 2: SmaI; A mini-library was made by cloning products
 derived from ORESTES PCR (U.S. Letters Patent application
 No. 196,716 - Ludwig Institute for Cancer Research)
 profiles into the pUC 18 vector. Reverse transcription of
 tissue mRNA and cDNA amplification were performed under
 low stringency conditions."

ORIGIN

Query Match 87.8%; Score 79; DB 10; Length 401;
 Best Local Similarity 98.9%; Pred. No. 7.3e-12;

mRNA and cDNA amplification were performed under low
 stringency conditions."

Matches	90;	Conservative	0;	Mismatches	0;	Indels	1;	Gaps	1;
Qy	1	GAACGGATGATGGCTCTGCGAG-ACCGACATTGTGGACTTACAGAGGAGCCCCCATGGCGG	59						
Db	43	GAACGGATGATGGCTCTGCGAGAACCGACATTGTGGACTTACAGAGGAGCCCCCATGGCGG	102						
Qy	60	GAAGCAGGGGGGAACGCTGGACGACCTAGAG	90						
Db	103	GAAGCAGGGGGGAACGCTGGACGACCTAGAG	133						

Search completed: September 23, 2004, 21:02:15
 Job time : 2495 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2004, 19:41:56 ; Search time 369 Seconds
(without alignments)
135.354 Million cell updates/sec

Title: US-09-806-701-15_COPY_991_1080

Perfect score: 90
Sequence: 1 gaacgatgatgctctgca.....gaacgtggacgacctagag 90

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents NA.*
- 1: /cgn2_6/ptodata/2/ina/5A_COMB.seq.*
 - 2: /cgn2_6/ptodata/2/ina/5B_COMB.seq.*
 - 3: /cgn2_6/ptodata/2/ina/6A_COMB.seq.*
 - 4: /cgn2_6/ptodata/2/ina/6B_COMB.seq.*
 - 5: /cgn2_6/ptodata/2/ina/PCTUS_COMB.seq.*
 - 6: /cgn2_6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	90	100.0	1055	3	US-09-215-131-3
2	90	100.0	1055	3	US-09-222-734-3
3	90	100.0	2268	2	US-08-890-853-1
4	90	100.0	2268	2	US-09-099-125A-1
5	90	100.0	2268	2	US-09-099-124A-1
6	90	100.0	2268	2	US-09-197-008-1
7	90	100.0	2268	3	US-09-032-476-1
8	90	100.0	2268	3	US-08-890-854-1
9	90	100.0	2268	3	US-09-023-324-1
10	90	100.0	2268	4	US-09-109-986-1
11	90	100.0	2271	3	US-08-910-820-8
12	90	100.0	2271	4	US-09-844-908-8
13	90	100.0	2931	3	US-09-168-629-14
14	90	100.0	3966	3	US-09-215-131-1
15	90	100.0	3966	3	US-09-222-734-1
16	35.6	39.6	1874	4	US-09-536-882A-6
17	35.6	39.6	2025	3	US-09-160-483-2
18	35.6	39.6	3314	4	US-09-536-882A-5
19	34.6	38.4	2146	3	US-09-032-476-5
20	34.6	38.4	2146	3	US-08-890-854-5
21	34.6	38.4	2146	4	US-09-023-324-5
22	34.6	38.4	2146	4	US-09-109-986-5
23	34.6	38.4	2238	2	US-08-890-853-3
24	34.6	38.4	2238	2	US-09-099-125A-3
25	34.6	38.4	2238	2	US-09-099-124A-3
26	34.6	38.4	2238	3	US-09-032-476-3
27	34.6	38.4	2238	3	US-08-890-854-3

28	34.6	38.4	2238	3	US-09-023-324-3	Sequence 3, Appli
29	34.6	38.4	2238	4	US-09-109-986-3	Sequence 3, Appli
30	34.6	38.4	2251	3	US-08-910-820-7	Sequence 7, Appli
31	34.6	38.4	2251	4	US-09-844-908-7	Sequence 7, Appli
32	34.6	38.4	2273	3	US-09-168-629-1	Sequence 1, Appli
33	34.6	38.4	2273	3	US-08-810-131A-1	Sequence 1, Appli
34	33	36.7	2273	2	US-09-197-360-1	Sequence 1, Appli
35	33	36.7	2273	4	US-09-856-074B-1	Sequence 1, Appli
36	33	36.7	2291	4	US-09-417-197-120	Sequence 122, App
37	33	36.7	2294	4	US-09-417-197-120	Sequence 15957, A
38	30.2	33.6	909	4	US-09-252-991A-15957	Sequence 16324, A
39	30.2	33.6	1221	4	US-09-252-991A-16324	Sequence 29, Appl
40	29.2	32.4	1074	2	US-08-463-081B-29	Sequence 29, Appl
41	29.2	32.4	1074	2	US-08-461-379A-29	Sequence 29, Appl
42	29.2	32.4	1074	2	US-08-462-390B-29	Sequence 29, Appl
43	29.2	32.4	1074	3	US-08-463-074B-29	Sequence 29, Appl
44	29.2	32.4	1074	3	US-08-465-585C-29	Sequence 29, Appl
45	29.2	32.4	1074	3	US-08-652-446-29	Sequence 29, Appl

ALIGNMENTS

RESULT 1
US-09-215-131-3
; Sequence 3, Application US/09215131
; Patent No. 6030834
; GENERAL INFORMATION:
; APPLICANT: Chu, Keting
; APPLICANT: Pot, David
; TITLE OF INVENTION: IKK Beta Regulates Transcription Factors
; FILE REFERENCE: 1449.002
; CURRENT APPLICATION NUMBER: US/09/215,131
; CURRENT FILING DATE: 1998-12-18
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 1055
; TYPE: DNA
; ORGANISM: human
US-09-215-131-3

Query Match 100.0%; Score 90; DB 3; Length 1055;
Best Local Similarity 100.0%; Pred. No. 1.7e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GAACGATGATGCTCTGCAGACCGCATTTGGACTTACAGAGAGCCCATGGGCCGG 60
DB	322	GAACGATGATGCTCTGCAGACCGCATTTGGACTTACAGAGAGCCCATGGGCCGG 381
QY	61	AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
DB	382	AAGCAGGGGGGAACGCTGGACGACCTAGAG 411

RESULT 2
US-09-222-734-3
; Sequence 3, Application US/09222734A
; Patent No. 6077701
; GENERAL INFORMATION:
; APPLICANT: Chu, Keting
; APPLICANT: Pot, David
; TITLE OF INVENTION: IKK-beta Regulates Transcription Factors
; FILE REFERENCE: 12441.78080
; CURRENT APPLICATION NUMBER: US/09/222,734A
; CURRENT FILING DATE: 1998-12-29
; EARLIER APPLICATION NUMBER: 09/215,131
; EARLIER FILING DATE: 1998-12-18
; EARLIER APPLICATION NUMBER: 60/068,954
; EARLIER FILING DATE: 1997-12-30
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3

```
; LENGTH: 1055
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-222-734-3

Query Match      100.0%; Score 90; DB 3; Length 1055;
Best Local Similarity 100.0%; Pred. No. 1.7e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 322 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 381

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 382 AAGCAGGGGGAACGCTGGACGACCTAGAG 411

RESULT 3
US-08-890-853-1
; Sequence 1, Application US/08890853
; Patent No. 5851812
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Woronicz, John
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,853
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2268 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-890-853-1

Query Match      100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 1662

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 4
US-08-890-853-1

Query Match      100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 1662

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGAACGCTGGACGACCTAGAG 1692
```

```
US-09-099-125A-1
; Sequence 1, Application US/09099125A
; Patent No. 5916760
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Woronicz, John
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/099,125A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,853
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2268 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-09-099-125A-1

Query Match      100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 1662

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 5
US-09-099-124A-1
; Sequence 1, Application US/09099124A
; Patent No. 5939302
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Woronicz, John
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/099,124A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,853
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2268 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-09-099-124A-1

Query Match 100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 6
US-09-197-008-1
; Sequence 1, Application US/09197008
; Patent No. 5977341
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION
; FILE REFERENCE: RTS-0019
; CURRENT APPLICATION NUMBER: US/09/197,008
; CURRENT FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 1
; LENGTH: 2268
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(2268)
; US-09-197-008-1

Query Match 100.0%; Score 90; DB 2; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

```

```

RESULT 7
US-09-032-476-1
; Sequence 1, Application US/09032476
; Patent No. 6235492
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Cao, Zhaodan
; APPLICANT: R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/032,476
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/890,854
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2268 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-09-032-476-1

Query Match 100.0%; Score 90; DB 3; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 8
US-08-890-854-1
; Sequence 1, Application US/08890854
; Patent No. 6235512
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Cao, Zhaodan
; APPLICANT: R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO

```

STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/890,854
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: T97-006-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 343-4341
TELEFAX: (415) 343-4342
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2268 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-890-854-1

Query Match 100.0%; Score 90; DB 3; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGCCCATGGGCCGG 60
|||||
Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
|||||
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 9
US-09-023-324-1
Sequence 1, Application US/09023324
Patent No. 6235513
GENERAL INFORMATION:
APPLICANT: Rothe, Mike
APPLICANT: Cao, Zhaodan
APPLICANT: R gnier, Catherine
TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 268 BUSH STREET, SUITE 3200
CITY: SAN FRANCISCO
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/023,324
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/890,854
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627

REFERENCE/DOCKET NUMBER: T97-006-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 343-4341
TELEFAX: (415) 343-4342
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2268 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-023-324-1

Query Match 100.0%; Score 90; DB 3; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGCCCATGGGCCGG 60
|||||
Db 1603 GAACGGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
|||||
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 10
US-09-109-986-1
Sequence 1, Application US/09109986
Patent No. 6479266
GENERAL INFORMATION:
APPLICANT: Rothe, Mike
APPLICANT: Cao, Zhaodan
APPLICANT: R gnier, Catherine
TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 268 BUSH STREET, SUITE 3200
CITY: SAN FRANCISCO
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/109,986
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/890,854
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: T97-006-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 343-4341
TELEFAX: (415) 343-4342
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2268 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-109-986-1

Query Match 100.0%; Score 90; DB 4; Length 2268;
Best Local Similarity 100.0%; Pred. No. 2e-20;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662
 QY 61 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 90
 Db 1663 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 1692

RESULT 11

US-08-910-820-8
 ; Sequence 8, Application US/08910820
 ; Patent No. 6258579
 ; GENERAL INFORMATION:
 ; APPLICANT: Mercurio, Frank
 ; APPLICANT: Zhu, Hengyi
 ; APPLICANT: Barbosa, Miguel
 ; APPLICANT: Li, Gian
 ; APPLICANT: Murray, Brian W.
 ; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
 ; TITLE OF INVENTION: COMPLEX AND METHODS OF USE THEREFOR
 ; NUMBER OF SEQUENCES: 25
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SEED and BERRY LLP
 ; STREET: 6300 Columbia Center, 701 Fifth Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/910,820
 ; FILING DATE: 12-AUG-1997
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Maki, David J.
 ; REGISTRATION NUMBER: 31,392
 ; REFERENCE/DOCKET NUMBER: 860098.413C1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 622-4900
 ; TELEFAX: (206) 682-6031
 ; INFORMATION FOR SEQ ID NO: 8:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2271 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-910-820-8
 Query Match 100.0%; Score 90; DB 3; Length 2271;
 Best Local Similarity 100.0%; Pred. No. 2e-20;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662
 QY 61 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 90
 Db 1663 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 1692

RESULT 12

US-09-844-908-8
 ; Sequence 8, Application US/09844908
 ; Patent No. 6576437
 ; GENERAL INFORMATION:

APPLICANT: Mercurio, Frank
 ; Zhu, Hengyi
 ; Barbosa, Miguel
 ; Li, Gian
 ; Murray, Brian W.
 ; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
 ; TITLE OF INVENTION: COMPLEX AND METHODS OF USE THEREFOR
 ; NUMBER OF SEQUENCES: 25
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SEED and BERRY LLP
 ; STREET: 6300 Columbia Center, 701 Fifth Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/844,908
 ; FILING DATE: 27-Apr-2001
 ; CLASSIFICATION: <Unknown>
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/910,820
 ; FILING DATE: 12-AUG-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Maki, David J.
 ; REGISTRATION NUMBER: 31,392
 ; REFERENCE/DOCKET NUMBER: 860098.413C1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 622-4900
 ; TELEFAX: (206) 682-6031
 ; INFORMATION FOR SEQ ID NO: 8:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2271 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-09-844-908-8
 Query Match 100.0%; Score 90; DB 4; Length 2271;
 Best Local Similarity 100.0%; Pred. No. 2e-20;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 60
 Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCGG 1662
 QY 61 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 90
 Db 1663 AAGCAGGGGGGAAACGCTGGACGACCTAGAG 1692

RESULT 13

US-09-168-629-14
 ; Sequence 14, Application US/09168629
 ; Patent No. 6242253
 ; GENERAL INFORMATION:
 ; APPLICANT: Karin, Michael
 ; APPLICANT: Didonato, Joseph A.
 ; APPLICANT: Rothwarf, David M.
 ; APPLICANT: Hayakawa, Makio
 ; APPLICANT: Zandi, Ebrahim
 ; TITLE OF INVENTION: Ikb Kinase, Subunits Thereof, and Methods of Using Same
 ; FILE REFERENCE: P-UD 3295
 ; CURRENT APPLICATION NUMBER: US/09/168,629
 ; CURRENT FILING DATE: 1998-10-08
 ; EARLIER APPLICATION NUMBER: 60/061,470
 ; EARLIER FILING DATE: 1997-10-09
 ; NUMBER OF SEQ ID NOS: 20

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 2931
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (36)..(2306)
US-09-168-629-14

Query Match      100.0%; Score 90; DB 3; Length 2931;
Best Local Similarity 100.0%; Pred. No. 2.1e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 60
Db 1638 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 60

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1698 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1727

RESULT 14
US-09-215-131-1
; Sequence 1, Application US/09215131
; Patent No. 6030834
; GENERAL INFORMATION:
; APPLICANT: Chu, Keting
; APPLICANT: Pot, David
; TITLE OF INVENTION: IKK Beta Regulates Transcription Factors
; FILE REFERENCE: 1449.002
; CURRENT APPLICATION NUMBER: US/09/215,131
; CURRENT FILING DATE: 1998-12-18
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 3966
; TYPE: DNA
; ORGANISM: human
US-09-215-131-1

Query Match      100.0%; Score 90; DB 3; Length 3966;
Best Local Similarity 100.0%; Pred. No. 2.3e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692

Search completed: September 23, 2004, 21:08:32
Job time : 370 secs
```

```
Query Match      100.0%; Score 90; DB 3; Length 3966;
Best Local Similarity 100.0%; Pred. No. 2.3e-20;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGATGGCTCTGACAGACCGACATTGTGGACTTACAGAGGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1692
```

```
RESULT 15
US-09-222-734-1
; Sequence 1, Application US/09222734A
; Patent No. 6077701
; GENERAL INFORMATION:
; APPLICANT: Chu, Keting
; APPLICANT: Pot, David
; TITLE OF INVENTION: IKK-beta Regulates Transcription Factors
; FILE REFERENCE: 12441.78080
; CURRENT APPLICATION NUMBER: US/09/222,734A
; CURRENT FILING DATE: 1998-12-29
; EARLIER APPLICATION NUMBER: 09/215,131
; EARLIER FILING DATE: 1998-12-18
; EARLIER APPLICATION NUMBER: 60/068,954
; EARLIER FILING DATE: 1997-12-30
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2004, 20:20:37 ; Search time 350 Seconds

(without alignments)
1302.416 Million cell updates/sec

Title: US-09-806-701-15_COPY_991_1080

Perfect score: 90
Sequence: 1 gaacgatgctgctgca.....gaacgtgacacctagag 90

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 3337386 seqs, 2532474682 residues

Total number of hits satisfying chosen parameters: 6674772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/2/pubpna/US09A_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/2/pubpna/US09B_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/2/pubpna/US09C_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
- 13: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq2:*
- 14: /cgn2_6/ptodata/2/pubpna/US10A_PUBCOMB.seq:*
- 15: /cgn2_6/ptodata/2/pubpna/US10B_PUBCOMB.seq:*
- 16: /cgn2_6/ptodata/2/pubpna/US10C_PUBCOMB.seq:*
- 17: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
- 18: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
- 19: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	90	100.0	506	10	US-09-918-995-24344
2	90	100.0	1558	15	Sequence 24344, A
3	90	100.0	2268	10	US-10-106-698-455
4	90	100.0	2268	15	US-09-847-946A-1
5	90	100.0	2268	15	US-10-156-610-1
6	90	100.0	2271	9	US-10-243-408-1
7	90	100.0	2271	9	US-09-844-908-8
8	90	100.0	2271	15	US-10-338-462-8
9	90	100.0	2331	9	US-09-796-872-14
10	90	100.0	4154	13	US-10-087-192-1757
11	86	95.6	81099	13	US-10-087-192-1756
12	77.2	85.8	3038	15	US-10-156-610-83
13	74	82.2	2274	15	US-10-156-610-48
14	74	82.2	3210	13	US-10-087-192-1754

15	70	77.8	67076	13	US-10-087-192-1753	Sequence 1753, Ap
16	35.6	39.6	1875	15	US-10-188-937A-6	Sequence 6, Appli
17	35.6	39.6	3314	15	US-10-188-937A-5	Sequence 5, Appli
18	34.6	38.4	2146	15	US-10-243-408-5	Sequence 5, Appli
19	34.6	38.4	2238	15	US-10-243-408-3	Sequence 3, Appli
20	34.6	38.4	2251	9	US-09-844-908-7	Sequence 7, Appli
21	34.6	38.4	2251	9	US-09-844-988-7	Sequence 7, Appli
22	34.6	38.4	2251	15	US-10-338-462-7	Sequence 7, Appli
23	34.6	38.4	2273	9	US-09-796-872-1	Sequence 1, Appli
24	34.6	38.4	3525	15	US-10-101-510-632	Sequence 632, App
25	34.6	38.4	3618	17	US-10-741-601-91	Sequence 91, Appl
26	33.6	37.3	53328	17	US-10-741-601-5639	Sequence 5639, Ap
27	33	36.7	2273	15	US-10-145-857-1	Sequence 1, Appli
28	33	36.7	2291	15	US-10-072-036-122	Sequence 122, App
29	33	36.7	2294	15	US-10-072-036-120	Sequence 120, App
30	30.6	34.0	649	13	US-10-027-632-115364	Sequence 115364,
31	30.6	34.0	649	13	US-10-027-632-115365	Sequence 115365,
32	30.6	34.0	649	13	US-10-027-632-115366	Sequence 115366,
33	30.6	34.0	649	16	US-10-027-632-115364	Sequence 115364,
34	30.6	34.0	649	16	US-10-027-632-115365	Sequence 115365,
35	30.6	34.0	649	16	US-10-027-632-115366	Sequence 115366,
36	30.6	34.0	715	13	US-10-425-114-18909	Sequence 18909, A
37	30.6	34.0	993	17	US-10-389-566-188	Sequence 188, App
38	30.2	33.6	1087	17	US-10-437-963-44491	Sequence 44491, A
39	30.2	33.6	1754	17	US-10-437-963-44490	Sequence 44490, A
40	29.8	32.7	3471	16	US-10-369-493-45054	Sequence 45054, A
41	29.4	32.7	366	15	US-10-156-761-2009	Sequence 2009, Ap
42	29.4	32.7	9025608	15	US-10-156-761-1	Sequence 1, Appli
43	29.2	32.4	780	17	US-10-437-963-3953	Sequence 3953, Ap
44	29.2	32.4	1077	11	US-09-826-509-558	Sequence 558, App
45	29.2	32.4	1345	9	US-09-853-450-7	Sequence 7, Appli

ALIGNMENTS

RESULT 1

US-09-918-995-24344
; Sequence 24344, Application US/0918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 24344
; LENGTH: 506
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(506)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-24344

Query Match	100.0%	Score 90;	DB 10;	Length 506;
Best Local Similarity	100.0%	Pred. No. 1.1e-21;		
Matches	90;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	GAACGATGATGGCTCTGACACCGACATTGTGACTTACAGAGGCCATGGCGG	60	
Db	64	GAACGATGATGGCTCTGACACCGACATTGTGACTTACAGAGGCCATGGCGG	123	
Qy	61	AAGCAGGGGGAACGCTGGACGACTAGAG	90	
Db	124	AAGCAGGGGGAACGCTGGACGACTAGAG	153	

RESULT 2

US-10-106-698-455
; Sequence 455, Application US/10106698
; Publication No. US20030109690A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Colon and Colon Cancer Associated Polynucleotides and Polypeptide
; FILE REFERENCE: PA005P1
; CURRENT APPLICATION NUMBER: US/10/106,698
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: PCT/US00/26524
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/157,137
; PRIOR FILING DATE: 1999-09-29
; PRIOR APPLICATION NUMBER: US 60/163,280
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 8564
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 455
; LENGTH: 1558
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (420)..(420)
; OTHER INFORMATION: n equals a,t,g, or c
US-10-106-698-455

Query Match 100.0%; Score 90; DB 15; Length 1558;

Best Local Similarity 100.0%; Pred. No. 1.2e-21;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 817 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 876
QY 61 AAGCAGGGGGGAACGCTGGACACCTAGAG 90
Db 877 AAGCAGGGGGGAACGCTGGACACCTAGAG 906

RESULT 3

US-09-847-946A-1
; Sequence 1, Application US/09847946A
; Publication No. US20030054999A1
; GENERAL INFORMATION:
; APPLICANT: May, Michael J
; APPLICANT: Ghosh, Sankar
; APPLICANT: Finkel, Mark A
; APPLICANT: Phillips, Kathryn
; APPLICANT: Hannig, Gerhard
; TITLE OF INVENTION: ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF
; FILE REFERENCE: PFI-119
; CURRENT APPLICATION NUMBER: US/09/847,946A
; CURRENT FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/201,261
; PRIOR FILING DATE: 2000-05-02
; PRIOR APPLICATION NUMBER: 09/643,260
; PRIOR FILING DATE: 2000-08-22
; NUMBER OF SEQ ID NOS: 160
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 2268
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:wild-type IKK
; OTHER INFORMATION: NBD
US-09-847-946A-1

Query Match 100.0%; Score 90; DB 10; Length 2268;

Best Local Similarity 100.0%; Pred. No. 1.2e-21;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
QY 61 AAGCAGGGGGGAACGCTGGACACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACACCTAGAG 1692

RESULT 4

US-10-156-610-1
; Sequence 1, Application US/10156610
; Publication No. US20030050270A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; APPLICANT: Erich Koller
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION
; FILE REFERENCE: ISPH-0666
; CURRENT APPLICATION NUMBER: US/10/156,610
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US 09/856,246
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: PCT/US99/16959
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: US 09/197,008
; PRIOR FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 83
; SEQ ID NO 1
; LENGTH: 2268
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(2268)
US-10-156-610-1

Query Match

Best Local Similarity 100.0%; Score 90; DB 15; Length 2268;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662
QY 61 AAGCAGGGGGGAACGCTGGACACCTAGAG 90
Db 1663 AAGCAGGGGGGAACGCTGGACACCTAGAG 1692

RESULT 5

US-10-243-408-1
; Sequence 1, Application US/10243408
; Publication No. US20030077683A1
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Cao, Zhaodan
; APPLICANT: R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/243,408
FILING DATE: 13-Sep-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/109,986
FILING DATE: <Unknown>
APPLICATION NUMBER: 08/890,854
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: T97-006-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 343-4341
TELEFAX: (415) 343-4342
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2268 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-243-408-1

Query Match 100.0%; Score 90; DB 15; Length 2268;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 1662
QY 61 AAGCAGGGGGGAGCGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAGCGCTGGACGACCTAGAG 1692

RESULT 6
US-09-844-908-8
Sequence 8, Application US/09844908
Patent No. US20020151021A1
GENERAL INFORMATION:
APPLICANT: Mercurio, Frank
Zhu, Hengyi
Barbosa, Miguel
Li, Gian
Murray, Brion W.
TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/844,908
FILING DATE: 27-Apr-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/910,820
FILING DATE: 12-AUG-1997
ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.413C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 2271 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-844-908-8
Query Match 100.0%; Score 90; DB 9; Length 2271;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 60
Db 1603 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGCG 1662
QY 61 AAGCAGGGGGGAGCGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGAGCGCTGGACGACCTAGAG 1692

RESULT 7
US-09-844-988-8
Sequence 8, Application US/09844988
Patent No. US20020158764A1
GENERAL INFORMATION:
APPLICANT: Mercurio, Frank
Zhu, Hengyi
Barbosa, Miguel
Li, Gian
Murray, Brion W.
TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/844,988
FILING DATE: 26-Apr-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/910,820
FILING DATE: 1997-08-13
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.413C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 2271 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-844-988-8

Query Match 100.0%; Score 90; DB 9; Length 2271;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1603 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 8

US-10-338-462-8
; Sequence 8, Application US/10338462
; Publication No. US20030100026A1
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
; Zhu, Hengyi
; Barbosa, Miguel
; Li, Gian
; Murray, Brian W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; COMPLEX AND METHODS OF USE THEREFOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA: US/10/338,462
FILING DATE: 08-Jan-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/844,908
FILING DATE: 27-Apr-2001
APPLICATION NUMBER: US/08/910,820
FILING DATE: 12-AUG-1997
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.413C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 2271 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 8:

US-10-338-462-8

Query Match 100.0%; Score 90; DB 15; Length 2271;

Best Local Similarity 100.0%; Pred. No. 1.2e-21;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60

Db 1603 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1662

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGAACGCTGGACGACCTAGAG 1692

RESULT 9

US-09-796-872-14
; Sequence 14, Application US/09796872
; Patent No. US20020045235A1
; GENERAL INFORMATION:
; APPLICANT: Karin, Michael
; APPLICANT: DiDonato, Joseph A.
; APPLICANT: Rothwarf, David M.
; APPLICANT: Hayakawa, Makio
; APPLICANT: Zandi, Ebrahim
; TITLE OF INVENTION: Ikb Kinase, Subunits Thereof, and Methods of Using Same
; FILE REFERENCE: P-UD 3295
; CURRENT APPLICATION NUMBER: US/09/796,872
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/168,629
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/061,470
; PRIOR FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 2931
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (36)..(2306)
US-09-796-872-14

Query Match 100.0%; Score 90; DB 9; Length 2931;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 60
Db 1638 GAACGATGATGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGGCCGG 1697

QY 61 AAGCAGGGGGAACGCTGGACGACCTAGAG 90
Db 1698 AAGCAGGGGGAACGCTGGACGACCTAGAG 1727

RESULT 10

US-10-087-192-1757
; Sequence 1757, Application US/10087192
; Publication No. US20020182586A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David W.
; APPLICANT: Engelhard, Eric K.
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 529452000122
; CURRENT APPLICATION NUMBER: US/10/087,192
; CURRENT FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 09/747,377
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 09/798,586
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 2059
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1757
; LENGTH: 4154
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-087-192-1757

Query Match 100.0%; Score 90; DB 13; Length 4154;

```
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 60
Db 1813 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 1872

Qy 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1873 AAGCAGGGGGGAACGCTGGACGACCTAGAG 1902

RESULT 11
US-10-087-192-1756
; Sequence 1756, Application US/10087192
; Publication No. US20020182586A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David W.
; APPLICANT: Engelhard, Eric K.
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 529452000122
; CURRENT APPLICATION NUMBER: US/10/087,192
; CURRENT FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 09/747,377
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 09/798,586
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 2059
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1756
; LENGTH: 81099
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)...(81099)
; OTHER INFORMATION: n = A,T,C or G
US-10-087-192-1756

Query Match 95.6%; Score 86; DB 13; Length 81099;
Best Local Similarity 100.0%; Pred. No. 3.6e-20;
Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 60
Db 59517 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 59576

Qy 61 AAGCAGGGGGGAACGCTGGACGACCT 86
Db 59577 AAGCAGGGGGGAACGCTGGACGACCT 59602

RESULT 12
US-10-156-610-83
; Sequence 83, Application US/10156610
; Publication No. US20030050270A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; APPLICANT: Erich Koller
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION
; FILE REFERENCE: ISPH-0666
; CURRENT APPLICATION NUMBER: US/10/156,610
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US 09/856,246
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: PCT/US99/16959
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: US 09/197,008
; PRIOR FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 83
; SEQ ID NO 83
```

```
; LENGTH: 3038
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-156-610-83

Query Match 85.8%; Score 77.2; DB 15; Length 3038;
Best Local Similarity 91.1%; Pred. No. 3.5e-17;
Matches 82; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 60
Db 1628 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACCTACAGAGAGCCCATGGGTCGG 1687

Qy 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1688 AAGCAGGGGGGACCTTTGGATGACCTAGAG 1717

RESULT 13
US-10-156-610-48
; Sequence 48, Application US/10156610
; Publication No. US20030050270A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; APPLICANT: Erich Koller
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION
; FILE REFERENCE: ISPH-0666
; CURRENT APPLICATION NUMBER: US/10/156,610
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US 09/856,246
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: PCT/US99/16959
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: US 09/197,008
; PRIOR FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 83
; SEQ ID NO 48
; LENGTH: 2274
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-156-610-48

Query Match 82.2%; Score 74; DB 15; Length 2274;
Best Local Similarity 88.9%; Pred. No. 4.6e-16;
Matches 80; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 1 GAACGGATGATGGCTCTGCAGACCGACATTGTGGACTTACAGAGAGCCCATGGCGG 60
Db 1603 GAGCGGATGATGGCACTGCAGACTGACATTGTGGACCTGCAGAGAGCCCATGGGTCGG 1662

Qy 61 AAGCAGGGGGGAACGCTGGACGACCTAGAG 90
Db 1663 AAGCAGGGGGGACCTTGGATGACCTAGAG 1692

RESULT 14
US-10-087-192-1754
; Sequence 1754, Application US/10087192
; Publication No. US20020182586A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David W.
; APPLICANT: Engelhard, Eric K.
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 529452000122
; CURRENT APPLICATION NUMBER: US/10/087,192
; CURRENT FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: PCT/US99/16959
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: US 09/747,377
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 09/798,586
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 2059
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 09:40:54 ; Search time 121 Seconds
(without alignments)
70.053 Million cell updates/sec

Title: US-09-806-701-16_COPY_331_360

Perfect score: 151

Sequence: 1 ERMAWQTQDIVDLQRSPMGKQGGTLLDLE 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : A Geneseq 29Jan04:*

- 1: geneseqp1980s:*
- 2: geneseqp1980s:*
- 3: geneseqp2000s:*
- 4: geneseqp2001s:*
- 5: geneseqp2002s:*
- 6: geneseqp2003as:*
- 7: geneseqp2003bs:*
- 8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	151	100.0	149	4 AAB63781	Aab63781 Human pro
2	151	100.0	552	3 AAY84883	Aay84883 A GFP-I-k
3	151	100.0	750	5 ABB77294	Abb77294 Human IKK
4	151	100.0	756	2 AAW56328	Aaw56328 Inhibitor
5	151	100.0	756	2 AAW49097	Aaw49097 Human I-k
6	151	100.0	756	2 AAW82499	Aaw82499 Human IKK
7	151	100.0	756	2 AAW96158	Aaw96158 Human I k
8	151	100.0	756	2 AAY43247	Aay43247 Human inh
9	151	100.0	756	2 AAW86163	Aaw86163 Human IKK
10	151	100.0	756	2 AAY24051	Aay24051 Human kin
11	151	100.0	756	2 AAW81566	Aaw81566 Ikb kinas
12	151	100.0	756	2 AAY14515	Aay14515 Human IKK
13	151	100.0	756	2 AAW81563	Aaw81563 Ikb kinas
14	151	100.0	756	5 ABB77306	Abb77306 Human IKK
15	151	100.0	756	5 ABB77296	Abb77296 Human IKK
16	151	100.0	756	5 ABB77295	Abb77295 Human IKK
17	151	100.0	756	5 ABB77300	Abb77300 Human IKK
18	151	100.0	756	5 ABB77293	Abb77293 Human IKK
19	151	100.0	756	5 ABB77304	Abb77304 Human IKK
20	151	100.0	756	5 ABB77298	Abb77298 Human IKK
21	151	100.0	756	5 ABB77302	Abb77302 Human IKK
22	151	100.0	756	5 ABB77297	Abb77297 Human IKK
23	151	100.0	756	5 ABB77308	Abb77308 Human IKK
24	151	100.0	756	5 ABB77307	Abb77307 Human IKK
25	151	100.0	756	5 ABB77299	Abb77299 Human IKK

ALIGNMENTS

RESULT 1

AAB63781
ID AAB63781 standard; protein; 149 AA.

XX AC AAB63781;

XX DT 26-MAR-2001 (first entry)

XX XX Human prostate cancer associated antigen protein sequence SEQ ID NO:1143.

XX KW Human; breast cancer; gastric cancer; prostate cancer; diagnosis;

XX KW cancer associated antigen; cytostatic; cancer vaccine.

XX OS Homo sapiens.

XX PN WO200073801-A2.

XX PD 07-DEC-2000.

XX PP 26-MAY-2000; 2000WO-US014749.

XX PR 28-MAY-1999; 99US-0136526P.

XX PR 10-SEP-1999; 99US-0153454P.

XX XX (LUDW-) LUDWIG INST CANCER RES.

XX Obata Y;

XX WPI; 2001-025274/03.

XX Nucleic acids encoding breast, gastric and prostate cancer associated antigen precursors, useful for diagnosing and treating a condition characterized by expression of an abnormal amount of a protein, e.g. cancer.

XX Example 1; Page 715; 799pp; English.

XX AAF22422 to AAF22626, AAF22627 to AAF22773 and AAF22774 to AAF23014 represent nucleotide sequences encoding human breast, gastric and prostate cancer associated antigen precursors (CAAP) respectively. AAB63232 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970 represent human breast, gastric and prostate CAAP protein sequence respectively. CAAPs have cytostatic activity and can be used in the production of cancer vaccines. The human CAAP proteins, peptides, nucleic acids or anti-CAAP antibodies are useful for diagnosing and treating a condition characterised by expression of an abnormal amount of a protein, e.g. cancer

Abb77301 Human IKK
Abb77305 Human IKK
Abb77310 Human IKK
Abb77309 Human IKK
Abb775804 Human IKK
Abo32508 Human ini
Aay84882 Amino aci
Aay84880 Amino aci
Aab94488 Human pro
Aay92057 Murine I
Abb57325 Mouse isc
Abr42682 Mouse IKK
Aaw56329 Inhibitor
Aaw82498 Human IKK
Aaw86157 Human IKK
Aaw86164 Human IKK
Aay24052 Human kin
Aaw81565 Ikb kinas
Aay14516 Human IKK

SQ Sequence 149 AA;

Query Match 100.0%; Score 151; DB 4; Length 149;
 Best Local Similarity 100.0%; Pred. No. 5.7e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
 |||||
 DB 9 ERMALQTDIVDLQSPMGKQGGTLDLLE 38

RESULT 2
 AAY84883
 ID AAY84883 standard; protein; 552 AA.
 AC AAY84883;
 XX
 DT 21-AUG-2000 (first entry)
 XX
 DE A GFP-I-kappaB kinase-LZ domain fusion protein.
 XX
 KW I-kappaB kinase; cyclic nucleotide phosphodiesterase; cyclic AMP;
 KW cyclic GMP; PDE3; PDE7; PDE8; PDE4 splice variant; PDE4D;
 KW inflammatory disease; chronic inflammation; airway disease; asthma;
 KW chronic bronchial hyper-reactivity; joint disorder; rheumatoid arthritis;
 KW pelvespondylitis; bowel disease; ulcerative colitis; Crohn's disease;
 KW autoimmune disease; diabetes mellitus type I; Hashimoto's thyroiditis;
 KW systemic lupus erythromatosus; myasthenia gravis; Grave's disease;
 KW immune thrombocytopenic purpura; acute respiratory distress syndrome;
 KW septic shock; depression; PDE1; PDE2; PDE6; PDE9; PDE10; Jet lag;
 KW PDE5 splice variant; tension; erectile dysfunction; circadian rhythm;
 KW green fluorescent protein; GFP.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS Aequorea victoria.
 XX
 PN WO200023091-A2.
 XX
 PD 27-APR-2000.
 XX
 PF 15-OCT-1999; 99WO-DK000567.
 XX
 PR 15-OCT-1998; 98DK-00001321.
 PR 15-OCT-1998; 98DK-00001322.
 PR 15-OCT-1998; 98DK-00001323.
 XX
 PA (BIOI-) BIOIMAGE AS.
 XX
 PI Arkhammar POG, Terry BR, Scudder KM, Bjorn SP, Thastrup O;
 XX
 DR WPI; 2000-399281/34.
 DR N-PSDB; AAA14961.
 XX
 PT Modulating the activity of I-kappaB kinases or cyclic nucleotide
 phosphodiesterases for the treatment of inflammatory disorders,
 PT autoimmune disorders (e.g. diabetes and Crohn's disease) and depression.
 XX
 PS Example 3; Page 127-128; 128pp; English.
 XX
 CC The specification describes a method for modulating the specific
 effectiveness of I-kappaB kinases or cyclic nucleotide phosphodiesterases
 CC which have the ability to cleave cyclic AMP and/or GMP. This involves
 CC modulating the specific effectiveness of the cyclic nucleotide
 CC phosphodiesterase or I-kappaB kinase by modulating the spatial
 CC distribution within cells of the animal. If the cyclic nucleotide
 CC phosphodiesterase used is a PDE3, PDE7, PDE8 or a splice variant of PDE4
 CC (such as PDE4D), the method is used to treat inflammatory diseases such
 CC as chronic inflammation (especially airway diseases such as asthma and
 CC chronic bronchial hyper-reactivity of non-asthma etiology, joint
 CC disorders such as rheumatoid arthritis and pelvespondylitis and bowel
 CC diseases such as ulcerative colitis and Crohn's disease), autoimmune
 CC diseases associated with inflammation (such as diabetes mellitus type I,

CC systemic lupus erythromatosus, myasthenia gravis, Hashimoto's
 CC thyroiditis, Grave's disease and immune thrombocytopenic purpura),
 CC dysregulations of the immune system (such as acute respiratory distress
 CC syndrome (ARDS) and septic shock) and/or depression. Alternatively, if
 CC the cyclic nucleotide phosphodiesterase is PDE1, PDE2, PDE6, PDE9, PDE10
 CC or a splice variant of PDE5, the method is used to treat hypo- or
 CC hypertension, erectile dysfunction, circadian rhythm resetting or jet-
 CC lag. The present sequence represents a fusion protein of green
 CC fluorescent protein (GFP) and I-kappaB kinase and the LZ domain, which is
 CC used in the course of the invention
 XX
 SQ Sequence 552 AA;

Query Match 100.0%; Score 151; DB 3; Length 552;
 Best Local Similarity 100.0%; Pred. No. 2.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
 |||||
 DB 331 ERMALQTDIVDLQSPMGKQGGTLDLLE 360

RESULT 3
 ABB77294
 ID ABB77294 standard; protein; 750 AA.
 XX
 AC ABB77294;
 XX
 DT 14-JUN-2002 (first entry)
 XX
 DE Human IKKbeta mutant delNBN 737-742.
 XX
 KW IKKbeat; IKKalpha; NEMO; NEMO binding domain; NBD; NF-kappaB; NF-kB;
 KW kinase activation; leukocyte; inflammation; E-selectin; osteoclast;
 KW autoimmune disease; transplant rejection; osteoporosis; cancer;
 KW Alzheimer's disease; viral infection; asthma; anaphylaxis; psoriasis;
 KW rheumatoid arthritis; Crohn's disease; multiple sclerosis; HIV;
 KW corticosteroid; immunosuppression; antiinflammatory; immunosuppressive;
 KW osteostatic; cytostatic; neurotropic; neuroprotective; anti-HIV; human;
 KW antiarteriosclerotic; virucide; antiasthmatic; antiallergic;
 KW dermatologic; antibacterial; antipsoriatic; antirheumatic;
 KW antiarthritic; osteopathic; antiulcer; mutant; mutein.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200183547-A2.
 XX
 PD 08-NOV-2001.
 XX
 PF 02-MAY-2001; 2001WO-US040654.
 XX
 PR 02-MAY-2000; 2000US-0201261P.
 PR 22-AUG-2000; 2000US-00643260.
 XX
 PA (UYVA) UNIV YALE.
 XX
 PI May MJ, Ghosh S;
 XX
 DR WPI; 2002-179350/23.
 XX
 PT Modulating NF-kappaB induction in a cell, useful for treating e.g.
 PT inflammatory disorders, osteoporosis and cancer, comprises contacting a
 PT cell with an anti-inflammatory compound comprising at least one NEMO
 PT binding domain.
 XX
 PS Example 4; Page; 82pp; English.
 XX
 CC The invention relates to modulating NF-kappaB (NF-kB) induction in a cell
 CC comprises contacting a cell with an anti-inflammatory compound (ABB08725-
 CC ABB08742) comprising at least one NEMO binding domain (ABB77313). The
 CC compound has acts through selective inhibition of cytokine-mediated NF-kB
 CC activation by blocking the interaction of NEMO with IKKbeta at the NEMO

CC binding domain. Blockage of IKKbeta-NEMO interaction results in
 CC inhibition of IKKbeta kinase activation and subsequent decreased
 CC phosphorylation of Ikbppab. The compound may also act (directly or
 CC indirectly) by blocking the recruitment of leukocytes into sites of acute
 CC and chronic inflammation, by down-regulating the expression of E-selectin
 CC on leukocytes or by blocking osteoclast differentiation. The compound is
 CC useful in treating NF-kB mediated conditions, where the condition is an
 CC inflammatory disorder, an autoimmune disease, transplant rejection,
 CC osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral
 CC infection or ataxia telangiectasia. The inflammatory disorder is asthma,
 CC allergies, urticaria, anaphylaxis, cutaneous inflammation, sepsis,
 CC psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,
 CC inflammatory bowel disease, chronic obstructive pulmonary disease,
 CC vasculitis and bursitis. The inflammatory disorder may also be
 CC dermatitis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus
 CC and spondylarthritis. Also for Crohn's disease, ulcerative colitis,
 CC polymyalgia, scleroderma, Wegner's granulomatosis, temporal arteritis,
 CC cryoglobulinemia or multiple sclerosis. For chronic viral infections
 CC caused by Epstein-Bart, cytomegalovirus or herpes simplex. Other viral
 CC diseases include HIV and influenza. The compound may also be useful for
 CC treating anaphylaxis, drug and food sensitivity, contact dermatitis,
 CC sunburn or aging. The compound may be used to replace corticosteroids in
 CC any application in which corticosteroids are used, including
 CC immunosuppression in transplants and cancer therapy. Also for identifying
 CC antiinflammatory compounds and for diagnosis of an inflammatory disorder.
 CC The compound may be administered alone or in combination with other known
 CC anti-inflammatory agents. The present sequence is that of an IKKbeta
 CC deletion mutant, useful in examples of the invention. Note: The present
 CC sequence is not given in the specification but is derived from GenBank
 CC Accession No. 014920 (ABB77294)

XX Sequence 750 AA;

Query Match 100.0%; Score 151; DB 5; Length 750;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGLDLE 30
 |||||
 Db 535 ERMALQTDIVDLQSPMGKQGGLDLE 564

RESULT 4

AAW56328
 ID AAW56328 standard; protein; 756 AA.

XX AAW56328;

XX 24-JUL-1998 (first entry)

XX Inhibitory subunit I-kappa-B signalsome kinase 2 amino acid sequence.

XX Inhibitory subunit; I-kappa-B-beta; nuclear factor kappa-B;
 KW NF-kappa-B/Rel dimer; inhibitory activity; phosphorylation;
 KW stimulus-inducible I-kappa-B kinase; IKK; signalsome; I-kappa-B-alpha;
 KW identification; stimulate; signal transduction; the NF-kappa-B cascade;
 KW therapeutic composition; inflammatory; neurodegenerative; disease;
 KW autoimmune disease; cancer.

XX Homo sapiens.

XX WO9808955-A1.

XX 05-MAR-1998.

XX 26-AUG-1997; 97WO-US015003.

XX 26-AUG-1996; 96US-00697393.

XX 13-AUG-1997; 97US-00910820.

XX (SIGN-) SIGNAL PHARM INC.

XX Mercurio F, Zhu H, Barbosa M, Li G, Murray BW;

XX WPI; 1998-179440/16.
 DR N-ESDB; AAV22842.

XX New isolated stimulus-inducible I-kappa-B kinase signalsome - useful for
 PT developing products for treating, e.g. inflammatory neuro-degenerative
 PT and auto-immune diseases.

XX Claim 3; Page 60-64; 115pp; English.

XX The present sequence represents an inhibitory subunit I-kappa-B kinase
 CC (IKK) 2. IKK kinases, when incorporated into an IKK signalsome, are
 CC capable of phosphorylating inhibitory subunit I-kappa-B-alpha, at serine
 CC residues 32 and 36. I-kappa-B-alpha retains nuclear factor (NF) kappa-B
 CC in the cytoplasm. I-kappa-B proteins contain 5-7 ankyrin-like repeats
 CC which are required for association with the NF-kappa-B/Rel dimer and for
 CC inhibitory activity. A stimulus-inducible IKK "signalsome" is described
 CC that is capable of specifically phosphorylating I-kappa-B-alpha at
 CC residues S32 and S36, without the addition of exogenous cofactors. The
 CC proteins of the invention can be used to identify agents that inhibit or
 CC stimulate signal transduction via the NF-kappa-B cascade. Therapeutic
 CC compositions comprising such agents may be used for treating a patient
 CC afflicted with a disorder associated with the activation of an IKK
 CC signalsome. The agents may be used to treat, e.g. inflammatory,
 CC neurodegenerative diseases and autoimmune diseases, cancer and viral
 CC infections. The antibodies may be used in a kit for detecting IKK
 CC signalsome activity in a sample

XX Sequence 756 AA;

Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGLDLE 30
 |||||
 Db 535 ERMALQTDIVDLQSPMGKQGGLDLE 564

RESULT 5

AAW49097

XX AAW49097 standard; protein; 756 AA.

XX AAW49097;

XX 07-DEC-1998 (first entry)

XX Human I-kappa-B kinase (IKK) beta subunit.

XX I-kappa-B kinase; IKK; human; protein kinase; NF-kappa-B; inflammation;
 KW signal transduction.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Domain 15..300

XX Region /note= "kinase domain"

XX /note= "regions contains leucine residues involved in

XX leucine zippers"

XX Domain 602..642

XX /note= "helix-loop-helix domain"

XX WO9837228-A1.

XX 27-AUG-1998.

XX 23-FEB-1998; 98WO-US003511.

XX 25-FEB-1997; 97US-00810131.

XX 09-OCT-1997; 97US-0061470P.

XX (REGC) UNIV CALIFORNIA.

XX PI Karin M, Didonato JA, Rothwarf DM, Hayakawa M, Zandi E;
 XX DR WPI; 1998-467580/40.
 XX DR N-PSDB; AAV32970.
 XX PT Nucleic acid encoding I-kappa-B kinase subunits and antibodies - the sub-
 PT units phosphorylate the inhibitor of NF-kappa-B, for studying the
 PT inflammatory response and signal transduction pathways.
 XX PS Claim 3; Fig 3; 101pp; English.
 XX CC This is the amino acid sequence of the alpha beta of a human serine
 CC protein kinase, designated I-kappa-B kinase (IKK). The IKK beta and alpha
 CC (see AAW49096) subunits are cytokine-inducible, share substantial
 CC sequence homology, and are activated in response to proinflammatory
 CC signals to phosphorylate proteins (I-kappa-Bs) that inhibit the activity
 CC of the NF-kappa-B transcription factor. Their amino acid sequences were
 CC deduced from cDNA clones (see AAV32969-70). The invention also provides
 CC vectors comprising IKK-alpha and -beta nucleic acid molecules, isolated
 CC IKK catalytic subunits which can phosphorylate the I-kappa-B protein at
 CC Ser-32 and Ser-36, and peptide portions of such IKK subunits. The
 CC invention also provides anti-IKK antibodies and their IKK-binding
 CC fragments, as well as methods of purifying an IKK complex, methods of
 CC identifying an agent which alters the association of an IKK complex or an
 CC IKK catalytic subunit with a second protein, and methods of identifying
 CC proteins that can interact with an IKK complex or an IKK catalytic
 CC subunit. IKK nucleic acids, catalytic subunits and antibodies may be used
 CC to study the signal transduction pathways involved in the inflammatory
 CC and immune responses, and to identify agents that alter IKK activity,
 CC such as protein kinase inhibitors
 XX SQ Sequence 756 AA;
 Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ERMALQTDIVDLQSPMGKKGGLDDLE 30
 Db 535 ERMALQTDIVDLQSPMGKKGGLDDLE 564
 RESULT 6
 AAW82499
 ID AAW82499 standard; protein; 756 AA.
 XX AC AAW82499;
 XX DT 04-MAR-1999 (first entry)
 XX DE Human IKK-beta protein.
 XX KW IKK; Nuclear factor-kappa B; NF-kB; signal transduction; TNF; human;
 XX KW tumour necrosis factor; NF-kB-inducing kinase; screening; interaction;
 XX KW modulator; immune response; inflammatory response; viral gene;
 XX KW diagnostic; therapy; IKK-beta.
 XX OS Homo sapiens.
 XX PI Wu L, Rothe M;
 XX DR WPI; 1999-094902/08.
 XX PS Claim 9; Page 21-23; 32pp; English.
 XX CC I-kappa-B, deletion mutants of it retaining I-kappa-B kinase activity and
 CC I-kappa-B polypeptides (comprising a six residue domain of I-kappa-B
 CC containing one of Ser32 and Ser36, and a candidate agent) can be used to

XX PT Screening agents for modulating interaction of nuclear factor kappaB
 PT inducing kinase - with kinase-binding target, useful for controlling
 PT levels of the kinase, for treatment and diagnosis of conditions
 PT associated with e.g. inhibition of signal transduction by tumour necrosis
 PT factor.
 XX PS Disclosure; Col 23-28; 16pp; English.
 XX CC This sequence represents the human IKK-beta protein, which is used in the
 CC isolation of a novel nuclear factor-kappaB (NFkB)-inducing kinase (NIK).
 CC This protein is used to screen for agents that modulate the interaction
 CC of NIK with a NIK-binding target. The protein can be used as a modulator
 CC of cellular functions at the NIK level, or for development of such
 CC compounds. NFkB is involved in expression of many immune and inflammatory
 CC responses and of some important viral genes. The protein may be used
 CC diagnostically and therapeutically, in conditions associated with
 CC abnormal utilisation of pathways that involve NFkB, e.g. inhibition of
 CC signal transduction by tumour necrosis factor (TNF)
 XX SQ Sequence 756 AA;
 Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ERMALQTDIVDLQSPMGKKGGLDDLE 30
 Db 535 ERMALQTDIVDLQSPMGKKGGLDDLE 564
 RESULT 7
 AAW96158
 ID AAW96158 standard; peptide; 756 AA.
 XX AC AAW96158;
 XX DT 27-APR-1999 (first entry)
 XX DE Human I kappa B kinase.
 XX KW I-kappa-B kinase; IKK-alpha; gene expression; modulation; suppression;
 XX KW activation; tumour necrosis factor; TNF; interleukin-1; IL-1;
 XX KW TNF receptor associated factor; TRAF.
 XX OS Homo sapiens.
 XX PI WO9901541-A1.
 XX PN 14-JAN-1999.
 XX PD 01-JUL-1998; 98WO-US013782.
 XX PF 01-JUL-1997; 97US-00887115.
 XX PR 10-JUL-1997; 97US-00890854.
 XX PA (TULA-) TULARIK INC.
 XX PI Rothe M, Cao Z, Regnier C;
 XX DR WPI; 1999-106044/09.
 XX DR N-PSDB; AAX08919.
 XX PT Newly isolated human kinase IkappaB Kinase (IKK- α) polypeptides - useful
 PT in screening for agents that modulate the interaction of an IKK
 PT polypeptide to a binding target and for modulating signal transduction
 PT involving IkappaB in a cell.
 XX PS Claim 9; Page 21-23; 32pp; English.
 XX CC I-kappa-B, deletion mutants of it retaining I-kappa-B kinase activity and
 CC I-kappa-B polypeptides (comprising a six residue domain of I-kappa-B
 CC containing one of Ser32 and Ser36, and a candidate agent) can be used to

CC screen for agents that modulate the interaction of an IKK polypeptide to
 CC a binding target. The modulation of the kinase activity of IKK-alpha
 CC (AAW96157) forms a method for modulating signal transduction involving I-
 CC kappa-B in a cell. The IKK-alpha polypeptides are useful for generating
 CC oligonucleotide primers and probes for use in the isolation of natural
 CC IKK-alpha-encoding nucleic acids. The nucleic acids are useful as
 CC translatable transcripts, hybridization probes, polymerase chain reaction
 CC (PCR) probes and primers. Their diagnostic applications include IKK-alpha
 CC hybridization probes for identifying wild-type and mutant IKK-alpha
 CC alleles in clinical and laboratory samples. Therapeutic application
 CC includes the use of IKK- alpha nucleic acids for modulating cellular
 CC expression or intracellular concentration/availability of active IKK-
 CC alpha. Catalytically inactive IKK-alpha mutants suppress NF-kappa-B
 CC activation induced by tissue necrosis factor (TNF), interleukin-1 (IL-1)
 CC stimulation, TNF receptor-associated factor (TRAF), and NF-kappa-B-
 CC inducing kinase (NIK) overexpression
 XX
 SQ Sequence 756 AA;

Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ERMMALQTDIVDLQSPMGKQGGTLDLLE 30
 |||||
 Db 535 ERMMALQTDIVDLQSPMGKQGGTLDLLE 564

RESULT 8
 AAY43247
 ID AAY43247 standard; protein; 756 AA.
 XX
 AC AAY43247;
 XX
 DT 13-JAN-2000 (first entry)
 XX
 DE Human inhibitor-kappa B kinase-beta protein sequence.
 XX
 KW Inhibitor-kappa B kinase-beta; IKB-beta; human; T-cell leukaemia; asthma;
 KW inflammatory response; inflammatory disease; juvenile diabetes mellitus;
 KW Graves' disease; rheumatoid arthritis; allograft rejection; diagnosis;
 KW inflammatory bowel disease; multiple sclerosis; contact dermatitis;
 KW rhinitis; allergy; hyperproliferative disorder; tumour; therapy.
 XX
 OS Homo sapiens.
 XX
 PI US5977341-A.
 XX
 PD 02-NOV-1999.
 XX
 PF 20-NOV-1998; 98US-00197008.
 XX
 PR 20-NOV-1998; 98US-00197008.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Cowser LM;
 XX
 DR WPI; 1999-619715/53.
 DR N-PSDB; AAZ31590.
 XX
 PT Antisense oligonucleotides inhibiting human Inhibitor-kappa B Kinase-
 PT beta, useful for treating conditions such as inflammation, asthma,
 PT diabetes, allograft rejection, allergies, hyperproliferative disorders or
 PT tumors.
 XX
 PS Claim 1; Col 41-48; 32pp; English.

CC This sequence represents the human inhibitor-kappa B kinase-beta. The
 CC invention relates to an antisense oligonucleotide (I) 8 to 30 nucleotides
 CC in length inhibiting the expression of human Inhibitor-kappa B kinase-
 CC beta (IKB-beta). (I) inhibits the expression of human IKB-beta which
 CC plays a role in the development of T-cell leukaemia and in the activation

CC of inflammatory responses. (I) is therefore useful for treating
 CC inflammatory diseases or disorders with an inflammatory component such as
 CC asthma, juvenile diabetes mellitus, Graves' disease, rheumatoid
 CC arthritis, allograft rejection, inflammatory bowel disease, multiple
 CC sclerosis, contact dermatitis, rhinitis and various allergies, or
 CC hyperproliferative disorders such as leukaemias and other tumours. (I)
 CC may also be used for detection of the above disorders
 XX
 SQ Sequence 756 AA;

Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ERMMALQTDIVDLQSPMGKQGGTLDLLE 30
 |||||
 Db 535 ERMMALQTDIVDLQSPMGKQGGTLDLLE 564

RESULT 9
 AAW86163
 ID AAW86163 standard; protein; 756 AA.
 XX
 AC AAW86163;
 XX
 DT 03-MAR-1999 (first entry)
 XX
 DE Human IKK-beta polypeptide.
 XX
 KW IKK-beta; IkappaB kinase; inhibitor; NF-kappaB; nuclear factor-kappaB;
 KW nuclear translocation; NF-kappaB-inducing kinase; NIK; recombinant;
 KW human.
 XX
 OS Homo sapiens.
 XX
 PN US5851812-A.
 XX
 PD 22-DEC-1998.
 XX
 PF 10-JUL-1997; 97US-00890853.
 XX
 PR 01-JUL-1997; 97US-00887114.
 XX
 PA (TULA-) TULARIK INC.
 XX
 PI Woronicz J, Goeddel DV;
 XX
 DR WPI; 1999-080407/07.
 DR N-PSDB; AAV84689.
 XX
 PT DNA encoding IKK-beta polypeptides - useful for producing recombinant
 PT polypeptides.
 XX
 PS Claim 8; Col 13-18; 13pp; English.

CC This represents a IKK-beta (IkappaB kinase) polypeptide. The IkappaB
 CC (inhibitor of nuclear factor (NF)-kappaB nuclear translocation) kinase is
 CC a NF-kappaB-inducing kinase (NIK)-interacting protein. A host cell
 CC containing a recombinant nucleic acid encoding the IKK-beta polypeptide
 CC can be used for the recombinant production of the polypeptide
 XX
 SQ Sequence 756 AA;

Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ERMMALQTDIVDLQSPMGKQGGTLDLLE 30
 |||||
 Db 535 ERMMALQTDIVDLQSPMGKQGGTLDLLE 564

RESULT 10

```
AAAY24051
ID AAY24051 standard; protein; 756 AA.
XX
AC AAY24051;
XX
XX 20-MAR-2003 (revised)
DT 01-OCT-1999 (first entry)
XX
XX Human kinase I-kappa-B kinase (IKK-beta).
DE
XX Nuclear factor kappa-B inducing kinase; NIK; NIK-interacting protein;
KW human; I-kappa-B kinase; IKK-beta; IKK-beta disorder.
XX
XX Homo sapiens.
OS
XX US5939302-A.
PN
XX 17-AUG-1999.
PD
XX 17-JUN-1998; 98US-00099124.
PF
XX 01-JUL-1997; 97US-00887114.
PR
XX 10-JUL-1997; 97US-00890853.
XX
XX (TULA-) TULARIK INC.
PA
XX Woronicz J, Goeddel DV;
PI
XX WPI; 1999-468406/39.
DR
XX N-PSDB; AAX98271.
DR
XX Polypeptides comprising a novel I-kappa-B Kinase useful as hybridization
PT probes.
PT
XX Claim 2; Col 13-18; 13pp; English.
PS
XX The present sequence represents a human I-kappa-B kinase (IKK-beta). The
CC protein is a nuclear factor kappa-B inducing kinase (NIK) interacting
CC protein. The IKK-beta nucleic acids, polypeptides, and/or antibodies may
CC be useful as hybridization primers or probes, translatable transcripts,
CC diagnostic probes (e.g. for identifying the presence of IKK-beta in a
CC sample), to detect mutant IKK-beta alleles, in the diagnosis and therapy
CC of IKK-beta disorders, and in the identification of compounds or agents
CC that are able to modulate IKK-beta function. (Updated on 20-MAR-2003 to
CC correct PF field.)
XX
XX Sequence 756 AA;
SQ
Query Match 100.0%; Score 151; DB 2; Length 756;
Best Local Similarity 100.0%; Pred. No. 3.5e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ERMALQTDIVDLQSPMGKQGGTLDDLE 30
DB 535 ERMALQTDIVDLQSPMGKQGGTLDDLE 564
RESULT 11
AAW81566
ID AAW81566 standard; protein; 756 AA.
XX
XX AAW81566;
AC
XX 04-FEB-1999 (first entry)
DT
XX Ikb kinase (IKK)-beta polypeptide.
DE
XX NIK; Ikb; NF-kB; TNF; kinase; nuclear factor kappa B; inhibition;
KW tumour necrosis factor; binding; genetic hybridisation; screening;
KW signal transduction; biopharmaceutical; human.
XX
XX Homo sapiens.
OS
XX
```

```
PN US5843721-A.
XX
PD 01-DEC-1998.
XX
XX 03-JUL-1997; 97US-00887518.
PF
XX 03-JUL-1997; 97US-00887518.
PR
XX (TULA-) TULARIK INC.
PA
XX Wu L, Rothe M;
PI
XX WPI; 1999-044580/04.
DR
XX Probe, vector or recombinant nucleic acid encoding a polypeptide, - useful
PT especially human nuclear factor kappa-B-inducing kinase protein - useful
PT for producing recombinant protein.
PT
XX Example; Col 23-26; 15pp; English.
PS
XX This represents a Ikb kinase (IKK)-alpha polypeptide sequence. The
CC binding activity of this polypeptide can be activated or inhibited by the
CC nuclear factor kappa B (NF-kB)-inducing kinase (NIK) polypeptide of the
CC invention. The NIK polypeptide or its fragment has one or more activities
CC selected from kinase activity and inhibitory activity; Ikb kinase-alpha
CC and beta binding activity and binding inhibitory activity; tumour
CC necrosis factor (TNF) receptor-associated factor 2 binding activity and
CC binding inhibitory activity; Ikb binding activity and binding inhibitory
CC activity, NF-kB activating and inhibitory activity. A vector containing
CC the NIK nucleic acid can be used to transform host cells for the
CC recombinant production of the protein. The NIK nucleic acid and the
CC polypeptide may be used in diagnosis (e.g. genetic hybridisation screen
CC for NIK transcripts), therapy (e.g. NIK kinase inhibitors to inhibit TNF
CC signal transduction), and in the biopharmaceutical industry
XX
XX Sequence 756 AA;
SQ
Query Match 100.0%; Score 151; DB 2; Length 756;
Best Local Similarity 100.0%; Pred. No. 3.5e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ERMALQTDIVDLQSPMGKQGGTLDDLE 30
DB 535 ERMALQTDIVDLQSPMGKQGGTLDDLE 564
RESULT 12
AAV14515
ID AAV14515 standard; protein; 756 AA.
XX
XX AAV14515;
AC
XX 31-AUG-1999 (first entry)
DT
XX Human IKK-beta protein sequence.
DE
XX Human; IKK-beta; I-Kappa B-Kinase; inhibitory protein; diagnosis; NF-kB;
KW Nuclear Factor Kappa B; interaction; binding target.
XX
XX Homo sapiens.
OS
XX US5916760-A.
PN
XX 29-JUN-1999.
PD
XX 17-JUN-1998; 98US-00099125.
PF
XX 01-JUL-1997; 97US-00887114.
PR
XX 10-JUL-1997; 97US-00890853.
XX
XX (TULA-) TULARIK INC.
PA
XX Goeddel DV, Woronicz J;
PI
```

XX WPI; 1999-384722/32.
 DR N-PSDB; AAX79304.
 XX
 PT Screening for agents which modulate the interaction of IKK-beta
 PT polypeptides and their binding targets.
 XX
 PS Claim 2; Col 13-18; 14pp; English.
 XX
 CC This sequence represents human IKK-beta, a novel IKK Kinase (I-Kappa B-
 CC Kinase, one of a family of inhibitory proteins which interact with
 CC Nuclear Factor Kappa B (NF-kB)). The invention relates to a method of
 CC screening for agents which modulate the interaction of human IKK-beta
 CC polypeptides and their binding targets. Agents which modulate the IKK-
 CC beta binding are useful in a variety of diagnostic and therapeutic
 CC applications where the disease is associated with improper utilization of
 CC a pathway involving IKK-beta proteins (e.g. NF-kB activation and IKK-beta
 CC -dependent transcriptional activation)
 XX
 SQ Sequence 756 AA;
 Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ERMALQTDIVDLQSPMGKQGGLDDLE 30
 DB 535 ERMALQTDIVDLQSPMGKQGGLDDLE 564
 RESULT 13
 AAW81563
 ID AAW81563 standard; protein; 756 AA.
 XX
 AC AAW81563;
 XX
 DT 04-FEB-1999 (first entry)
 XX
 DE IKK kinase (IKK)-beta polypeptide.
 XX
 KW NIK; IKK; NF-kB; TNF; kinase; nuclear factor kappa B; inhibition;
 KW tumour necrosis factor; binding; genetic hybridisation; screening;
 KW signal transduction; biopharmaceutical; immunogen; pharmacological;
 KW transcription regulator; human.
 XX
 OS Homo sapiens.
 XX
 XX US5844073-A.
 XX
 XX 01-DEC-1998.
 XX
 XX 13-FEB-1998; 98US-00023321.
 XX
 XX 03-JUL-1997; 97US-00887518.
 XX
 XX (TULA-) TULARIK INC.
 XX
 XX Wu L, Rothe M;
 XX
 XX WPI; 1999-044664/04.
 XX
 XX New isolated peptide comprising a specified 947 amino acid sequence - has
 XX e.g. kinase activity, kinase inhibitory activity, IKK kinase-alpha
 XX binding activity, and IKK kinase-alpha binding inhibitory activity.
 XX
 XX Example; Col 23-26; 15pp; English.
 XX
 CC This represents a IKK kinase (IKK)-beta polypeptide sequence. The binding
 CC activity of this polypeptide can be activated or inhibited by the nuclear
 CC factor kappa B (NF-kB)-inducing kinase (NIK) polypeptide of the
 CC invention. The NIK polypeptide or its fragment has one or more activities
 CC selected from kinase activity and inhibitory activity; IKK kinase-alpha
 CC and beta binding activity and binding inhibitory activity; tumour

CC necrosis factor (TNF) receptor-associated factor 2 binding activity and
 CC binding inhibitory activity; IKK binding activity and binding inhibitory
 CC activity, NF-kB activating and inhibitory activity. The NIK nucleic acid
 CC and the polypeptide may be used in diagnosis (e.g. genetic hybridisation
 CC screen for NIK transcripts), therapy (e.g. NIK kinase inhibitors to
 CC inhibit TNF signal transduction), and in the biopharmaceutical industry
 CC (e.g. as immunogens, reagents for isolating other transcription
 CC regulators, and reagents for screening chemical libraries for
 CC pharmacological agents)
 XX
 SQ Sequence 756 AA;
 Query Match 100.0%; Score 151; DB 2; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ERMALQTDIVDLQSPMGKQGGLDDLE 30
 DB 535 ERMALQTDIVDLQSPMGKQGGLDDLE 564
 RESULT 14
 ABB77306
 ID ABB77306 standard; protein; 756 AA.
 XX
 AC ABB77306;
 XX
 DT 14-JUN-2002 (first entry)
 XX
 DE Human IKKbeta mutant S740A.
 XX
 KW IKKbeat; IKKalpha; NEMO; NEMO binding domain; NBD; NF-kappaB; NF-kB;
 KW kinase activation; leukocyte; inflammation; E-selectin; osteoclast;
 KW autoimmune disease; transplant rejection; osteoporosis; cancer;
 KW Alzheimer's disease; viral; infection; asthma; anaphylaxis; psoriasis;
 KW rheumatoid arthritis; Crohn's disease; multiple sclerosis; HIV;
 KW corticosteroid; immunosuppression; antiinflammatory; immunosuppressive;
 KW osteopathic; cytostatic; nootropic; neuroprotective; anti-HIV; human;
 KW antiarteriosclerotic; virucide; antiasthmatic; antiallergic;
 KW dermatological; antibacterial; antipsoriatic; antirheumatic;
 KW antiarthritic; osteopathic; antiulcer; mutant; mutein.
 XX
 OS Homo sapiens.
 XX
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 XX Key Misc-difference 740 /note= "Wildtype Ser substituted by Ala"
 XX
 XX WO200183547-A2.
 XX
 XX 08-NOV-2001.
 XX
 XX 02-MAY-2001; 2001WO-US040654.
 XX
 XX 02-MAY-2000; 2000US-0201261P.
 XX
 XX 22-AUG-2000; 2000US-00843260.
 XX
 XX (UYA) UNIV YALE.
 XX
 XX May MJ, Ghosh S;
 XX
 XX WPI; 2002-179350/23.
 XX
 XX Modulating NF-kappaB induction in a cell, useful for treating e.g.
 XX inflammatory disorders, osteoporosis and cancer, comprises contacting a
 XX cell with an anti-inflammatory compound comprising at least one NEMO
 XX binding domain.
 XX
 XX Example 11; Page; 82pp; English.
 XX
 CC The invention relates to modulating NF-kappaB (NF-kB) induction in a cell
 CC comprises contacting a cell with an anti-inflammatory compound (ABB08725-

CC ABB08742) comprising at least one NEMO binding domain (ABB77313). The
 CC compound has acts through selective inhibition of cytokine-mediated NF-kB
 CC activation by blocking the interaction of NEMO with IKKbeta at the NEMO
 CC binding domain. Blockage of IKKbeta-NEMO interaction results in
 CC inhibition of IKKbeta kinase activation and subsequent decreased
 CC phosphorylation of IkappaB. The compound may also act (directly or
 CC indirectly) by blocking the recruitment of leukocytes into sites of acute
 CC and chronic inflammation, by down-regulating the expression of E-selectin
 CC on leukocytes or by blocking osteoclast differentiation. The compound is
 CC useful in treating NF-kB mediated conditions, where the condition is an
 CC inflammatory disorder, an autoimmune disease, transplant rejection,
 CC osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral
 CC infection or ataxia telangiectasia. The inflammatory disorder is asthma,
 CC allergies, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,
 CC inflammatory bowel disease, chronic obstructive pulmonary disease,
 CC vasculitis and bursitis. The inflammatory disorder may also be
 CC dermatitis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus
 CC and spondylarthritis. Also for Crohn's disease, ulcerative colitis,
 CC polymyalgia, scleroderma, Wegner's granulomatosis, temporal arteritis,
 CC cryoglobulinaemia or multiple sclerosis. For chronic viral infections as
 CC caused by Epstein-Barr, cytomegalovirus or herpes simplex. Other viral
 CC diseases include HIV and influenza. The compound may also be useful for
 CC treating anaphylaxis, drug and food sensitivity, contact dermatitis,
 CC sunburn or aging. The compound may be used to replace corticosteroids in
 CC any application in which corticosteroids are used, including
 CC immunosuppression in transplants and cancer therapy. Also for identifying
 CC anti-inflammatory compounds and for diagnosis of an inflammatory disorder.
 CC The compound may be administered alone or in combination with other known
 CC anti-inflammatory agents. The present sequence is that of an IKKbeta
 CC mutant, useful in examples of the invention. Note: The present sequence
 CC is not given in the specification but is derived from Genbank Accession
 CC No. O14920 (ABB77294)

XX Sequence 756 AA;

Query Match 100.0%; Score 151; DB 5; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMMALQTDIVDLQSRPMGRKQGGLDLE 30
 DB 535 ERMMALQTDIVDLQSRPMGRKQGGLDLE 564

RESULT 15

ABB77296
 ID ABB77296 standard; protein; 756 AA.

XX ABB77296;

XX 14-JUN-2002 (first entry)

DE Human IKKbeta mutant W739F.

XX IKKbeat; IKKalpha; NEMO; NEMO binding domain; NBD; NF-kappaB; NF-kB;
 KW kinase activation; leukocyte; inflammation; E-selectin; osteoclast;
 KW autoimmune disease; transplant rejection; osteoporosis; cancer;
 KW Alzheimer's disease; viral; infection; asthma; anaphylaxis; psoriasis;
 KW rheumatoid arthritis; Crohn's disease; multiple sclerosis; HIV;
 KW corticosteroid; immunosuppression; anti-inflammatory; immunosuppressive;
 KW osteopathic; cytostatic; nootropic; neuroprotective; anti-HIV; human;
 KW antiarteriosclerotic; virucide; antiasthmatic; anti-allergic;
 KW dermatological; antibacterial; antipsoriatic; antirheumatic;
 KW antiarthritic; osteopathic; antiulcer; mutant; muten.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

PH Misc-difference 739

FT /note= "Wildtype Trp substituted by Phe"

XX

PN WO200183547-A2.

XX 08-NOV-2001.

XX 02-MAY-2001; 2001WO-US040654.

XX 02-MAY-2000; 2000US-0201261P.

PR 22-AUG-2000; 2000US-00643260.

XX (UYUA) UNIV YALE.

PA May MJ, Ghosh S;

XX WPI; 2002-179350/23.

DR Modulating NF-kappaB induction in a cell, useful for treating e.g.
 XX inflammatory disorders, osteoporosis and cancer, comprises contacting a
 PT cell with an anti-inflammatory compound comprising at least one NEMO
 PT binding domain.

XX Example 11; Page; 82pp; English.

XX The invention relates to modulating NF-kappaB (NF-kB) induction in a cell
 CC comprises contacting a cell with an anti-inflammatory compound (ABB08725-
 CC ABB08742) comprising at least one NEMO binding domain (ABB77313). The
 CC compound has acts through selective inhibition of cytokine-mediated NF-kB
 CC activation by blocking the interaction of NEMO with IKKbeta at the NEMO
 CC binding domain. Blockage of IKKbeta-NEMO interaction results in
 CC inhibition of IKKbeta kinase activation and subsequent decreased
 CC phosphorylation of IkappaB. The compound may also act (directly or
 CC indirectly) by blocking the recruitment of leukocytes into sites of acute
 CC and chronic inflammation, by down-regulating the expression of E-selectin
 CC on leukocytes or by blocking osteoclast differentiation. The compound is
 CC useful in treating NF-kB mediated conditions, where the condition is an
 CC inflammatory disorder, an autoimmune disease, transplant rejection,
 CC osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral
 CC infection or ataxia telangiectasia. The inflammatory disorder is asthma,
 CC allergies, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,
 CC inflammatory bowel disease, chronic obstructive pulmonary disease,
 CC vasculitis and bursitis. The inflammatory disorder may also be
 CC dermatitis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus
 CC and spondylarthritis. Also for Crohn's disease, ulcerative colitis,
 CC polymyalgia, scleroderma, Wegner's granulomatosis, temporal arteritis,
 CC cryoglobulinaemia or multiple sclerosis. For chronic viral infections
 CC caused by Epstein-Barr, cytomegalovirus or herpes simplex. Other viral
 CC diseases include HIV and influenza. The compound may also be useful for
 CC treating anaphylaxis, drug and food sensitivity, contact dermatitis,
 CC sunburn or aging. The compound may be used to replace corticosteroids in
 CC any application in which corticosteroids are used, including
 CC immunosuppression in transplants and cancer therapy. Also for identifying
 CC anti-inflammatory compounds and for diagnosis of an inflammatory disorder.
 CC The compound may be administered alone or in combination with other known
 CC anti-inflammatory agents. The present sequence is that of an IKKbeta
 CC mutant, useful in examples of the invention. Note: The present sequence
 CC is not given in the specification but is derived from Genbank Accession
 CC No. O14920 (ABB77294)

XX Sequence 756 AA;

Query Match 100.0%; Score 151; DB 5; Length 756;
 Best Local Similarity 100.0%; Pred. No. 3.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMMALQTDIVDLQSRPMGRKQGGLDLE 30

DB 535 ERMMALQTDIVDLQSRPMGRKQGGLDLE 564

Search completed: September 24, 2004, 09:43:05

Job time : 123 secs

Query Match 36.4%; Score 55; DB 2; Length 283;
 Best Local Similarity 46.4%; Pred. No. 1.2;
 Matches 13; Conservative 3; Mismatches 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKRGQGTLD 28
 DB 91 EGMALAEADIEDPAASPIFSKYPGVKLD 118

RESULT 3

XUEC
 acetyl-CoA C-acyltransferase (EC 2.3.1.16) - Escherichia coli (strain K-12)
 N:Alternate names: 3-ketoacyl-CoA thiolase; beta-ketothiolase; degradative thiolase; fat
 C:Species: Escherichia coli
 C:Date: 30-Jun-1991 #sequence revision 10-Oct-1997 #text change 01-Mar-2002
 C:Accession: F65189; J00109; J00655; A35436; S30736; A40816
 R:Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Co
 A.; Rose, D.J.; Mau, B.; Shao, Y.
 Science 277, 1453-1462, 1997
 A:Title: The complete genome sequence of Escherichia coli K-12.
 A:Reference number: A64720; MUID:97426617; PMID:9278503
 A:Accession: F65189
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-387 <BLAT>
 A:Cross-references: GB:AE000460; GB:U00096; NID:G2367315; PIDN:AACT6848.1; PID:G2367316;
 A:Experimental source: strain K-12, substrain MGL655
 R:Dirusso, C.C.
 J. Bacteriol. 172, 6459-6468, 1990
 A:Title: Primary sequence of the Escherichia coli fadBA operon, encoding the fatty acid-
 A:Reference number: J00108; MUID:91035260; PMID:1699931
 A:Accession: J00109
 A:Molecule type: DNA
 A:Residues: 1-36, 'S', 38-387 <DIR>
 A:Cross-references: GB:M59368; GB:M36149; NID:G145899; PIDN:AAA23751.1; PID:G145901
 R:Nakahigashi, K.; Inokuchi, H.
 Nucleic Acids Res. 18, 4937, 1990
 A:Title: Nucleotide sequence of the fadA and fadB genes from Escherichia coli.
 A:Reference number: JQ0654; MUID:90370500; PMID:2204034
 A:Accession: JQ0655
 A:Molecule type: DNA
 A:Residues: 1-118, 'G', 120-387 <NAK>
 A:Cross-references: EMBL:X52837; NID:G41370; PIDN:CAB40810.1; PID:G4584723
 R:Yang, S.Y.; Yang, X.Y.H.; Healy-Louie, G.; Schulz, H.; Elzinga, M.
 J. Biol. Chem. 265, 10424-10429, 1990
 A:Title: Nucleotide sequence of the fadA gene. Primary structure of 3-ketoacyl-coenzyme
 A:Reference number: A35436; MUID:90285166; PMID:2191949
 A:Accession: A35436
 A:Molecule type: DNA
 A:Residues: 1-118, 'G', 120-387 <NAK>
 A:Cross-references: EMBL:M87049
 R:Daniels, D.L.; Plunkett III, G.; Burland, V.; Blattner, F.R.
 Science 257, 771-778, 1992
 A:Title: Analysis of the Escherichia coli genome: DNA sequence of the region from 84.5 b
 A:Reference number: S30660; MUID:92358234; PMID:1379743
 A:Accession: S30736
 A:Molecule type: DNA
 A:Residues: 1-48, 'X', 83-170, 'XX', 173-339, 'X', 341-387 <DAN>
 A:Cross-references: EMBL:M87049
 R:Yang, S.Y.; Yang, X.Y.H.; Healy-Louie, G.; Schulz, H.; Elzinga, M.
 J. Biol. Chem. 266, 16255, 1991
 A:Reference number: A40816; MUID:91340783; PMID:1678742
 A:Contents: erratum
 A:Accession: A40816
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 368-377 <YA2>
 C:Genetics:
 A:Gene: fadA
 A:Map position: 87 min
 C:Function:
 A:Description: catalyzes the transfer of the acyl group from acyl-CoA to acetyl-CoA to f
 A:Pathway: fatty acid beta-oxidation

A>Note: the E. coli enzyme is the beta chain of the fatty acid complex
 C:Superfamily: acetyl-CoA acetyltransferase
 C:Keywords: acyltransferase; coenzyme A; fatty acid beta-oxidation
 F:91/Active site: Cys #status predicted

Query Match 35.8%; Score 54; DB 1; Length 387;
 Best Local Similarity 61.1%; Pred. No. 2.4;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDIVDLQSPMGKRGQGG 24
 DB 3 QVIVDAITPMGRSKGG 20

RESULT 4

E91225
 acetyl-CoA transferase [imported] - Escherichia coli (strain O157:H7, substrain RIMD 050
 C:Species: Escherichia coli
 C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 03-Aug-2001
 C:Accession: E91225
 R:Havashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.
 gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shingawa, H.
 DNA Res. 8, 11-22, 2001
 A:Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and geno
 A:Reference number: A99629; MUID:21156231; PMID:11258796
 A:Accession: E91225
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-387 <HAY>
 A:Cross-references: GB:BA000007; PIDN:BAR38196.1; PID:G13364249; GSPDB:GN00154
 A:Experimental source: strain O157:H7, substrain RIMD 0509952
 C:Genetics:
 A:Gene: ECs4773
 C:Superfamily: acetyl-CoA acetyltransferase

Query Match 35.8%; Score 54; DB 2; Length 387;
 Best Local Similarity 61.1%; Pred. No. 2.4;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDIVDLQSPMGKRGQGG 24
 DB 3 QVIVDAITPMGRSKGG 20

RESULT 5

C86072
 acetyl-CoA transferase [imported] - Escherichia coli (strain O157:H7, substrain EDL933)
 C:Species: Escherichia coli
 C:Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 27-Nov-2001
 C:Accession: C86072
 R:Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew
 iller, L.; Grothbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,
 Nature 409, 529-533, 2001
 A:Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.
 A:Reference number: A85480; MUID:21074935; PMID:11206551
 A:Accession: C86072
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-387 <STO>
 A:Cross-references: GB:AE005174; NID:G12518723; PIDN:AAAGS9039.1; GSPDB:GN00145; UNCF:253
 A:Experimental source: strain O157:H7, substrain EDL933
 C:Genetics:
 A:Gene: fadA
 C:Superfamily: acetyl-CoA acetyltransferase

Query Match 35.8%; Score 54; DB 2; Length 387;
 Best Local Similarity 61.1%; Pred. No. 2.4;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDIVDLQSPMGKRGQGG 24
 DB 3 QVIVDAITPMGRSKGG 20

```

RESULT 6
A10914
small (beta) chain of the fatty acid-oxidizing multienzyme complex [imported] - Salmonella
C:Species: Salmonella enterica subsp. enterica serovar Typhi
A:Note: this species has also been called Salmonella typhi
C>Date: 09-Nov-2001 #sequence_revision 09-Nov-2001 #text_change 18-Nov-2002
C:Accession: A10914
R:Parkhill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Churcher,
th, T.; Connerton, P.; Cronin, A.; Davis, P.; Davies, R.M.; Dowd, L.; White, N.; Farrar,
S.; Moule, S.; O'Gaora, P.
Nature 413, 848-852, 2001
A:Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.;
A>Title: Complete genome sequence of a multiple drug resistant Salmonella enterica serov
A:Reference number: AB0502; MUID:21534947; PMID:11677608
A:Accession: A10914
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-387 <PAR>
A:Cross-references: GB:AL513382; PIDN:CAD07911.1; PID:g16504456; GSPDB:GN00176
C:Genetics:
A:Gene: STY3578
C:Superfamily: acetyl-CoA acetyltransferase

Query Match 35.8%; Score 54; DB 2; Length 387;
Best Local Similarity 61.1%; Pred. No. 2.4;
Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDIVDLQRSPMGRKQGG 24
||| ||| ||| ||| |||
Db 3 QVWIVDAIRTPMGRSKGG 20

RESULT 7
JS0624
fatty-acid beta-oxidation multienzyme complex beta chain - Pseudomonas fragi
N:Alternate names: acetyl-CoA C-acyltransferase homolog
N:Contains: acetyl-CoA C-acyltransferase (EC 2.3.1.16)
C:Species: Pseudomonas fragi
C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 16-Jun-2000
C:Accession: JS0624; PS0268
R:Sato, S.; Hayashi, M.; Imamura, S.; Ozeki, Y.; Kawaguchi, A.
J. Biochem. 111, 8-15, 1992
A>Title: Primary structures of the genes, faoA and faoB, from Pseudomonas fragi B-0771
A:Reference number: JX0199; MUID:92299657; PMID:1607366
A:Accession: JS0624
A:Molecule type: DNA
A:Residues: 1-391 <SAT>
A:Cross-references: GB:D10390; GB:D90447; NID:g391838; PIDN:BAA01228.1; PID:g391840
A:Experimental source: strain B-0771
A:Accession: PS0268
A:Molecule type: protein
A:Residues: 20-41;161-182;207-229;262-294;298-320;336-350,'X',352-353 <SAT1>
C:Genetics:
A:Gene: faoB
C:Complex: heterotetramer of 2 alpha and 2 beta chains
C:Function:
A:Description: catalyzes the cleavage of a 3-ketoacyl-coenzyme A by coenzyme A to acetyl
A:Pathway: fatty acid beta-oxidation
C:Superfamily: acetyl-CoA acetyltransferase
C:Keywords: acyltransferase; coenzyme A; fatty acid beta-oxidation; heterotetramer
F:2-391/Product: fatty-acid beta-oxidation multienzyme complex beta chain #status predic

Query Match 35.8%; Score 54; DB 1; Length 391;
Best Local Similarity 66.7%; Pred. No. 2.4;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQRSPMGRKQGG 24
||| ||| ||| ||| |||
Db 10 IVDLQRTPMGRSKGG 24

RESULT 8

```

```

P83269
fatty-acid oxidation complex beta-subunit PA3013 [imported] - Pseudomonas aeruginosa (str
C:Species: Pseudomonas aeruginosa
C>Date: 15-Sep-2000 #sequence_revision 15-Sep-2000 #text_change 31-Dec-2000
C:Accession: F83269
R:Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warren, P.; Hickey, M.J.; Bri
adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Larbig, K.; Lim,
L.; Lory, S.; Olson, M.V.
Nature 406, 959-964, 2000
A>Title: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathog
A:Reference number: AB2950; MUID:20437337; PMID:10984043
A:Accession: F83269
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-391 <SFO>
A:Cross-references: GB:AE004726; GB:AE004091; NID:g9949108; PIDN:AAG06401.1; GSPDB:GN001
A:Experimental source: strain PA01
C:Genetics:
A:Gene: faoB; PA3013
C:Superfamily: acetyl-CoA acetyltransferase

Query Match 35.8%; Score 54; DB 2; Length 391;
Best Local Similarity 66.7%; Pred. No. 2.4;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQRSPMGRKQGG 24
||| ||| ||| ||| |||
Db 10 IVDLQRTPMGRSKGG 24

RESULT 9
A82036
fatty oxidation complex, beta chain VC2759 [imported] - Vibrio cholerae (strain N16961 se
C:Species: Vibrio cholerae
C>Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 02-Feb-2001
R:Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.;
chardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, P.
L., R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.
Nature 406, 477-483, 2000
A>Title: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae.
A:Reference number: A82035; MUID:20406833; PMID:10952301
A:Accession: A82036
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-387 <HEI>
A:Cross-references: GB:AE004342; GB:AE003852; NID:g9657358; PIDN:AAF95898.1; GSPDB:GN001
A:Experimental source: serogroup O1; strain N16961; biotype El Tor
C:Genetics:
A:Gene: VC2759
A:Map position: 1
C:Superfamily: acetyl-CoA acetyltransferase

Query Match 35.1%; Score 53; DB 2; Length 387;
Best Local Similarity 66.7%; Pred. No. 3.4;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQRSPMGRKQGG 24
||| ||| ||| ||| |||
Db 6 IVDLQRTPMGRSKGG 20

RESULT 10
C90113
Glucose inhibited division protein A [imported] - Giardia theta nucleomorph
C:Species: nucleomorph Giardia theta
A:Note: a nucleomorph is the vestigial nucleus of a eukaryotic endosymbiont
C>Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 15-Jun-2001
C:Accession: C90113
R:Douglas, S.; Zauner, S.; Fraunholz, M.; Beaton, M.; Penny, S.; Deng, L.T.; Wu, X.; Reil
Nature 410, 1091-1096, 2001
A>Title: The highly reduced genome of an enslaved algal nucleus.
A:Reference number: A99082; MUID:11323671; PMID:11323671

```

A:Accession: C90113
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-649 <DOU>
A:Cross-references: GB:AJ010592; NID:gl2580753; PIDN:CAC27071.1; GSPDB:GN00151
C:Genetics:
A:Gene: putative N-terminal transit sequence
A:Map position: 2
A:Genome: nucleomorph
C:Superfamily: gida protein
C:Keywords: nucleomorph

Query Match 34.8%; Score 52.5; DB 2; Length 649;
Best Local Similarity 41.4%; Pred. No. 7.1;
Matches 12; Conservative 6; Mismatches 10; Indels 1; Gaps 1;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDL 29
Db 459 EYRMLLRGDNADIRLKLGRKY-GLVDDI 486

RESULT 11
AG0458
acetyl-CoA C-acyltransferase (EC 2.3.1.16) [imported] - Yersinia pestis (strain C092)
C:Species: Yersinia pestis
C:Date: 02-Nov-2001 #sequence_revision 02-Nov-2001 #text_change 27-Nov-2001
C:Accession: AG0458
R:Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.; Prentice, M.B.;
deno-Tarraga, A.M.; Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G.;
il, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; Whitehead, S.; Barrell,
Nature 413, 523-527, 2001
A:Title: Genome sequence of Yersinia pestis, the causative agent of plague.
A:Reference number: AB0001; MUID:21470413; PMID:11586360
A:Accession: AG0458
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-387 <KUR>
A:Cross-references: GB:AL590842; PIDN:CAC93235.1; PID:g15981682; GSPDB:GN00175
C:Genetics:
A:Gene: fadA
C:Superfamily: acetyl-CoA acetyltransferase
C:Keywords: acyltransferase; coenzyme A

Query Match 34.4%; Score 52; DB 2; Length 387;
Best Local Similarity 60.0%; Pred. No. 4.8;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQSPMGKQGG 24
Db 6 IIDAVRTPMGKSGG 20

RESULT 12
JQ0729
60K inner-membrane protein - Proteus mirabilis (fragment)
C:Species: Proteus mirabilis
C:Date: 12-Mar-1993 #sequence_revision 12-Mar-1993 #text_change 08-Oct-1999
C:Accession: JQ0729
R:Skovgaard, O.
Gene 93, 27-34, 1990
A:Title: Nucleotide sequence of a Proteus mirabilis DNA fragment homologous to the 60K-
A:Reference number: JQ0729; MUID:91033012; PMID:2172087
A:Accession: JQ0729
A:Molecule type: DNA
A:Residues: 1-237 <SKO>
A:Cross-references: GB:MS6352; GB:M31295; NID:g150873; PIDN:AAA83954.1; PID:g150874
A:Experimental source: strain LM1509
C:Keywords: DNA replication; membrane protein

Query Match 33.8%; Score 51; DB 2; Length 237;
Best Local Similarity 31.0%; Pred. No. 4;
Matches 9; Conservative 12; Mismatches 4; Indels 4; Gaps 1;

QY 2 RMALQTDIVDLQSPMGKQGGTLDL 30
Db 61 KLITVTDVLDLRIN----TGGTIDEAD 85

RESULT 13
C83776
oxidoreductase BH1011 [imported] - Bacillus halodurans (strain C-125)
C:Species: Bacillus halodurans
C:Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001
C:Accession: C83776
R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hira-
Nucleic Acids Res. 28, 4317-4331, 2000
A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A:Reference number: A83650; MUID:20512582; PMID:11058132
A:Accession: C83776
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-297 <STO>
A:Cross-references: GB:AP001510; GB:BA000004; NID:gl0173440; PIDN:BA04730.1; GSPDB:GN000
A:Experimental source: strain C-125
C:Genetics:
A:Gene: BH1011
C:Superfamily: fission yeast pyridoxine 4-dehydrogenase

Query Match 32.8%; Score 49.5; DB 2; Length 297;
Best Local Similarity 39.3%; Pred. No. 8.7;
Matches 11; Conservative 5; Mismatches 7; Indels 5; Gaps 1;

QY 1 ERMALQTDIVDLQSPMGKQGGTLD 28
Db 103 DSLRLQTDYIDLY-----QLHGGTIDD 125

RESULT 14
E86530
initiation factor-2 [imported] - Chlamydomophila pneumoniae (strain J138)
C:Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae
C:Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 23-Mar-2001
C:Accession: E86530
R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Is
Nucleic Acids Res. 28, 2311-2314, 2000
A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.
A:Reference number: A86491; MUID:20330349; PMID:10871362
A:Accession: E86530
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-890 <STO>
A:Cross-references: GB:BA000008; NID:gb978691; PIDN:BAA98527.1; GSPDB:GN00142
A:Experimental source: strain J138
C:Genetics:
A:Gene: infB
C:Superfamily: translation initiation factor IF-2; translation elongation factor Tu homo

Query Match 32.5%; Score 49; DB 2; Length 890;
Best Local Similarity 38.1%; Pred. No. 34;
Matches 8; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

QY 3 MMALQTDIVDLQSPMGKQGG 23
Db 553 MLALQAEVLELKADFSARAG 573

RESULT 15
E81576
translation initiation factor 2 CP0440 [imported] - Chlamydomophila pneumoniae (strain AR3
C:Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae
C:Date: 31-Mar-2000 #sequence_revision 31-Mar-2000 #text_change 21-Jul-2000
C:Accession: E81576
R:Read, T.D.; Brunham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hickey, J.
C.; Dodson, R.; Gwinn, M.; Nelson, W.; DeBoy, R.; Kolonay, J.; McClarty, G.; Salzberg,
Nucleic Acids Res. 28, 1397-1406, 2000
A:Title: Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.

A,Reference number: A81500; MUID:20150255; PMID:10684935
A,Accession: E81576
A,Status: preliminary
A,Molecule type: DNA
A,Residues: 1-890 <REA>
A,Cross-references: GB:AE002205; GB:AE002161; NID:g7189360; PID:g7189360
A,Experimental source: strain AR39, HL cells
C:Genetics:
A:Gene: CP0440
C,Superfamily: translation initiation factor IF-2; translation elongation factor Tu homolog

Search completed: September 24, 2004, 09:46:21
Job time : 40 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 09:40:54 ; Search time 23 Seconds
(without alignments)
67.918 Million cell updates/sec

Title: US-09-806-701-16_COPY_331_360
Perfect score: 151
Sequence: 1 ERWALQTDIVDLQSPMKRKGQGTLDLLE 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	151	100.0	756	1 IKKB HUMAN	O14920 homo sapien
2	151	100.0	757	1 IKKB MOUSE	O88351 mus musculus
3	151	100.0	757	1 IKKB RAT	O9gy78 rattus norv
4	84	55.6	745	1 IKKA MOUSE	O60680 m inhibitor
5	79	52.3	745	1 IKKA HUMAN	O51111 h inhibitor
6	54	35.8	387	1 THIK_ECO57	O8x8j4 escherichia
7	54	35.8	387	1 THIK_ECOLI	P21151 escherichia
8	54	35.8	387	1 THIK_SALTY	O91616 salmonella
9	54	35.8	390	1 THIK_PSEFR	P28790 pseudomonas
10	52	34.4	387	1 THIK_YERPE	O8zam9 versinia pe
11	51	33.8	237	1 OXAA_PROMI	P22833 proteus mir
12	51	33.8	656	1 ACSA_SYNEL	O8dkh2 synechococc
13	50	33.1	887	1 IF2_CHLCV	O823f2 chlamydophi
14	49	32.5	890	1 IF2_CHLEN	O9z8m1 chlamydia p
15	49	32.5	892	1 IF2_CHLTR	O84098 chlamydia t
16	49	32.5	896	1 IF2_CHLMU	O9pku0 chlamydia m
17	48	31.8	539	1 TCPD_HUMAN	P50991 homo sapien
18	48	31.8	539	1 TCPD_MOUSE	P80315 mus musculus
19	48	31.8	601	1 SG2_FANRI	P30945 rana ridibu
20	48	31.8	605	1 DY14_HUMAN	O9gz80 homo sapien
21	47	31.1	528	1 TCPD_YEAST	P39078 saccharomyc
22	47	31.1	533	1 TCPD_AEDTR	O9nb32 aedes trise
23	47	31.1	880	1 IF2_LEPIN	O8f7k1 leptospira
24	46.5	30.8	350	1 CMTG_PSEPU	Q51983 pseudomonas
25	46	30.5	536	1 TCPD_FUGRU	P53451 fugu rubrip
26	46	30.5	874	1 SYA_PASMU	P57933 pasteurella
27	45	29.8	281	1 VPM_BPHPL	P51721 bacterioph
28	45	29.8	358	1 RNFD_RHOCA	O52715 rhodobact
29	45	29.8	360	1 CGST_PSPRK	O88ci7 pseudomonas
30	45	29.8	401	1 CATF_ACICA	O43935 acinetobact
31	45	29.8	401	1 PCAF_ACICA	Q43974 acinetobact
32	45	29.8	415	1 PGK_SULTO	O971k1 sulfolobus
33	45	29.8	429	1 PUR2_VIBCH	O9kv81 vibrio chol

RESULT 1

IKKB_HUMAN

ID IKKB_HUMAN STANDARD; PRT; 756 AA.

AC O14920; O75327; 431 1 PUR2_XANCP

DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Inhibitor of nuclear factor kappa B kinase beta subunit (EC 2.7.1.1.-)

DE (I-kappa-B-kinase beta) (IKKB) (IKK-B) (I-kappa-B kinase

2) (IKK2) (Nuclear factor NF-kappa-B inhibitor kinase beta) (NFKB1KB).

GN IKKB OR IKK2.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Carnivora; Hominidae; Homo.

OC NCBI_TaxID=9606;

RN [1]

SEQUENCE FROM N.A., AND MUTAGENESIS OF LYS-44; SER-177 AND SER-181.

RC TISSUE=Cervical carcinoma;

RX MEDLINE=98008813; PubMed=9346484;

RA Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L.,

Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A.;

"IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for

NF-kappaB activation.";

RN Science 278:860-866 (1997).

[2]

SEQUENCE FROM N.A., AND MUTAGENESIS OF LYS-44.

RX MEDLINE=98008814; PubMed=9346485;

RA Woronicz J.D., Cao X., Cao Z., Rothe M., Goeddel D.V.;

"IkappaB kinase-beta: NF-kappaB activation and complex formation with

IkappaB kinase-alpha and NIK.";

RN Science 278:866-869 (1997).

[3]

SEQUENCE FROM N.A.

RC TISSUE=Heart;

RX MEDLINE=99032998; PubMed=9813230;

RA Hu M.C.-T., Wang Y.-P.;

"IkappaB kinase-alpha and -beta genes are coexpressed in adult and

embryonic tissues but localized to different human chromosomes.";

RN Gene 222:31-40 (1998).

[4]

SEQUENCE FROM N.A., AND GENE MAPPING.

RX MEDLINE=98438415; PubMed=9763654;

RA Shindo M., Nakano H., Sakon S., Yagita H., Mihara M., Okumura K.;

"Assignment of IkappaB kinase beta (IKKB) to human chromosome band

8p12-->p11 by in situ hybridization.";

RN Cytogenet. Cell Genet. 82:32-33 (1998).

[5]

SEQUENCE OF 1-256 FROM N.A.

RC TISSUE=Lung;

RX MEDLINE=22388257; PubMed=12477932;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

Diatchenko L., Marusina K., Farmer A.F., Rubin G.M., Hong L.,

Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramsen R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fabey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [16]
RP IKK PHOSPHORYLATION.
RX MEDLINE=99038238; PubMed=9819420;
RA Nemoto S., Diodato J.A., Lin A.;
RT "Coordinate regulation of IkappaB kinases by mitogen-activated protein
RT kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
RL Mol. Cell. Biol. 18:7336-7343(1998).
RN [17]
RP REVIEW.
RX MEDLINE=20178139; PubMed=10712233;
RA Jobin C., Sartor R.B.;
RT "The I kappa B/NF-kappa B system: a key determinant of mucosal
RT inflammation and protection.";
RL Am. J. Physiol. 278:C451-C462(2000).
RN [18]
RP IDENTIFICATION IN A COMPLEX WITH CREBBP; NCOA2; NCOA3; IKKA AND IKKBG.
RX MEDLINE=21968797; PubMed=11971985;
RA Wu R.C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.J.,
RA O'Malley B.W.;
RT "Regulation of SRC-3 (pCIP/ACTE/ATB-1/RAC-3/TRAM-1) coactivator
RT activity by I kappa B kinase.";
RL Mol. Cell. Biol. 22:3549-3561(2002).
CC -!- FUNCTION: Phosphorylates inhibitors of NF-kappa-B thus leading to
CC the dissociation of the inhibitor/NF-kappa-B complex and
CC ultimately the degradation of the inhibitor. Also phosphorylates
CC NCOA3 (by similarity).
CC -!- SUBUNIT: Preferentially found as a heterodimer with IKK-alpha but
CC also as a homodimer. Directly interacts with IKK-gamma/NEMO.
CC Heterodimers form the active complex. The tripartite complex can
CC also bind to MEK1, MAP3K14/NIK, IKAP and IKB-alpha-p65-p50
CC complex. Phosphorylated IKB-alpha is further released from the
CC complex. Found in a complex composed of NCOA2, NCOA3, IKKA, IKKBG
CC and CREBBP.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- TISSUE SPECIFICITY: Highly expressed in heart, placenta, skeletal
CC muscle, kidney, pancreas, spleen, thymus, prostate, testis and
CC peripheral blood.
CC -!- PTM: Phosphorylated by MEK1 and probably also by MAP3K14/NIK.
CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC IKAPPAB KINASE SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AF023684; AAC51860.1; -;
CC EMBL; AF080158; AAD08997.1; -;
CC EMBL; AF031416; AAC64675.1; -;
CC EMBL; BC006231; AAH06231.1; -;
CC HSP; Q63450; 1A06.
CC Genew; HGNC:5960; IKKBK.
CC MIM; 603258; -;
CC C:cytoplasm; NAS.
CC GO; GO:0005737; F:ATP binding; NAS.
CC GO; GO:0005524; F:ATP binding; NAS.

DR GO; GO:0004674; F:protein serine/threonine kinase activity; NAS.
DR GO; GO:0016563; F:transcriptional activator activity; NAS.
DR GO; GO:0006468; P:protein amino acid phosphorylation; NAS.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR008271; Ser thr_pkin_AS.
DR Pfam; PF00069; pkinase; 1.
DR Pfam; PF00240; ubiquitin; 1.
DR ProDom; PD000001; Prot kinase; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
KW Transferase; Serine/threonine-protein kinase; ATP-binding;
KW Phosphorylation.
FT DOMAIN 15 300 PROTEIN KINASE.
FT DOMAIN 458 479 LEUCINE-ZIPPER (POTENTIAL).
FT NP_BIND 21 29 NEMO-BINDING.
FT BINDING 44 44 ATP (BY SIMILARITY).
FT ACT_SITE 145 145 ATP (BY SIMILARITY).
FT MOD_RES 23 23 BY SIMILARITY.
FT MOD_RES 177 177 PHOSPHORYLATION (BY SIMILARITY).
FT MOD_RES 181 181 PHOSPHORYLATION.
FT MUTAGEN 44 44 K->A: LOSS OF KINASE ACTIVITY AND NO
FT MUTAGEN 177 177 EFFECT ON BINDING TO NIK.
FT MUTAGEN 177 177 S->A: DECREASE OF ACTIVITY.
FT MUTAGEN 181 181 S->E: FULL ACTIVATION.
FT MUTAGEN 181 181 S->A: DECREASE OF ACTIVITY.
FT MUTAGEN 181 181 S->E: FULL ACTIVATION.
FT CONFLICT 231 255 WHSKVRQKSEDIVVSDINGTVKF -> CVERWPGTVVHNS
FT CONFLICT 425 425 CNPSTLGGGRWVI (IN REF. 5).
FT CONFLICT 425 425 Q -> H (IN REF. 1).
SQ SEQUENCE 756 AA; 86563 MW; F9CADF671AE9B14E CRC64;
Query Match 100.0%; Score 151; DB 1; Length 756;
Best Local Similarity 100.0%; Pred. No. 4.1e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ERMALQTDIVDLQSPMGKKGGLDLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLDLE 564
RESULT 2
ID IKKB MOUSE STANDARD; PRT; 757 AA.
AC Q88351; Q9R1J6;
DT 16-OCT-2001 (Rel. 40, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE Inhibitor of nuclear factor kappa B kinase beta subunit (IC 2.7.1.-)
DE (I-kappa-B-kinase beta) (IKKB) (IKK-beta) (I-kappa-B kinase
DE 2) (IKK2) (Nuclear factor NF-kappa-B inhibitor kinase beta) (NFKB1KB).
GN IKKB OR IKKB.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A., AND PHOSPHORYLATION BY MEK1.
RC STRAIN=C57BL/6; TISSUE=Spleen;
RX MEDLINE=9818238; PubMed=9520401;
RA Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H.,
RA Okumura K.;
RT "Differential regulation of IkappaB kinase alpha and beta by two
RT upstream kinases, NF-kappaB-inducing kinase and mitogen-activated
RT protein kinase/ERK kinase kinase-1.";
RL Proc. Natl. Acad. Sci. U.S.A. 95:3537-3542(1998).
RN [2]
RP SEQUENCE FROM N.A.
RA Hu M.C.-T., Wang Y.-P., Mikhail A., Qiu W.R.;
RT "Murine Ikb kinase-B, a developmentally regulated protein kinase that
RT constitutively phosphorylates serine residues of IKB.";
RT Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.

[3]
 RN DEVELOPMENTAL STAGE
 RP MEDLINE=99453228; PubMed=10523828;
 RA Hu M.C.-I., Wang Y.-P., Qiu W.R., Mikhail A., Meyer C.F., Tan T.-H.;
 RT "Hematopoietic progenitor kinase-1 (HPK1) stress response signaling
 pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a
 developmentally regulated protein kinase.";
 RL Oncogene 18:5514-5524(1999).
 RN [4]
 RP IKK PHOSPHORYLATION.
 RX MEDLINE=99038238; PubMed=9819420;
 RA Nemoto S., DiDonato J.A., Lin A.;
 RT "Coordinate regulation of IkappaB kinases by mitogen-activated protein
 kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
 RL Mol. Cell. Biol. 18:7336-7343(1998).
 RN [5]
 RP REVIEW.
 RX MEDLINE=20178139; PubMed=10712233;
 RA Jobin C., Sartor R.B.;
 RT "The I kappa B/NF-kappa B system: a key determinant of mucosal
 inflammation and protection.";
 RL Am. J. Physiol. 278:C451-C462(2000).
 CC -!- FUNCTION: Phosphorylates inhibitors of NF-kappa-B thus leading to
 the dissociation of the inhibitor/NF-kappa-B complex and
 ultimately the degradation of the inhibitor. Also phosphorylates
 NCOA3.
 CC -!- SUBUNIT: Preferentially found as a heterodimer with IKK-alpha but
 also as a homodimer. Directly interacts with IKK-gamma/NEMO.
 CC Heterodimers form the active complex. The tripartite complex can
 also bind to MEKK1, MAP3K14/NIK, IKAP and IKK-alpha-p65-p50
 complex. Phosphorylated IKK-alpha is further released from the
 complex. Found in a complex composed of NCOA2, NCOA3, IKKA, IKKBG
 and CREBBP (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -!- TISSUE SPECIFICITY: Expressed in liver, kidney and spleen.
 CC -!- DEVELOPMENTAL STAGE: While it is expressed ubiquitously throughout
 the mouse embryo, at E9.5 day its expression begins to be
 localized to the brain, neural ganglia, neural tube, and in liver
 at E12.5 day. At E15.5 day, the expression is further restricted
 to specific tissues of the embryo.
 CC -!- PTM: Phosphorylated by MEKK1 and probably also by MAP3K14/NIK.
 CC Weakly autophosphorylated.
 CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
 CC IKAPPAB KINASE SUBFAMILY.

 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).

 DR EMBL; AF026524; AAC23557.1; +.
 DR EMBL; AF088910; AAD52095.1; +.
 DR HSSP; Q63450; 1A06.
 DR MGD; MGI:1338071; Ikbkb.
 DR InterPro; IPR000719; Prot_kinase.
 DR InterPro; IPR008271; Ser_thr_pkin_AS.
 DR InterPro; IPR001245; Tyr_pkinase.
 DR Pfam; PF00069; pkinase; 1.
 DR PRINTS; PR00109; TYRKINASE.
 DR ProDom; PD000001; Prot_kinase; 1.
 DR PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
 DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
 DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
 DR Transferrase; Serine/threonine-protein kinase; ATP-binding;
 KW Phosphorylation.
 FT DOMAIN 15 300 PROTEIN KINASE.
 FT DOMAIN 458 479 LEUCINE-ZIPPER (POTENTIAL).
 FT DOMAIN 737 742 NEMO-BINDING.
 FT NP_BIND 21 29 ATP (BY SIMILARITY).
 FT BINDING 44 44 ATP (BY SIMILARITY).

FT ACT_SITE 145 145 BY SIMILARITY.
 FT MOD_RES 23 23 PHOSPHORYLATION (BY SIMILARITY).
 FT MOD_RES 177 177 PHOSPHORYLATION (BY SIMILARITY).
 FT MOD_RES 181 181 PHOSPHORYLATION (BY SIMILARITY).
 FT CONFLICT 56 56 N -> D (IN REF. 2).
 FT CONFLICT 343 343 N -> D (IN REF. 2).
 FT CONFLICT 356 356 K -> E (IN REF. 2).
 FT CONFLICT 390 390 L -> F (IN REF. 2).
 FT CONFLICT 406 406 P -> Q (IN REF. 2).
 FT CONFLICT 573 573 K -> R (IN REF. 2).
 FT CONFLICT 736 736 TLDMSWLQMEDEERCSLEQACD -> VTA (IN REF. 2).
 SQ SEQUENCE 757 AA; 86690 MW; FED962F095449CSE CRC64;
 Query Match 100.0%; Score 151; DB 1; Length 757;
 Best Local Similarity 100.0%; Pred. No. 4; le-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ERMALQTDIVDLQSPMGRKQGGLDDLE 30
 Db 535 ERMALQTDIVDLQSPMGRKQGGLDDLE 564
 RESULT 3
 ID IKKB RAT STANDARD; PRT; 757 AA.
 AC Q9QY78;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 26-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Inhibitor of nuclear factor kappa B kinase beta subunit (EC 2.7.1.-)
 DE (I-kappa-B-kinase beta) (IKKB) (IKK-beta) (I-kappa-B kinase
 2) (IKK2) (Nuclear factor NF-kappa-B inhibitor kinase beta) (NFKB1KB).
 GN IKKB OR IKKB.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Zhang Y., Sun S., Ravidi K.;
 RT "IKK beta in megakaryocyte differentiation.";
 RL Submitted (DEC-1998) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP IKK PHOSPHORYLATION.
 RX MEDLINE=99038238; PubMed=9819420;
 RA Nemoto S., DiDonato J.A., Lin A.;
 RT "Coordinate regulation of IkappaB kinases by mitogen-activated protein
 kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
 RL Mol. Cell. Biol. 18:7336-7343(1998).
 RN [3]
 RP REVIEW.
 RX MEDLINE=20178139; PubMed=10712233;
 RA Jobin C., Sartor R.B.;
 RT "The I kappa B/NF-kappa B system: a key determinant of mucosal
 inflammation and protection.";
 RL Am. J. Physiol. 278:C451-C462(2000).
 CC -!- FUNCTION: Phosphorylates inhibitors of NF-kappa-B thus leading to
 the dissociation of the inhibitor/NF-kappa-B complex and
 ultimately the degradation of the inhibitor. Also phosphorylates
 NCOA3.
 CC -!- SUBUNIT: Preferentially found as a heterodimer with IKK-alpha but
 also as a homodimer. Directly interacts with IKK-gamma/NEMO.
 CC Heterodimers form the active complex. The tripartite complex can
 also bind to MEKK1, MAP3K14/NIK, IKAP and IKK-alpha-p65-p50
 complex. Phosphorylated IKK-alpha is further released from the
 complex. Found in a complex composed of NCOA2, NCOA3, IKKA, IKKBG
 and CREBBP (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -!- PTM: Phosphorylated by MEKK1 and probably also by MAP3K14/NIK.
 CC Weakly autophosphorylated.
 CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
 CC IKAPPAB KINASE SUBFAMILY.

 This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@isb-sib.ch).

 EMBL; AF115282; AAF21978.1; --
 HSSP; Q63450; 1A06.
 DR InterPro; IPR000719; Prot_kinase.
 DR InterPro; IPR008271; Ser_thr_kin_AS.
 DR InterPro; IPR001245; Tyr_kinase.
 DR Pfam; PF00069; pkinase; 1
 DR PRINTS; PR00109; TYRKINASE.
 DR ProDom; PD000001; Prot_kinase; 1.
 DR PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
 DR PROSITE; PS00107; PROTEIN_KINASE_DOM; 1.
 DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
 DR TRANSFAC; Serine/threonine-protein kinase; ATP-binding;
 KW Phosphorylation.
 FT DOMAIN 15 300 PROTEIN KINASE.
 FT DOMAIN 458 479 LEUCINE-ZIPPER (POTENTIAL).
 FT DOMAIN 737 742 NEMO-BINDING.
 FT NP_BIND 21 29 ATP (BY SIMILARITY).
 FT BINDING 44 44 ATP (BY SIMILARITY).
 FT ACT_SITE 145 145 BY SIMILARITY.
 FT MOD_RES 23 23 PHOSPHORYLATION (BY SIMILARITY).
 FT MOD_RES 177 177 PHOSPHORYLATION (BY SIMILARITY).
 FT MOD_RES 181 181 PHOSPHORYLATION (BY SIMILARITY).
 SQ SEQUENCE 757 AA; 86866 MW; 3APFE46A7DF91P9C CRC64;
 Query Match 100.0%; Score 151; DB 1; Length 757;
 Best Local Similarity 100.0%; Pred. No. 4.1e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
 Db 535 ERMALQTDIVDLQSPMGKQGGTLDLLE 564
 RESULT 4
 IKKA MOUSE
 ID IKKA MOUSE STANDARD; PRT; 745 AA.
 AC Q6080; Q9D2X3;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Inhibitor of nuclear factor kappa-B kinase alpha subunit (EC 2.7.1.1-)
 DE (I kappa-B kinase alpha) (IKK α) (IKK-alpha) (IkappaB kinase
 DE (I-kappa-B kinase 1) (IKK1) (Conserved helix-loop-helix ubiquitous
 DE kinase) (Nuclear factor NFkappaB inhibitor kinase alpha) (NFKB1KA).
 GN CHUK OR IKK α .
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10030;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC STRAIN=BALB/c;
 RX MEDLINE=9604444; PubMed=7558004;
 RA Mock B.A., Connelly M.A., McBride O.W., Kozak C.A., Marcu K.B.;
 RT "CHUK, a conserved helix-loop-helix ubiquitous kinase, maps to human
 RT chromosome 10 and mouse chromosome 19";
 RL Genomics 27:3348-351 (1995).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC STRAIN=BALB/c;
 RX MEDLINE=96258427; PubMed=8777433;
 RA Connelly M.A., Marcu K.B.;
 RT "CHUK, a new member of the helix-loop-helix and leucine zipper
 RT families of interacting proteins, contains a serine-threonine kinase

RT catalytic domain.";
 RL Cell. Mol. Biol. Res. 41:537-549 (1996).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM 3).
 RC STRAIN=C57BL/6J; TISSUE=Colon;
 RX MEDLINE=21085660; PubMed=11217951;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
 RA Saito T., Okazaki Y., Gojohori T., Bono H., Kasukawa T., Saio R.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
 RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi T.,
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
 RA Wyszaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohtsuki S.,
 RA Hayashizaki Y.;
 RT "Functional annotation of a full-length mouse cDNA collection.";
 RL Nature 409:685-690 (2001).
 RN [4]
 RP ALTERNATIVE SPLICING.
 RX MEDLINE=20198447; PubMed=10733566;
 RA McKenzie F.R., Connelly M.A., Ballarano D., Mueller J.R.,
 RA Gelezianas R., Marcu K.B.;
 RT "Functional isoforms of IkappaB kinase alpha (IKKalpha) lacking
 RT leucine zipper and helix-loop-helix domains reveal that IKKalpha and
 RT IKKbeta have different activation requirements.";
 RL Mol. Cell. Biol. 20:2635-2649 (2000).
 RN [5]
 RP PHOSPHORYLATION BY MAP3K1/NIK.
 RX MEDLINE=98188238; PubMed=9520401;
 RA Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H.,
 RA Okumura K.;
 RT "Differential regulation of IkappaB kinase alpha and beta by two
 RT upstream kinases, NF-kappaB-inducing kinase and mitogen-activated
 RT protein kinase/ERK kinase kinase-1.";
 RL Proc. Natl. Acad. Sci. U.S.A. 95:3537-3542 (1998).
 RN [6]
 RP IKKA-IKKB BINDING.
 RX MEDLINE=99212141; PubMed=10195894;
 RA Delnase M., Hayakawa M., Chen Y., Karin M.;
 RT "Positive and negative regulation of IkappaB kinase activity through
 RT IKKbeta subunit phosphorylation.";
 RL Science 284:309-313 (1999).
 RN [7]
 RP IKK PHOSPHORYLATION.
 RX MEDLINE=99038238; PubMed=9819420;
 RA Nemoto S., Dizonato J.A., Lin A.;
 RT "Coordinate regulation of IkappaB kinases by mitogen-activated protein
 RT kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
 RL Mol. Cell. Biol. 18:7336-7343 (1998).
 RN [8]
 RP REVIEW.
 RX MEDLINE=20178139; PubMed=10712233;
 RA Jobin C., Sartor R.B.;
 RT "The I kappa B/NF-kappa B system: a key determinant of mucosal
 RT inflammation and protection.";
 RL Am. J. Physiol. 278:C451-C462 (2000).
 CC -I- FUNCTION: Phosphorylates inhibitors of NF-kappa-B thus leading to
 CC the dissociation of the inhibitor/NF-kappa-B complex and
 CC ultimately the degradation of the inhibitor. Also phosphorylates
 CC NCOA3.
 CC -I- ENZYME REGULATION: Activated when phosphorylated and inactivated
 CC when dephosphorylated.
 CC -I- SUBUNIT: Preferentially found as a heterodimer with IKK-beta but
 CC also as an homodimer. Directly interacts with IKK-gamma/NEMO.
 CC

Heterodimers form the active complex. The tripartite complex can also bind to MAP3K14/NIK, MEK1, IKAP and IKK-alpha-p65-p50 complex. A weak interaction with TRAF2 cannot be excluded. Part of a complex composed of NCOA2, NCOA3, IKK1, IKK2 and CRBBP (By similarity).

-1- SUBCELLULAR LOCATION: Cytoplasmic.

-1- ALTERNATIVE PRODUCTS:

Event=Alternative splicing; Named isoforms=3;

Name=1;

isoId=Q0680-1; Sequence=Displayed;

Name=2; Synonyms=Delta LH;

isoId=Q0680-2; Sequence=VSP_004866, VSP_004867;

Name=3; Synonyms=Delta H;

isoId=Q0680-3; Sequence=VSP_004868, VSP_004869;

-1- TISSUE SPECIFICITY: Ubiquitous only for isoform 1, isoforms 2 and 3 are expressed predominantly in brain and T-lymphocytes.

-1- DEVELOPMENTAL STAGE: Maximally expressed at E7 day followed by E11, E15 and E17 days. In the limb development, its expression predominates in the limb buds at E12.5 day.

-1- PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent by MEK1, and dephosphorylated by PP2A. Autophosphorylated.

-1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES. IKAPPAB KINASE SUBFAMILY.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; U12473; AAC52589.1; --

EMBL; AK018671; BAB31335.1; --

PIR; I49101; I49101.

HSP; Q63450; IA06.

MGI; MGI:99484; Chuk.

InterPro; IPR000719; Prot kinase.

InterPro; IPR008271; Ser_Thr_kinase.

InterPro; IPR001245; Tyr_kinase.

Pfam; PF00069; pkinase; 1.

PRINTS; PR00109; TYRKINASE.

ProDom; PD000001; Prot kinase; 1.

PROSITE; PS00107; PROTEIN KINASE ATP; 1.

PROSITE; PS00108; PROTEIN KINASE ST; 1.

PROSITE; PS00011; PROTEIN KINASE_DOM; 1.

Transferase; Serine/threonine-protein kinase; ATP-binding; Phosphorylation; Alternative splicing.

FT DOMAIN 15 300 PROTEIN KINASE.

FT DOMAIN 455 476 LEUCINE-ZIPPER (POTENTIAL).

FT DOMAIN 738 743 NEMO-BINDING.

FT NP_BIND 21 29 ATP (BY SIMILARITY).

FT BINDING 44 44 ATP (BY SIMILARITY).

FT ACT_SITE 144 144 BY SIMILARITY.

FT MOD_RES 23 23 PHOSPHORYLATION (BY PKB/AKT1) (BY SIMILARITY).

FT MOD_RES 176 176 PHOSPHORYLATION (BY MAP3K14) (BY SIMILARITY).

FT VARSPLIC 452 471 MSLRLRNANUTRMKNTLS -> IFRNVKSMERNRKGKH SLF (in isoform 2).

FT VARSPLIC 472 745 /FTid=VSP_004866.

FT VARSPLIC 577 584 Missing (in isoform 2).

FT VARSPLIC 585 745 /FTid=VSP_004867.

FT VARSPLIC 585 745 /FTid=VSP_004868.

FT VARSPLIC 585 745 Missing (in isoform 3).

FT VARSPLIC 585 745 /FTid=VSP_004869.

FT CONFLICT 236 236 K -> E (IN REF. 3).

FT CONFLICT 400 400 S -> Y (IN REF. 3).

SEQUENCE 745 AA; 84728 MW; 3FEF5582AFF92233 CRC64;

Query Match 55.6%; Score 84; DB 1; Length 745;

Best Local Similarity 46.7%; Pred. No. 6.9e-05;

Matches 14; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVLQSPMGKQGGTLDLLE 30

Db 532 DQIMSLTEIMELQSPYGRGQDLMESLE 561

RESULT 5

IKKA HUMAN

ID IKKA HUMAN STANDARD; PRT; 745 AA.

AC O5111; O14666; Q13132; Q92467;

DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Inhibitor of nuclear factor kappa-B kinase alpha subunit (EC 2.7.1.1.-)

DE (I kappa-B kinase alpha) (IKK-alpha) (IKK-A) (IkkappaB kinase)

DE (I-kappa-B kinase 1) (IKK1) (Conserved helix-loop-helix ubiquitous kinase) (Nuclear factor NF-kappaB inhibitor kinase alpha) (NFKBIA).

GN CHUK OR IKKA.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OC NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A., AND MUTAGENESIS OF LYS-44.

RC TISSUE=T-cell;

RX MEDLINE=97386461; PubMed=9244310;

RA Regnier C.H., Song H.Y., Gao X., Goeddel D.V., Cao Z., Rothe M.;

RT "Identification and characterization of an IkappaB kinase.";

RL Cell 90:373-383(1997).

RN [2]

RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.

RX MEDLINE=97394468; PubMed=9252186;

RA DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M.;

RT "A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.";

RL Nature 388:548-554(1997).

RN [3]

RP SEQUENCE FROM N.A., PARTIAL SEQUENCE, AND MUTAGENESIS OF LYS-44 AND SER-176.

RX MEDLINE=98008813; PubMed=9346484;

RA Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A.;

RT "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.";

RL Science 278:860-866(1997).

RN [4]

RP SEQUENCE FROM N.A.

RX MEDLINE=99032998; PubMed=9813230;

RA Hu M.C.-T., Wang Y.-P.;

RT "IkappaB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes.";

RL Gene 222:31-40(1998).

RN [5]

RP SEQUENCE OF 32-745 FROM N.A.

RX MEDLINE=96258427; PubMed=8777433;

RA Connolly M.A., Marcu K.B.;

RT "CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain.";

RL Cell. Mol. Biol. Res. 41:537-549(1995).

RN [6]

RP PHOSPHORYLATION BY MAP3K14/NIK, AND MUTAGENESIS OF SER-176; THR-179 AND SER-180.

RX MEDLINE=98188283; PubMed=9520446;

RA Ling L., Cao Z., Goeddel D.V.;

RT "NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.";

RL Proc. Natl. Acad. Sci. U.S.A. 95:3792-3797(1998).

RN [7]

RP PHOSPHORYLATION BY AKT, AND MUTAGENESIS OF THR-23.
 RX MEDLINE=994113720; PubMed=10485710; Pfeiffer S.R., Pfeiffer L.M.,
 RA Ozes C.N., Mayo L.D., Gustin J.A.,
 RA Donner D.B.;
 RT "NF-kappaB activation by tumour necrosis factor requires the Akt
 RT serine-threonine kinase";
 RL Nature 401:82-85(1999).
 RN [8];
 RP IKKA-IKKB BINDING.
 RX MEDLINE=99212141; PubMed=10195894;
 RA Delhase M., Hayakawa M., Chen Y., Karin M.;
 RA "Positive and negative regulation of IkappaB kinase activity through
 RT IKKbeta subunit phosphorylation";
 RL Science 284:309-313(1999).
 RN [9];
 RP IKK PHOSPHORYLATION.
 RX MEDLINE=99038238; PubMed=9819420;
 RA Nemoto S., DiDonato J.A., Lin A.;
 RA "Coordinate regulation of IkappaB kinases by mitogen-activated protein
 RT kinase kinase kinase 1 and NF-kappaB-inducing kinase";
 RL Mol. Cell. Biol. 18:7336-7343(1998).
 RN [10];
 RP REVIEW.
 RX MEDLINE=20178139; PubMed=10712233;
 RA Jobin C., Sartor R.B.;
 RA "The I kappa B/NF-kappa B system: a key determinant of mucosal
 RT inflammation and protection";
 RL Am. J. Physiol. 278:C451-C462(2000).
 RN [11];
 RP SUBUNIT OF A COMPLEX CONTAINING CREBBP, NCOA2, NCOA3, IKKB AND IKKKG.
 RX MEDLINE=21968797; PubMed=11971985;
 RA Wu R.C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.J.,
 RA O'Malley B.W.;
 RA "Regulation of SRC-3 (pCIP/ACTR/ATB-1/RAC-3/TRAM-1) coactivator
 RT activity by I kappa B kinase";
 RL Mol. Cell. Biol. 22:3549-3561(2002).
 CC -!- FUNCTION: Phosphorylates inhibitors of NF-kappa-B thus leading to
 CC the dissociation of the inhibitor/NF-kappa-B complex and
 CC ultimately the degradation of the inhibitor. Also phosphorylates
 CC NCOA3
 CC -!- ENZYME REGULATION: Activated when phosphorylated and inactivated
 CC when dephosphorylated.
 CC -!- SUBUNIT: Preferentially found as a heterodimer with IKK-beta but
 CC also as an homodimer. Directly interacts with IKK-gamma/NEMO.
 CC Heterodimers form the active complex. The tripartite complex can
 CC also bind to MAPK14/NIK, MEK1, IKAP and IKB-alpha-p65-p50
 CC complex. A weak interaction with TRAF2 cannot be excluded. Part of
 CC a complex composed of NCOA2, NCOA3, IKKB, IKKG and CREBBP.
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -!- TISSUE SPECIFICITY: Widely expressed.
 CC -!- PTM: Phosphorylated by MAPK14/NIK, AKT and to a lesser extent by
 CC MEK1, and dephosphorylated by PP2A. Autophosphorylated.
 CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
 CC IKAPPAB KINASE SUBFAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AF012890; AAC51662.1; -;
 DR EMBL: AF009225; AAC51671.1; -;
 DR EMBL: AF080157; RAD08996.1; -;
 DR EMBL: U22512; AAC50713.1; -;
 DR HSSP: Q63450; 1A06.
 DR Genew: HGNC:1974; CHUK.
 DR MIM: 600664; -;
 DR GO: GO:0005737; C:cytoplasm; TAS.
 DR GO: GO:0008384; F:IkappaB kinase activity; TAS.
 DR GO: GO:0007345; P:embryogenesis and morphogenesis; TAS.

DR GO: GO:0007252; P:I-kappaB phosphorylation; TAS.
 DR GO: GO:0006955; P:immune response; TAS.
 DR InterPro: IPR000719; Prot_kinase.
 DR InterPro: IPR008271; Ser_thr_pkin_AS.
 DR InterPro: IPR002290; Ser_thr_pkinase.
 DR InterPro: IPR001245; Tyr_pkinase.
 DR Pfam: PF00069; pkinase; 1.
 DR PRINTS: PR00109; TYRKINASE.
 DR ProDom: PD000001; Prot_kinase; 1.
 DR SMART: SM00220; S_TKc; 1.
 DR PROSITE: PS00107; PROTEIN_KINASE_ATP; 1.
 DR PROSITE: PS00108; PROTEIN_KINASE_ST; 1.
 DR PROSITE: PS00111; PROTEIN_KINASE_DOM; 1.
 KW Transferase: Serine/threonine-protein kinase; ATP-binding;
 KW Phosphorylation.
 FT DOMAIN 15 302 PROTEIN KINASE.
 FT DOMAIN 455 476 LEUCINE-ZIPPER (POTENTIAL).
 FT NP_BIND 21 29 NEMO-BINDING.
 FT BINDING 44 44 ATP (BY SIMILARITY).
 FT ACT_SITE 144 144 ATP (BY SIMILARITY).
 FT MOD_RES 23 23 BY SIMILARITY.
 FT MOD_RES 176 176 PHOSPHORYLATION (BY PKB/AKT1).
 FT MUTAGEN 23 23 PHOSPHORYLATION (BY MAP3K14).
 FT MUTAGEN 44 44 T->A: LOSS OF PHOSPHORYLATION AND
 FT MUTAGEN 44 44 DECREASE OF KINASE ACTIVITY.
 FT MUTAGEN 176 176 K->A: LOSS OF KINASE ACTIVITY.
 FT MUTAGEN 176 176 K->M: LOSS OF AUTOPHOSPHORYLATION.
 FT MUTAGEN 176 176 S->A: LOSS OF PHOSPHORYLATION AND OF
 FT ACTIVITY.
 FT MUTAGEN 176 176 S->E: FULL ACTIVATION.
 FT MUTAGEN 179 179 T->A: NO CHANGE IN PHOSPHORYLATION.
 FT MUTAGEN 180 180 S->A: NO CHANGE IN PHOSPHORYLATION.
 FT CONFLICT 543 543 E -> G (IN REF. 2).
 FT CONFLICT 604 604 L -> R (IN REF. 5).
 FT CONFLICT 679 680 TS -> AY (IN REF. 5).
 FT CONFLICT 684 684 P -> A (IN REF. 3 AND 5).
 FT CONFLICT 686 687 TS -> DL (IN REF. 5).
 SQ SEQUENCE 745 AA; 84653 MW; 7A90B59BC98A56C2 CRC64;
 Query Match 52.3%; Score 79; DB 1; Length 745;
 Best Local Similarity 43.3%; Pred. No. 0.0004; Indels 0; Gaps 0;
 Matches 13; Conservative 11; Mismatches 6;
 QY 1 ERMALQTDIVDLQSPMGKQGGTLDLIE 30
 DB 532 DQMSLHAEIMELQKSPYGRQGDLMESLE 561
 RESULT 6
 ID THIK ECO57 STANDARD; PRT; 387 AA.
 AC Q8X874;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DE 3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Fatty oxidation complex beta
 GN subunit) [Beta-ketothiolase] (Acetyl-CoA acyltransferase).
 GN FADA OR Z5366 OR ECS4773.
 OS Escherichia coli O157:H7.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Escherichia.
 OX NCBI_TaxID=83334;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=O157:H7 / EDL933 / ATCC 700927;
 RX MEDLINE=21074935; PubMed=11208551;
 RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,
 RA Rose D.J., Mayhew G.R., Evans P.S., Gregor J., Kirkpatrick H.A.,
 RA Posfai G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,
 RA Grobeck E.J., Davis N.W., Lim A., Dimalanta E.T., Potamoudis K.,
 RA Apodaca J., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,
 RA Welch R.A., Blattner F.R.;
 RT "Genome sequence of enterohaemorrhagic Escherichia coli O157:H7";


```

RL Nature 409:529-533 (2001).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=O157:H7 / RMD 0509952;
RX MEDLINE=21156231; PubMed=11258796;
RA Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
RA Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T.,
RA Iida T., Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T.,
RA Kuhara S., Shiba I., Hattori M., Shinagawa H.;
RT "Complete genome sequence of enterohemorrhagic Escherichia coli
RT O157:H7 and genomic comparison with a laboratory strain K-12."
RL DNA Res. 8:11-22(2001).
CC -!- FUNCTION: FadB and fadA are the alpha and beta subunits of the
CC multifunctional enzyme complex of the fatty acid degradation
CC cycle. (By similarity).
CC -!- CATALYTIC ACTIVITY: Acyl-CoA + acetyl-CoA = CoA + 3-oxoacyl-CoA.
CC -!- PATHWAY: Fatty acid beta-oxidation cycle; third step.
CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By
CC similarity).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
CC -!- SIMILARITY: Belongs to the thiolase family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; AE005615; AAG59039.1; -.
CC DR EMBL; AP002567; BAB38196.1; -.
CC DR PIR; C86072; C86072.
CC DR PIR; E91225; E91225.
CC DR InterPro; IPR002155; Thiolase.
CC DR Pfam; PF00108; Thiolase; 1.
CC DR PROSITE; PS00098; THIOLEASE_1; 1.
CC DR PROSITE; PS00737; THIOLEASE_2; 1.
CC DR PROSITE; PS00099; THIOLEASE_3; 1.
CC KW Fatty acid metabolism; Transferase; Acyltransferase;
CC Complete proteome.
FT ACT_SITE 91 91 SUBSTRATE BINDING (BY SIMILARITY).
FT ACT_SITE 373 373 BASE (BY SIMILARITY).
FT ACT_SITE 387 387
SQ SEQUENCE 387 AA; 40841 MW; 98D3879B30B46CCC CRC64;
Query Match 35.8%; Score 54; DB 1; Length 387;
Best Local Similarity 61.1%; Pred. No. 1.3;
Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;
QY 7 QTQIVDLQSPMGKRGKG 24
Db 3 QQVIVDAIRTPMGKSGG 20
RESULT 7
THIK_ECOLI STANDARD; PRT; 387 AA.
AC P21151; P78130;
DT 01-MAY-1991 (Rel. 18, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE 3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Fatty oxidation complex beta
DE subunit) (Beta-ketothiolase) (Acetyl-CoA acyltransferase).
GN FADA OR OLDA OR B3845.
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=K12 / MG1655;
RX MEDLINE=92358234; PubMed=1379743;

```

```

RA Daniels D.L., Plunkett G. III, Burland V.D., Blattner F.R.;
RT "Analysis of the Escherichia coli genome: DNA sequence of the region
RT from 84.5 to 86.5 minutes."
RL Science 257:771-778(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=91035260; PubMed=1699931;
RA Dirusso C.C.;
RT "Primary sequence of the Escherichia coli fadBA operon, encoding the
RT fatty acid-oxidizing multienzyme complex, indicates a high degree of
RT homology to eucaryotic enzymes."
RL J. Bacteriol. 172:6459-6468(1990).
RN [3]
RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-10.
RC STRAIN=K12;
RX MEDLINE=90285166; PubMed=2191949;
RA Yang S.-Y., Yang X.-Y.H., Healy-Louie G., Schulz H., Elzinga M.;
RT "Nucleotide sequence of the fadA gene. Primary structure of
RT 3-ketoacyl-coenzyme A thiolase from Escherichia coli and the
RT structural organization of the fadAB operon."
RL J. Biol. Chem. 265:10424-10429(1990).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=K12 / W3110;
RX MEDLINE=90370500; PubMed=2204034;
RA Nakahigashi K., Inokuchi H.;
RT "Nucleotide sequence of the fadA and fadB genes from Escherichia
RT coli."
RL Nucleic Acids Res. 18:4937-4937(1990).
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=K12 / MG1655;
RX MEDLINE=97426617; PubMed=9278503;
RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.P.,
RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA Mau B., Shao Y.;
RT "The complete genome sequence of Escherichia coli K-12."
RL Science 277:1453-1474(1997).
CC -!- FUNCTION: FadB and fadA are the alpha and beta subunits of the
CC multifunctional enzyme complex of the fatty acid degradation
CC cycle.
CC -!- CATALYTIC ACTIVITY: Acyl-CoA + acetyl-CoA = CoA + 3-oxoacyl-CoA.
CC -!- PATHWAY: Fatty acid beta-oxidation cycle; third step.
CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- SIMILARITY: Belongs to the thiolase family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; M87049; AAA67642.1; -.
CC DR EMBL; M59368; AAA23751.1; -.
CC DR EMBL; X52837; CAB40810.1; -.
CC DR EMBL; M74164; AAA62778.1; -.
CC DR EMBL; AE000460; AAC76848.1; -.
CC DR PIR; F65189; XUEC.
CC DR HSP; P27796; IAFY.
CC DR ECO2DBASE; H038.6; 6TH EDITION.
CC DR ECO2DBASE; H038.7; 6TH EDITION.
CC DR EcoGene; EG10278; fadA.
CC DR InterPro; IPR002155; Thiolase.
CC DR Pfam; PF00108; Thiolase; 1.
CC DR PROSITE; PS00098; THIOLEASE_1; 1.
CC DR PROSITE; PS00099; THIOLEASE_3; 1.
CC DR PROSITE; PS00737; THIOLEASE_2; 1.
CC KW Fatty acid metabolism; Transferase; Acyltransferase;

```

Complete proteome. 91 SUBSTRATE BINDING (BY SIMILARITY).
 FT ACT SITE 373 BASE (BY SIMILARITY).
 FT ACT SITE 373 T -> S (IN REF. 2 AND 3).
 FT CONFLICT 37 E -> G (IN REF. 4).
 FT CONFLICT 119 TMCI -> DGVCS (IN REF. 3).
 FT CONFLICT 371 TMCI -> DGVCS (IN REF. 3).
 SQ SEQUENCE 387 AA; 40990 MW; CB0PF8EP4597D8BA CRC64;

Query Match 35.8%; Score 54; DB 1; Length 387;
 Best Local Similarity 61.1%; Pred. No. 1.3;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 7 QTVIVDLQSPMGKGG 24
 Db 3 QVIVDAIRTPMGSKGG 20

RESULT 8
 THIK_SALTY STANDARD; PRT; 387 AA.
 ID THIK_SALTY STANDARD; PRT; 387 AA.
 AC Q9L6L6;
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE 3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Fatty oxidation complex beta subunit) (Beta-ketothiolase) (Acetyl-CoA acyltransferase).
 DE subunit (Beta-ketothiolase) (Acetyl-CoA acyltransferase).
 GN FADA OR STM3982 OR STM1.7 OR STM3578 OR T3316.
 OS Salmonella typhimurium, and
 OS Salmonella typhi.
 OS Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Salmonella.
 OX NCBI_TaxID=602, 601;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC SPECIES=S.typhimurium; STRAIN=LT2 / SGSC1412 / ATCC 700720;
 RX MEDLINE=21534948; PubMed=11677609;
 RA McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P., Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D., Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E., Ryan E., Sun H., Florea L., Miller W., Stoneking T., Nhan M., Waterston R., Wilson R.K.;
 RA "Complete genome sequence of Salmonella enterica serovar Typhimurium LT2.";
 RT Nature 413:852-856(2001).
 RL [2]
 RP SEQUENCE FROM N.A.
 RC SPECIES=S.typhi; STRAIN=CT18;
 RX MEDLINE=21534947; PubMed=11677608;
 RA Parkhill J., Dougan G., James K.B., Thomson N.R., Pickard D., Wain J., Churcher C., Mungall K.L., Bentley S.D., Holden M.T.G., Sebaihia M., Baker S., Basham D., Brooks K., Chillingworth T., Connor P., Cronin A., Davis P., Davies R.M., Dowd L., White N., Farrar J., Feltwell T., Hamlin N., Haque A., Hien T.T., Holtroyd S., Jagels K., Krogh A., Larsen T.S., Leather S., Moulé S., O'Gaora P., Parry C., Quail M.A., Rutherford K., Simmonds M., Skelton J., Stevens K., Whitehead S., Barrrell B.G.;
 RA "Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18.";
 RT Nature 413:848-852(2001).
 RL [3]
 RP SEQUENCE FROM N.A.
 RC SPECIES=S.typhi; STRAIN=Ty2 / ATCC 700931;
 RX MEDLINE=22531367; PubMed=12644504;
 RA Deng W., Liou S.-R., Plunkett G. III, Mayhew G.F., Rose D.J., Burland V., Kodyouranni V., Schwartz D.C., Blattner F.R.;
 RA "Comparative genomics of Salmonella enterica serovar Typhi strains Ty2 and CT18.";
 RT J. Bacteriol. 185:2330-2337(2003).
 RL [4]
 CC -!- FUNCTION: PadB and fadA are the alpha and beta subunits of the multifunctional enzyme complex of the fatty acid degradation cycle (By similarity).
 CC -!- CATALYTIC ACTIVITY: Acyl-CoA + acetyl-CoA = CoA + 3-oxoacyl-CoA.
 CC -!- PATHWAY: Fatty acid beta-oxidation cycle; third step.

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains.
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announcement/> or send an email to license@sib-sib.ch).

CC -!- SUBUNIT: Tetramer of two alpha chains and two beta chains (By similarity).
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the thiolase family.

CC This SWISS-PROT entry is copyright. It is produced

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).

CC -----
 DR EMBL; D10390; BAA01228.1; --
 DR PIR; JS0624; JS0624.
 DR HSP; P27796; IPXT.
 DR InterPro; IPR002155; Thiolase.
 DR Pfam; PF00108; thiolase; 1.
 DR Pfam; PF02803; thiolase C; 1.
 DR PROSITE; PS00098; THIOLEASE_1; 1.
 DR PROSITE; PS00099; THIOLEASE_3; 1.
 DR PROSITE; PS00737; THIOLEASE_2; 1.
 KW Fatty acid metabolism; Transferase; Acyltransferase.
 FT INIT MET 0
 FT ACT SITE 94 94 SUBSTRATE BINDING (BY SIMILARITY).
 FT ACT SITE 376 376 BASE (BY SIMILARITY).
 SQ SEQUENCE 390 AA; 41475 MW; F9270235BCBE3D09 CRC64;

Query Match 35.8%; Score 54; DB 1; Length 390;
 Best Local Similarity 66.7%; Pred. No. 1.3;
 Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQSPMGKRGKG 24
 ||| :||| :|||
 Db 9 IVDLQSPMGKRGKG 23

RESULT 10

THIK YERPE
 ID THIK YERPE STANDARD; PRT; 387 AA.
 AC QSZAM9;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE 3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Fatty oxidation complex beta
 DE subunit) (Beta-ketothiolase) (Acetyl-CoA acyltransferase).
 GN FADA OR YPO3767 OR Y0463.
 OS Yersinia pestis.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Yersinia.
 OX NCBI_TaxID=632;
 RN [1]
 RP SEQUENCE FROM N.A.

RC STRAIN=CO-92 / Biovar Orientalis;
 RX MEDLINE=21470413; PubMed=11586360;
 RA Parkhill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
 RA Prentice M.B., Sebahia M., James K.D., Churcher C., Mungall K.L.,
 RA Baker S., Basham D., Bentley S.D., Brooks K., Cerdono-Tarraga A.M.,
 RA Chillingworth I., Cronin A., Davies R.M., Davis P., Dougan G.,
 RA Feitwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V.,
 RA Leather S., Moule S., Oyston P.C.F., Quail M.A., Rutherford K.,
 RA Stanmonds M., Skelton J., Stevens K., Whitehead S., Barrall B.G.;
 RT "Genome sequence of Yersinia pestis, the causative agent of plague."
 RL Nature 413:523-527(2001).
 RP [2]

RP SEQUENCE FROM N.A.
 RC STRAIN=KIMS / Biovar Mediaevalis;
 RX MEDLINE=22137863; PubMed=12142430;
 RA Deng W., Burland V., Plunkett G. III, Boutin A., Mayhew G.F., Liss P.,
 RA Perna N.T., Rose D.J., Mau B., Zhou S., Schwartz D.C.,
 RA Fetherston J.D., Lindler L.E., Brubaker R.R., Plano G.V.,
 RA Straley S.C., McDonough K.A., Nilles M.L., Matson J.S., Blattner F.R.,
 RA Perry R.D.;
 RT "Genome sequence of Yersinia pestis KIM."
 RL J. Bacteriol. 184:4601-4611(2002).
 CC -1- FUNCTION: FadB and fadA are the alpha and beta subunits of the
 CC multifunctional enzyme complex of the fatty acid degradation
 CC cycle (By similarity).
 CC -1- CATALYTIC ACTIVITY: Acyl-CoA + acetyl-CoA = CoA + 3-oxoacyl-CoA.
 CC -1- PATHWAY: Fatty acid beta-oxidation cycle; third step.

CC -1- SUBUNIT: Tetramer of two alpha chains and two beta chains (By
 CC similarity).
 CC -1- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -1- SIMILARITY: Belongs to the thiolase family.

CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).

CC -----
 DR EMBL; AJ414158; CAC93235.1; --
 DR EMBL; AE013646; AAM84052.1; --
 DR PIR; AG0458; AG0458.
 DR InterPro; IPR002155; Thiolase.
 DR Pfam; PF00108; thiolase; 1.
 DR Pfam; PF02803; thiolase C; 1.
 DR PROSITE; PS00098; THIOLEASE_1; 1.
 DR PROSITE; PS00737; THIOLEASE_2; 1.
 DR PROSITE; PS00099; THIOLEASE_3; 1.
 KW Fatty acid metabolism; Transferase; Acyltransferase;
 KW Complete proteome.
 FT ACT SITE 91 91 SUBSTRATE BINDING (BY SIMILARITY).
 FT ACT SITE 373 373 BASE (BY SIMILARITY).
 SQ SEQUENCE 387 AA; 40917 MW; 1690502C07AE9F63 CRC64;

Query Match 34.4%; Score 52; DB 1; Length 387;
 Best Local Similarity 60.0%; Pred. No. 2.6;
 Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQSPMGKRGKG 24
 ||| :||| :|||
 Db 6 IIDAVRTPMGKRGKG 20

RESULT 11

OXAA PROMI
 ID OXAA PROMI STANDARD; PRT; 237 AA.
 AC P22833;
 DT 01-AUG-1991 (Rel. 19, Created)
 DT 01-AUG-1991 (Rel. 19, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Inner membrane protein oxAA (fragment).
 GN OXAA.
 OS Proteus mirabilis.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Proteus.
 OX NCBI_TaxID=584;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=LM1509;
 RX MEDLINE=91033012; PubMed=2172087;
 RA Skovgaard O.;
 RT "Nucleotide sequence of a Proteus mirabilis DNA fragment homologous to
 RL the 60K-rnpA-rnpH-dnaA-dnaN-recF-gyrB region of Escherichia coli."
 RL Gene 93:27-34(1990).
 CC -1- FUNCTION: Required for the insertion of integral membrane proteins
 CC into the membrane. Probably plays an essential role in the
 CC integration of proteins of the respiratory chain complexes.
 CC Involved in integration of membrane proteins that insert
 CC independently and independently of the Sec translocase complex (By
 CC similarity).
 CC -1- SUBUNIT: Specifically interacts with transmembrane segments of
 CC nascent integral membrane proteins during membrane integration (By
 CC similarity).
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane
 CC (By similarity).
 CC -1- SIMILARITY: Belongs to the OXA1/oxAA family. Subfamily 1.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announcements/>
CC or send an email to license@isb-sib.ch).

EMBL; M58352; AAA83954.1; -
PIR; JQ0729; JQ0729.
HAMAP; MF_01810; -; 1.
InterPro; IPR001708; 60kDa innermemb.
DR PRINTS; PR00701; 60KDINNERMP.
KW Transmembrane; Inner membrane.
TRANSMEM 7 23
NON TER 237 237
SEQUENCE 237 AA; 26564 MW; 07FCC405B9DB3F36 CRC64;

Query Match 33.8%; Score 51; DB 1; Length 237;
Best Local Similarity 31.0%; Pred. No. 2.2;
Matches 9; Conservative 12; Mismatches 4; Indels 4; Gaps 1;

Qy 2 RMMALQTDIVDLQRSPMGKQGGLDDLE 30
:::|::|::|:|:|:|:|:|:|:|:|:|:
Db 61 KLITVKTDVLDLRIN---TGGGTIDEAD 85

```

RESULT 12
ACSA SYNEL
ID ACSA SYNEL STANDARD; PRT; 656 AA.
AC Q8DKH2;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Acetyl-coenzyme A synthetase (EC 6.2.1.1) (Acetyl-CoA ligase) (Acyl-
DE activating enzyme).
DE
DE ACSA OR TLL087.
GN Synchococcus elongatus (Thermosynechococcus elongatus).
OS Bacteria; Cyanobacteria; Chroococcales; Synchococcus.
OC OX
OC NCBI_TaxID=32046;
RN [1]
RP SEQUENCE FROM N.A.

```

RC STRAIN=BP-1;
RX MEDLINE=22225144; PubMed=12240834;
RY
RA Nakamura Y., Kaneko T., Sato S., Ikeuchi M., Katoh H., Sasamoto S.,
RA Wakatabe A., Iriiguchi M., Kawashima K., Kimura T., Kishida Y.,
RA Kiyokawa C., Kohara M., Matsumoto M., Matsuno A., Nakazaki N.,
RA Shimo S., Sugimoto M., Takeuchi C., Yamada M., Tabata S.;
RT "Complete genome structure of the thermophilic cyanobacterium
RT *Thermosynechococcus elongatus* BP-1.";
RL DNA Res. 9:123-130(2002).

CC -|- CATALYTIC ACTIVITY: ATP + acetate + CoA = AMP + diphosphate +
CC acetyl-CoA,
CC -|- PM: Acetylated. Deacetylation by the SIR2-homolog deacetylase
CC activates the enzyme (By similarity).
CC -|- SIMILARITY: Belongs to the ATP-dependent AMP-binding enzyme
CC family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to licenses@isb-sib.ch).

CC	EMBL; AP005372; BAC08439.1; --
DR	HAWAP; MF_01123; --; 1.
DR	InterPro; IPR000873; AMP-bind.
DR	Pfam; PF00501; AMP-binding; 1.
DR	PRINTS; PR00154; AMPEBINDING.
DR	PROSITE; PS00455; AMP BINDING; 1.
KW	Ligase; Acetylation; Complete proteome.
FT	ACT SITE 529 529 BY SIMILARITY.
FT	MOD RES 621 621 ACETYLATION (BY SIMILARITY).

SQ SEQUENCE 656 AA; 73164 MW; 73462DCAF43F8ED2 CRC64;
 Query Match 33.8%; Score 51; DB 1; Length 656;
 Best Local Similarity 50.0%; Pred. No. 6.6;
 Matches 9; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY	9	DIVDLQRSPMRKGGTTL	26
		: : : :	
Db	454	DVVDLEGNPVGVNEGGYL	471

RESULT 13		
IF2_CHLVCV		
ID	IF2_CHLVCV	STANDARD; PRT; 887 AA.
AC	Q823F2;	
DT	10-OCT-2003	(Rel. 42, Created)
DT	10-OCT-2003	(Rel. 42, Last sequence update)
DT	10-OCT-2003	(Rel. 42, Last annotation update)
DE	Translation initiation factor IF-2.	
GN	INFB OR CCA00465.	

OS Chlamydoportia caviae;
OC Bacteria; Chlamydiales; Chlamydiales; Chlamydiales; Chlamydiales;
OX Chlamydiales; Chlamydiales; Chlamydiales; Chlamydiales;
RN NCBI_TaxID=83557;
[1]

RP SEQUENCE FROM N.A.
RC STRAIN=GPIC;
RX MEDLINE=22569155; PubMed=12682364;
RA Read T.D., Myers G.S.A., Brunham R.C., Nelson W.C., Paulsen I.T.,
RA Heideberg J., Holzapple E., Khouri H., Federova N.B., Carty H.A.,
RA Umeyali L.A., Hatt D.H., Peterson J., Beanan M.J., White O.,
RA Salzberg S.L., Hsia R.-C., McClarty G., Rank R.G., Bavoil P.M.,
RA Praser C.M.;
RT "Genome sequence of *Chlamydomonada caviae* (*Chlamydomonada psittaci*) (GPI):
RT examining the role of niche-specific genes in the evolution of the
RL Nucleic Acids Res. 31:2134-2147(2003).
CC -!- FUNCTION: One of the essential components for the initiation of
CC protein synthesis. Protects formylmethionyl-tRNA from spontaneous
CC hydrolysis and promotes its binding to the 30S ribosomal subunits.
CC Also involved in the hydrolysis of GTP during the formation of the
CC 70S ribosomal complex (By similarity).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- SIMILARITY: Belongs to the IF-2 family.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@sib-sib.ch).

```

CC      EMBL; AEO16995; AAP05210.1; -.
DR      TIGR; CCA00465; -.
DR      HAMAP; MF_00100; -.
DR      InterPro; IPR000795; EF_GTPbind.
DR      InterPro; IPR004161; EFTU_D2.
DR      InterPro; IPR000178; IF2_N.
DR      InterPro; IPR008647; IF2_N.
DR      InterPro; IPR005225; Small_GTP.
DR      InterPro; IPR009000; Translat_factor.
DR      Pfam; PF00009; GTP_EFTU; 1.
DR      Pfam; PF03144; GTP_EFTU_D2; 2.
DR      Pfam; PF04760; IF2_N; 1.
DR      ProDom; PD186100; IF2; 1.
DR      TIGRFAMs; TIGR00487; IF-2; 1.
DR      TIGRFAMs; TIGR00231; small_GTP; 1.
DR      PROSITE; PS01176; IF2; 1.
KW      Initiation factor; Protein biosynthesis; GTP-binding;
KW      Complete proteome.
KW      DOMAIN 396 544 G-DOMAIN.
FT      NP_BIND 402 409 GTP (BY SIMILARITY).
FT      NP_BIND 448 452 GTP (BY SIMILARITY).

```

```

FT NP_BIND 502 505 GTP (BY SIMILARITY).
SQ SEQUENCE 887 AA; 96938 MW; F13EECD1700CF6B7 CRC64;

Query Match 33.1%; Score 50; DB 1; Length 887;
Best Local Similarity 33.1%; Pred. No. 13;
Matches 8; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

QY 3 MMALQTDIVLQRSMPGRKQG 23
| : | | : : : | : | : |
Db 551 MLALQAEVLKANPSARAG 571

RESULT 14
IF2 CHLPN STANDARD; PRT; 890 AA.
ID AC Q9ZM1; Q9JRX1;
AC 30-MAY-2000 (Rel. 39, Created)
DT DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Translation initiation factor IF-2.
GN INFB OR CPN0317 OR CP0440 OR CPB0327.
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).
OC Bacteria; Chlamydiae; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83558;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CWL029;
RX Kalmán S., Mitchell W., Marathe R., Lamell C., Fan J., Hyman R.W.,
RA Olinger L., Grinstead J., Davis R.W., Stephens R.S.;
RT "Comparative genomes of Chlamydia pneumoniae and C. trachomatis.";
RL Nat. Genet. 21:385-389(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=AR39;
RX MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
RW White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,
RA Gwinn M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,
RA Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
RL pneumoniae AR39.";
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=J138;
RX MEDLINE=20330349; PubMed=10871362;
RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,
RW Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;
RA "Comparison of whole genome sequences of Chlamydia pneumoniae J138
RL from Japan and CWL029 from USA.";
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=TW-183;
RX Geng M.M., Schuhmacher A., Muehlidorfer I., Bensch K.W., Schaefer K.P.,
RA Schneider S., Pohl T., Essig A., Marre R., Melchers K.;
RW "The genome sequence of Chlamydia pneumoniae TW183 and comparison with
RT other Chlamydia strains based on whole genome sequence analysis.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
CC -I- FUNCTION: One of the essential components for the initiation of
CC protein synthesis. Protects formylmethionyl-tRNA from spontaneous
CC hydrolysis and promotes its binding to the 30S ribosomal subunits.
CC Also involved in the hydrolysis of GTP during the formation of the
CC 70S ribosomal complex (By similarity).
CC -I- SUBCELLULAR LOCATION: Cytoplasmic.
CC -I- SIMILARITY: Belongs to the IF-2 family.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way

```

```

-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
DR EMBL; AE001283; AAC67687.1; -.
DR PIR; H71558; H71558.
DR HAMAP; MF_00100; -.
DR InterPro; IPR000795; EF_GTPbind.
DR InterPro; IPR004161; EFTU_D2.
DR InterPro; IPR000178; IF2_N.
DR InterPro; IPR006847; IF2_N.
DR InterPro; IPR005225; Small_GTP.
DR InterPro; IPR009000; Translat_factor.
DR Pfam; PF00009; GTP_EFTU; 1.
DR Pfam; PF03144; GTP_EFTU_D2; 2.
DR Pfam; PF04760; IF2_N; 1.
DR ProDom; PDL86100; IF2; 1.
DR TIGRFAMs; TIGR00487; IF-2; 1.
DR TIGRFAMs; TIGR00231; small_GTP; 1.
DR PROSITE; PS01176; IF2; 1.
KW Initiation factor; Protein biosynthesis; GTP-binding;
KW Complete proteome.
FT DOMAIN 400 548 G-DOMAIN
FT NP_BIND 406 413 GTP (BY SIMILARITY).
FT NP_BIND 452 456 GTP (BY SIMILARITY).
FT NP_BIND 506 509 GTP (BY SIMILARITY).
SQ SEQUENCE 892 AA; 97009 MW; 9D401C079D6B1A51 CRC64;

Query Match 32.5%; Score 49; DB 1; Length 892;
Best Local Similarity 38.1%; Pred. No. 19;
Matches 8; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

QY 3 MMALQTDIVDLQSPMGKQG 23
Db 555 MLALQAEVLELKADPSARARG 575

```

Search completed: September 24, 2004, 09:43:34
Job time : 25 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 09:40:58 ; Search time 116 Seconds
(without alignments)
81.600 Million cell updates/sec

Title: US-09-806-701-16_COPY_331_360
Perfect score: 151
Sequence: 1 ERMALQTDIVDLQRSPMKRQGGTLDDLE 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_25:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phage:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_virus:*
- 16: sp_bacteriap:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	151	100.0	756	6 Q95KV0	Q95kv0 bos taurus
2	84	55.6	584	11 Q80VU2	Q80vu2 mus musculus
3	84	55.6	740	6 Q95KV1	Q95kv1 bos taurus
4	84	55.6	745	11 Q8CBT3	Q8cbt3 mus musculus
5	83	55.0	758	13 Q7ZTU1	Q7ztu1 brachydanio
6	66.5	44.0	732	5 Q61565	Q61565 crassostrea
7	56	37.1	465	2 Q9APZ1	Q9apz1 pseudomonas
8	56	37.1	465	16 Q88DF2	Q88df2 pseudomonas
9	55	36.4	283	2 Q9X6F2	Q9x6f2 pseudomonas
10	55	36.4	283	16 Q9HUL1	Q9hul1 pseudomonas
11	55	36.4	283	16 Q87VU13	Q87vu13 pseudomonas
12	55	36.4	533	10 Q9ZEX1	Q9zrx1 glycine max
13	54	35.8	387	16 Q8FBI3	Q8fbi3 escherichia
14	54	35.8	387	16 Q83PG2	Q83pg2 shigella fl
15	54	35.8	391	2 Q93Q11	Q93q11 pseudomonas
16	54	35.8	391	2 Q9R9W0	Q9r9w0 pseudomonas

17	54	35.8	391	16 Q9HZJ3	Q9hzj3 pseudomonas
18	54	35.8	391	16 Q88L01	Q88l01 pseudomonas
19	54	35.8	391	16 Q87ZB3	Q87zb3 pseudomonas
20	53.5	35.4	1710	5 Q9V9N7	Q9v9n7 drosophila
21	53	35.1	387	16 Q9KN10	Q9kn10 vibrio chol
22	53	35.1	387	16 Q8DDK5	Q8ddk5 vibrio vuln
23	52.5	34.8	649	10 Q9AW00	Q9aw00 guillardia
24	52	34.4	387	2 Q9F0Y6	Q9f0y6 enterobacte
25	52	34.4	391	16 Q87TP0	Q87tp0 vibrio para
26	51	33.8	174	10 Q7XEP1	Q7xep1 chlorarachn
27	51	33.8	396	16 Q93JG7	Q93jg7 streptomyce
28	50.5	33.4	617	13 Q9PU64	Q9pu64 brachydanio
29	50.5	33.4	617	13 Q9IAA9	Q9iaa9 brachydanio
30	50.5	33.4	617	13 Q804R6	Q804r6 brachydanio
31	50.5	33.4	4317	16 Q88F56	Q88f56 pseudomonas
32	50	33.1	465	16 Q82XR0	Q82xr0 nitrosomona
33	49.5	32.8	297	16 Q9KE47	Q9ke47 bacillus ha
34	49	32.5	242	16 Q88IZ8	Q88iz8 pseudomonas
35	49	32.5	301	16 Q8DUQ1	Q8duq1 streptococc
36	49	32.5	401	16 Q7VV88	Q7vv88 bordetella
37	49	32.5	494	16 Q8F3M2	Q8f3m2 leptospira
38	49	32.5	536	10 Q8L994	Q8l994 arabidopsis
39	49	32.5	536	10 Q9LV21	Q9lv21 arabidopsis
40	49	32.5	676	2 O07365	O07365 chlamydia t
41	48.5	32.1	304	16 Q81MD1	Q81md1 bacillus an
42	48.5	32.1	304	16 Q818Z0	Q818z0 bacillus ce
43	48.5	32.1	351	2 Q8GI19	Q8gi19 gamma-prote
44	48.5	32.1	373	16 Q91140	Q91140 pseudomonas
45	48.5	32.1	373	16 Q88P67	Q88p67 pseudomonas

ALIGNMENTS

RESULT 1

Q95KV0 ID Q95KV0 PRELIMINARY; PRT; 756 AA.
AC Q95KV0;
DT 01-DEC-2001 (TREMREL. 19, Created)
DT 01-DEC-2001 (TREMREL. 19, Last sequence update)
DE 01-OCT-2003 (TREMREL. 25, Last annotation update)
DE IKB kinase-beta.
GN BIKKBETA.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RA Rottenberg S., Dobbelaere D.A.E., Heussler V.T.;
RT "Identification and characterisation of the bovine Ikb kinases (IKBs)
alpha, beta and gamma.";
RL Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
EMBL: AJ414556; CAC93687.1;
DR GO; GO:0005324; F:ATP binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; F:protein-tyrosine kinase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR000719; Prot_kinase.
DR InterPro; IPR008271; Ser_Chk_pkin_AS.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PR00109; TYRKINASE.
DR ProDom; PD000001; Prot_kinase; 1.
DR PROSITE; PS00011; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Kinase; Serine/threonine-protein kinase; Transferase.
SQ SEQUENCE 756 AA; 86647 MW; A072D15614A176E5 CRC64;

Query Match 100.0%; Score 151; DB 6; Length 756;

```
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKGGTLDLLE 30
   |||||
Db 535 ERMALQTDIVDLQSPMGKGGTLDLLE 564

RESULT 2
Q80VU2 ID Q80VU2 PRELIMINARY; PRT; 584 AA.
AC Q80VU2;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Conserved helix-loop-helix ubiquitous kinase.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_TaxID=10090;
RP SEQUENCE FROM N.A.
RC TISSUE=Eye;
RA Strausberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018243; AAH18243.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; F:protein-tyrosine kinase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW Kinase.
SQ SEQUENCE 584 AA; 66805 MW; D99BB8A6DF1CA4EB CRC64;

Query Match 55.6%; Score 84; DB 11; Length 584;
Best Local Similarity 46.7%; Pred. No. 0.00024;
Matches 14; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKGGTLDLLE 30
   |||||
Db 532 DQIMSLHTEIMELQSPYGRKQGLMESLE 561

RESULT 3
Q95KV1 ID Q95KV1 PRELIMINARY; PRT; 740 AA.
AC Q95KV1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Ikb kinase-alpha.
GN BIKKALPHA.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]_TaxID=9913;
RP SEQUENCE FROM N.A.
RC Rottenberg S., Dobbelaere D.A.E., Heussler V.T.;
RA "Identification and characterisation of the bovine Ikb kinases (IKBs)
RT alpha, beta and gamma.";
```

```
RL Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR EMBL; AJ414555; CAC93686.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; F:protein-tyrosine kinase activity; IEA.
DR GO; GO:0016740; P:transferase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR002290; Ser_thr_pkinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PS00107; TYRKINASE.
DR PRODom; PD000001; Prot kinase; 1.
DR SMART; SM00220; S_TKc; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Kinase; Serine/threonine-protein kinase; Transferase.
SQ SEQUENCE 740 AA; 84343 MW; 01903BELLF44D176 CRC64;

Query Match 55.6%; Score 84; DB 6; Length 740;
Best Local Similarity 46.7%; Pred. No. 0.00032;
Matches 14; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKGGTLDLLE 30
   |||||
Db 532 DQIMSLHTEIMELQSPYGRKQGLMESLE 561

RESULT 4
Q8CBT3 ID Q8CBT3 PRELIMINARY; PRT; 745 AA.
AC Q8CBT3;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Conserved helix-loop-helix ubiquitous kinase.
GN CHUK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_TaxID=10090;
RP SEQUENCE FROM N.A.
RC STRAIN=CS7BL/6J; TISSUE=Urinary bladder;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
DR EMBL; AK035326; BAC29034.1; -.
DR MGD; MGI:99484; Chuk.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; F:protein-tyrosine kinase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR002290; Ser_thr_pkinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PS00107; TYRKINASE.
DR PRODom; PD000001; Prot kinase; 1.
DR SMART; SM00220; S_TKc; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
SQ SEQUENCE 745 AA; 84770 MW; 48C9E01C17A61184 CRC64;
```


Query Match 55.6%; Score 84; DB 11; Length 745;
Best Local Similarity 46.7%; Pred. No. 0.00032;
Matches 14; Conservative 11; Mismatches 5; Indels 0; Gaps

QY 1 ERMVALQTDVLDQSPMGRKGGTLDLLE 30
DB 532 DQIMSLHTEIMELQKSPYGRQGLDWLESL 561

RESULT 5

Q7ZTUI PRELIMINARY; PRT; 758 AA.

ID Q7ZTUI
AC Q7ZTUI
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DE 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OC NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Body;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos J., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Body;
RX Strausberg R.;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC051614; AAH51614.1; ..
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; F:protein-tyrosine kinase activity; IEA.
DR GO; GO:0006468; F:protein amino acid phosphorylation; IEA.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR002290; Ser/thr kinase.
DR InterPro; IPR008271; Ser/thr_kinase.
DR InterPro; IPR01245; Tyr_kinase.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PR0109; TYRKINASE.
DR ProDom; PD000001; Prot kinase; 1.
DR SMART; SM00220; S_TKc; 1.
DR SMART; SM00219; TyrKc; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW Hypothetical protein.
SQ SEQUENCE 758 AA; 87187 MW; 6001AADA3F74A32 CFC64;

Query Match 55.0%; Score 83; DB 13; Length 758;
Best Local Similarity 50.0%; Pred. No. 0.00047;

DR PROSITE; PS00099; THIOLASE 3; 1.
 KW Acyltransferase; Transferase; Complete proteome.
 SQ SEQUENCE 387 AA; 40775 MW; 505E4A821C40C007 CRC64;

Query Match 35.8%; Score 54; DB 16; Length 387;
 Best Local Similarity 61.1%; Pred. No. 7.5;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDDIVLQSPMGRKGG 24
 | | | | | : | | | | : | |
 DB 3 QVVIIVDAIRTPMGRSKGG 20

RESULT 14
 Q33PG2 PRELIMINARY; PRT; 387 AA.
 ID Q83PG2;
 AC Q83PG2;
 DT 01-JUN-2003 (TReMBLrel. 24, Created)
 DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
 DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
 DE Fatty acid oxidizing complex (Thiolase I, 3-ketoacyl-CoA thiolase,
 acetyl-CoA transferase).
 GN PADA OR SF3921 OR S3831.
 OS Shigella flexneri.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Shigella.
 OX NCBI_TaxID=623;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=301 / Serotype 2a;
 RX MEDLINE=22272406; PubMed=12384590;
 RA Jin Q., Yuan Z., Xu J., Wang Y., Shen Y., Lu W., Wang J., Liu H.,
 RA Yang J., Yang F., Zhang X., Zhang J., Yang G., Wu H., Qu D., Dong J.,
 RA Sun L., Xue Y., Zhao A., Gao Y., Zhu J., Kan B., Ding X., Chen S.,
 RA Cheng H., Yao Z., He B., Chen R., Ma D., Qiang B., Wen Y., Hou Y.,
 RA Yu J.;
 RT "Genome sequence of Shigella flexneri 2a: insights into pathogenicity
 RT through comparison with genomes of Escherichia coli K12 and O157.";
 RL Nucleic Acids Res. 30:4432-4441(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=2457T / ATCC 700930 / Serotype 2a;
 RX MEDLINE=22590274; PubMed=12704152;
 RA Wei J., Goldberg M.B., Burland V., Venkatesan M.M., Deng W.,
 RA Fournier G., Mayhew G.F., Plunkett G. III, Rose D.J., Darling A.,
 RA Mau B., Perna N.T., Payne S.M., Runyen-Janecky L.J., Zhou S.,
 RA Schwartz D.C., Blattner F.R.;
 RT "Complete genome sequence and comparative genomics of Shigella
 RT flexneri serotype 2a strain 2457T.";
 RL Infect. Immun. 71:2775-2786(2003).
 DR EMBL; AR015399; AAN45356.1; -;
 DR EMBL; AE016990; RAP18842.1; -;
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0004812; F:RNA ligase activity; IEA.
 DR GO; GO:0006418; P:amino acid activation; IEA.
 DR InterPro; IPR002155; Thiolase.
 DR InterPro; IPR001412; tRNA-synt_I.
 DR Pfam; PF00108; thiolase; 1.
 DR Pfam; PF02803; thiolase_C; 1.
 DR PROSITE; PS00178; AA TRNA LIGASE I; 1.
 DR PROSITE; PS00098; THIOLASE 1; 1.
 DR PROSITE; PS00737; THIOLASE 2; 1.
 DR PROSITE; PS00099; THIOLASE 3; 1.
 KW Transferase; Complete proteome.
 SQ SEQUENCE 387 AA; 40846 MW; AE706AE0CB0B0F0 CRC64;

Query Match 35.8%; Score 54; DB 16; Length 387;
 Best Local Similarity 61.1%; Pred. No. 7.5;
 Matches 11; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 7 QTDDIVLQSPMGRKGG 24
 | | | | | : | | | | : | |
 DB 3 QVVIIVDAIRTPMGRSKGG 20

RESULT 15
 Q33Q11 PRELIMINARY; PRT; 391 AA.
 ID Q93Q11;
 AC Q93Q11;
 DT 01-DEC-2001 (TReMBLrel. 19, Created)
 DT 01-DEC-2001 (TReMBLrel. 19, Last sequence update)
 DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
 DE Beta-ketothiolase Fada.
 GN PADA.
 OS Pseudomonas oleovorans.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
 OC Pseudomonadaceae; Pseudomonas.
 OX NCBI_TaxID=301;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC29347;
 RA Fiedler S., Steinbuechel A., Rehm B.H.A.;
 RT "fadaB genes from Pseudomonas oleovorans ATCC29347.";
 RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AP288535; AAK83059.1; -;
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0004812; F:RNA ligase activity; IEA.
 DR GO; GO:0006418; P:amino acid activation; IEA.
 DR InterPro; IPR002155; Thiolase.
 DR InterPro; IPR001412; tRNA-synt_I.
 DR Pfam; PF00108; thiolase; 1.
 DR Pfam; PF02803; thiolase_C; 1.
 DR PROSITE; PS00178; AA TRNA LIGASE I; 1.
 DR PROSITE; PS00098; THIOLASE 1; 1.
 DR PROSITE; PS00737; THIOLASE 2; 1.
 SQ SEQUENCE 391 AA; 41645 MW; D7CAE2F37ED170A1 CRC64;

Query Match 35.8%; Score 54; DB 2; Length 391;
 Best Local Similarity 66.7%; Pred. No. 7.5;
 Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 10 IVDLQSPMGRKGG 24
 | | | | | : | | | | : | |
 DB 10 IVDLQSPMGRSKGG 24

Search completed: September 24, 2004, 09:45:37
 Job time : 119 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 09:40:59 ; Search time 18 Seconds
(without alignments)
86.043 Million cell updates/sec

Title: US-09-806-701-16_COPY_331_360

Perfect score: 151

Sequence: 1 ERMWALQTDIVDLQSPMGKQGGLDDLE 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA:*
- 1: /cgn2_6/ptodata/2/iaa/5A COMB.pep.*
 - 2: /cgn2_6/ptodata/2/iaa/5B COMB.pep.*
 - 3: /cgn2_6/ptodata/2/iaa/6A COMB.pep.*
 - 4: /cgn2_6/ptodata/2/iaa/6B COMB.pep.*
 - 5: /cgn2_6/ptodata/2/iaa/PCTUS COMB.pep.*
 - 6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	151	100.0	756	2	US-08-887-518-4
2	151	100.0	756	2	US-09-023-321-4
3	151	100.0	756	2	US-08-890-853-2
4	151	100.0	756	2	US-09-032-475-4
5	151	100.0	756	2	US-09-039-125A-2
6	151	100.0	756	2	US-09-099-124A-2
7	151	100.0	756	3	US-09-032-476-2
8	151	100.0	756	3	US-08-890-854-2
9	151	100.0	756	3	US-09-023-324-2
10	151	100.0	756	3	US-09-168-629-15
11	151	100.0	756	3	US-08-910-820-9
12	151	100.0	756	4	US-09-109-886-2
13	151	100.0	756	4	US-09-844-908-9
14	151	100.0	756	4	US-08-868-758-4
15	84	55.6	584	3	US-09-160-483-1
16	79	52.3	745	2	US-08-887-518-3
17	79	52.3	745	2	US-08-023-321-3
18	79	52.3	745	2	US-08-890-853-4
19	79	52.3	745	2	US-09-032-475-3
20	79	52.3	745	2	US-09-099-125A-4
21	79	52.3	745	2	US-09-099-124A-4
22	79	52.3	745	3	US-09-032-476-4
23	79	52.3	745	3	US-08-890-854-4
24	79	52.3	745	3	US-09-023-324-4
25	79	52.3	745	3	US-09-168-629-2
26	79	52.3	745	3	US-08-910-820-10
27	79	52.3	745	3	US-08-810-131A-2

Sequence 4, Appli
Sequence 10, Appli
Sequence 3, Appli
Sequence 123, App
Sequence 121, App
Sequence 32895, A
Sequence 15, Appl
Sequence 8065, Ap
Sequence 18619, A
Sequence 7532, Ap
Sequence 32240, A
Sequence 5675, Ap
Sequence 335, App
Sequence 23582, A
Sequence 27, Appl
Sequence 326, App
Sequence 326, App
Sequence 326, App

28 79 52.3 745 4 US-09-109-886-4
29 79 52.3 745 4 US-09-844-908-10
30 79 52.3 745 4 US-09-868-758-3
31 76 50.3 996 4 US-09-417-197-123
32 76 50.3 997 4 US-09-417-197-121
33 55 36.4 406 4 US-09-252-991A-32895
34 54 35.8 388 4 US-08-178-257-15
35 54 35.8 390 4 US-09-489-039A-8065
36 54 35.8 396 4 US-09-252-991A-18619
37 51 33.8 551 4 US-09-543-681A-7532
38 50 33.1 735 4 US-09-252-991A-32240
39 49 32.5 397 4 US-09-543-681A-5675
40 49 32.5 761 4 US-09-198-452A-335
41 48.5 32.1 374 4 US-09-252-991A-23582
42 48 31.8 539 3 US-08-687-590-27
43 48 31.8 539 4 US-09-702-705-326
44 48 31.8 539 4 US-09-736-457-326
45 48 31.8 539 4 US-09-614-124B-326

ALIGNMENTS

RESULT 1
US-08-887-518-4
; Sequence 4, Application US/08887518
; Patent No. 5843721
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Wu, Lin
; TITLE OF INVENTION: NIK Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/887,518
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-887-518-4

Query Match 100.0%; Score 151; DB 2; Length 756;
Best Local Similarity 100.0%; Pred. No. 2, 4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ERMWALQTDIVDLQSPMGKQGGLDDLE 30
Db 535 ERMWALQTDIVDLQSPMGKQGGLDDLE 564

```
RESULT 2
US-09-023-321-4
; Sequence 4, Application US/09023321
; Patent No. 584073
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Wu, Lin
; TITLE OF INVENTION: NIK Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/023,321
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/887,518
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-023-321-4

Query Match          100.0%; Score 151; DB 2; Length 756;
Best Local Similarity 100.0%; Pred.No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  ERMALQTDIVDLQSPMGRKGGTLDLLE 30
Db      535  ERMALQTDIVDLQSPMGRKGGTLDLLE 564

RESULT 3
US-08-890-853-2
; Sequence 2, Application US/08890853
; Patent No. 5851812
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Woronicz, John
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,853
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-890-853-2

Query Match          100.0%; Score 151; DB 2; Length 756;
Best Local Similarity 100.0%; Pred.No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  ERMALQTDIVDLQSPMGRKGGTLDLLE 30
Db      535  ERMALQTDIVDLQSPMGRKGGTLDLLE 564

RESULT 4
US-09-032-475-4
; Sequence 4, Application US/09032475
; Patent No. 5854003
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; TITLE OF INVENTION: NIK Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/032,475
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/887,518
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-032-475-4
```

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

```

; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-032-476-2

Query Match 100.0%; Score 151; DB 3; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLE 564

RESULT 8
US-08-890-854-2
; Sequence 2, Application US/08890854
; Patent No. 6235512
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Cao, Zhaodan
; APPLICANT: R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,854
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/890,854
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-890-854-2

Query Match 100.0%; Score 151; DB 3; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLE 564

RESULT 9
US-09-023-324-2
; Sequence 2, Application US/09023324
; Patent No. 6235513
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Cao, Zhaodan
; APPLICANT: R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/023,324
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/890,854
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-023-324-2

Query Match 100.0%; Score 151; DB 3; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLE 564

RESULT 10
US-09-168-629-15
; Sequence 15, Application US/09168629
; Patent No. 6242253
; GENERAL INFORMATION:
; APPLICANT: Karin, Michael
; APPLICANT: Didonato, Joseph A.
; APPLICANT: Rothwarf, David M.
; APPLICANT: Hayakawa, Makio
; APPLICANT: Zandi, Ebrahim
; TITLE OF INVENTION: IKK Kinase, Subunits Thereof, and Methods of Using Same
; FILE REFERENCE: P-UD 3295
; CURRENT APPLICATION NUMBER: US/09/168,629
; CURRENT FILING DATE: 1998-10-08
; EARLIER APPLICATION NUMBER: 60/061,470
; EARLIER FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 20
```



```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-168-629-15

Query Match      100.0%; Score 151; DB 3; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVDLQSPMGRKQGGLDLE 30
Db 535 ERMALQTDIVDLQSPMGRKQGGLDLE 564

RESULT 11
US-08-910-820-9
; Sequence 9, Application US/08910820
; Patent No. 6258579
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
; APPLICANT: Zhu, Hengyi
; APPLICANT: Barbosa, Miguel
; APPLICANT: Li, Gian
; APPLICANT: Murray, Brian W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; TITLE OF INVENTION: COMPLEX AND METHODS OF USE THEREFOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09109,986
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/890,854
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-109-986-2

Query Match      100.0%; Score 151; DB 4; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVDLQSPMGRKQGGLDLE 30
Db 535 ERMALQTDIVDLQSPMGRKQGGLDLE 564

RESULT 13
US-09-844-908-9
; Sequence 9, Application US/09844908
; Patent No. 6576437
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
; APPLICANT: Zhu, Hengyi
; APPLICANT: Barbosa, Miguel
; APPLICANT: Li, Gian
; APPLICANT: Murray, Brian W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; TITLE OF INVENTION: COMPLEX AND METHODS OF USE THEREFOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-168-629-15

Query Match      100.0%; Score 151; DB 3; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVDLQSPMGRKQGGLDLE 30
Db 535 ERMALQTDIVDLQSPMGRKQGGLDLE 564

RESULT 12
US-09-109-986-2
; Sequence 2, Application US/09109986
; Patent No. 6479266
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/844,908
; APPLICATION NUMBER: US/09/844,908
; FILING DATE: 27-Apr-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/910,820
; FILING DATE: 12-AUG-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 860098.413C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-844-908-9

Query Match 100.0%; Score 151; DB 4; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
Db 535 ERMALQTDIVDLQSPMGKQGGTLDLLE 564
```

```
RESULT 14
US-09-868-758-4
; Sequence 4, Application US/09868758
; Patent No. 6576439
; GENERAL INFORMATION:
; APPLICANT: Glaxo Wellcome KK
; APPLICANT: Takemoto, Yoshihiro
; APPLICANT: Sakai, Yutaka
; APPLICANT: Hashimoto, Yasuhiro
; TITLE OF INVENTION: IKK3
; FILE REFERENCE: 9950986P
; CURRENT APPLICATION NUMBER: US/09/868,758
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: GB 9828704.8
; PRIOR FILING DATE: 1998-12-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-868-758-4

Query Match 100.0%; Score 151; DB 4; Length 756;
Best Local Similarity 100.0%; Pred. No. 2.4e-16; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
Db 535 ERMALQTDIVDLQSPMGKQGGTLDLLE 564
```

```
RESULT 15
US-09-160-483-1
; Sequence 1, Application US/09160483A
; Patent No. 6083732
; GENERAL INFORMATION:
; APPLICANT: Marcu, Kenneth B.
; TITLE OF INVENTION: A BIOLOGICALLY ACTIVE ALTERNATIVE FORM OF THE IKK
```

```
; TITLE OF INVENTION: ALPHA IKB KINASE
; FILE REFERENCE: Docket No. 6083732; 178-255
; CURRENT APPLICATION NUMBER: US/09/160,483A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 584
; TYPE: PRT
; ORGANISM: mus.musculus domesticus
US-09-160-483-1

Query Match 55.6%; Score 84; DB 3; Length 584;
Best Local Similarity 46.7%; Pred. No. 1.8e-05;
Matches 14; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
Db 532 DQIMSLHTIMEIQKSPYGRQGDLMESLE 561

Search completed: September 24, 2004, 09:46:43
Job time : 19 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 09:45:44 ; Search time 128 Seconds

(without alignments)
75.365 Million cell updates/sec

Title: US-09-806-701-16_COPY_331_360

Perfect score: 151

Sequence: 1 ERMMALQTDIVLQSPMGKQGGLDDLE 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1349238 seqs, 32158718 residues

Total number of hits satisfying chosen parameters: 1349238

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	151	100.0	747	12	US-10-087-192-1755
2	151	100.0	756	9	US-09-796-872-15
3	151	100.0	756	9	US-09-771-161A-232
4	151	100.0	756	9	US-09-844-908-9
5	151	100.0	756	9	US-09-844-988-9
6	151	100.0	756	14	US-10-243-408-2
7	151	100.0	756	14	US-10-338-462-9
8	151	100.0	756	15	US-10-408-636-4
9	151	100.0	756	12	US-10-394-322A-33
10	151	100.0	756	12	US-10-087-192-1758
11	79	52.3	745	9	US-09-796-872-2
12	79	52.3	745	9	US-09-844-908-10
13	79	52.3	745	9	US-09-844-988-10
14	79	52.3	745	12	US-10-060-065-14
15	79	52.3	745	14	US-10-243-408-4

16	79	52.3	745	14	US-10-059-585-35	Sequence 35, Appl
17	79	52.3	745	14	US-10-338-462-10	Sequence 10, Appl
18	79	52.3	745	15	US-10-408-636-3	Sequence 3, Appl
19	79	52.3	745	15	US-10-394-322A-32	Sequence 32, Appl
20	79	52.3	745	16	US-10-741-601-375	Sequence 123, App
21	79	52.3	996	14	US-10-072-036-123	Sequence 121, App
22	76	50.3	997	14	US-10-072-036-121	Sequence 121, App
23	56	37.1	467	12	US-10-282-122A-67939	Sequence 67939, A
24	55	36.4	224	12	US-10-424-599-259148	Sequence 259148, A
25	55	36.4	482	12	US-10-424-599-199420	Sequence 199420, A
26	54	35.8	383	12	US-10-282-122A-69530	Sequence 69530, A
27	54	35.8	387	9	US-09-815-242-10416	Sequence 10416, A
28	54	35.8	387	9	US-09-815-242-13750	Sequence 13750, A
29	54	35.8	387	12	US-10-282-122A-56765	Sequence 56765, A
30	54	35.8	387	12	US-10-282-122A-60312	Sequence 60312, A
31	54	35.8	387	12	US-10-282-122A-73063	Sequence 73063, A
32	54	35.8	387	12	US-10-282-122A-75775	Sequence 75775, A
33	54	35.8	387	15	US-10-369-493-23631	Sequence 23631, A
34	54	35.8	388	16	US-10-357-521-15	Sequence 15, Appl
35	54	35.8	391	9	US-09-815-242-5123	Sequence 5123, Ap
36	54	35.8	391	12	US-10-282-122A-43443	Sequence 43443, A
37	54	35.8	391	12	US-10-282-122A-67603	Sequence 67603, A
38	54	35.8	391	15	US-10-447-515-26	Sequence 26, Appl
39	54	35.8	409	15	US-10-369-493-13890	Sequence 13890, A
40	53	35.1	387	12	US-10-282-122A-77565	Sequence 77565, A
41	53	35.1	507	15	US-10-369-493-10701	Sequence 10701, A
42	52	34.4	386	12	US-10-282-122A-56042	Sequence 56042, A
43	52	34.4	387	12	US-10-282-122A-77831	Sequence 77831, A
44	52	34.4	850	15	US-10-369-493-10111	Sequence 10111, A
45	51	33.8	331	16	US-10-437-963-173921	Sequence 173921, A

ALIGNMENTS

RESULT 1
US-10-087-192-1755
; Sequence 1755, Application US/10087192
; Publication No. US20020182586A1
; GENERAL INFORMATION:
; APPLICANT: Engelhard, Eric K.
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR
; FILE REFERENCE: 529452000122
; CURRENT FILING DATE: 2002-03-01
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 09/747,377
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 2059
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1755
; LENGTH: 747
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-087-192-1755

Query Match 100.0%; Score 151; DB 12; Length 747;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ERMMALQTDIVLQSPMGKQGGLDDLE 30
Db 549 ERMMALQTDIVLQSPMGKQGGLDDLE 578

RESULT 2
US-09-796-872-15
; Sequence 15, Application US/09796872
; Patent No. US20020045235A1
; GENERAL INFORMATION:

```
; APPLICANT: Karin, Michael
; APPLICANT: DiDonato, Joseph A.
; APPLICANT: Rothwarf, David M.
; APPLICANT: Hayakawa, Makio
; APPLICANT: Zandi, Ebrahim
; TITLE OF INVENTION: Ikb Kinase, Subunits Thereof, and Methods of Using Same
; FILE REFERENCE: P-UD 3295
; CURRENT APPLICATION NUMBER: US/09/796,872
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/168,629
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/061,470
; PRIOR FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-796-872-15

Query Match          100.0%; Score 151; DB 9; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  ERMALQTDIVDLQSPMGKKGGLDDLE 30
Db      535  ERMALQTDIVDLQSPMGKKGGLDDLE 564

RESULT 3
US-09-771-161A-232
; Sequence 232, Application US/09771161A
; Patent No. US20020110811A1
; GENERAL INFORMATION:
; APPLICANT: LEVINE, et al.
; TITLE OF INVENTION: VARIANTS OF PROTEIN KINASES
; FILE REFERENCE: 802620-2005.1
; CURRENT APPLICATION NUMBER: US/09/771,161A
; CURRENT FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: 09/724,676
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 136776
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 135619
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 273
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 232
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-771-161A-232

Query Match          100.0%; Score 151; DB 9; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  ERMALQTDIVDLQSPMGKKGGLDDLE 30
Db      535  ERMALQTDIVDLQSPMGKKGGLDDLE 564

RESULT 4
US-09-844-908-9
; Sequence 9, Application US/09844908
; Patent No. US20020151021A1
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
;           Zhu, Hengyi
;           Barbosa, Miguel
;           Li, Gian
;           Murray, Brion W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
```

```
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; COMPLEX AND METHODS OF USE THEREFOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/844,908
; FILING DATE: 27-Apr-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/910,820
; FILING DATE: 12-AUG-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 860098.413C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; TYPE: amino acid
; LENGTH: 756 amino acids
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-844-908-9

Query Match          100.0%; Score 151; DB 9; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  ERMALQTDIVDLQSPMGKKGGLDDLE 30
Db      535  ERMALQTDIVDLQSPMGKKGGLDDLE 564

RESULT 5
US-09-844-988-9
; Sequence 9, Application US/09844988
; Patent No. US20020158764A1
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
;           Zhu, Hengyi
;           Barbosa, Miguel
;           Li, Gian
;           Murray, Brion W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
```

```
;
; APPLICATION NUMBER: US/09/844,988
; FILING DATE: 26-Apr-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/910,820
; FILING DATE: 1997-08-13
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 860098.413C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-844-988-9

Query Match          100.0%; Score 151; DB 9; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSRPMGRKQGGLDDLE 30
Db 535 ERMALQTDIVDLQSRPMGRKQGGLDDLE 564

RESULT 6
US-10-243-408-2
; Sequence 2, Application US/10243408
; Publication No. US20030077683A1
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; Cao, Zhaodan
; R. gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/243,408
; FILING DATE: 13-Sep-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/109,986
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/890,854
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
```

```
;
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-243-408-2

Query Match          100.0%; Score 151; DB 14; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSRPMGRKQGGLDDLE 30
Db 535 ERMALQTDIVDLQSRPMGRKQGGLDDLE 564

RESULT 7
US-10-338-462-9
; Sequence 9, Application US/10338462
; Publication No. US20030100026A1
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
; Zhu, Hengyi
; Barbosa, Miguel
; Li, Gian
; Murray, Brian W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/338,462
; FILING DATE: 08-Jan-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/844,908
; FILING DATE: 27-Apr-2001
; APPLICATION NUMBER: US/08/910,820
; FILING DATE: 12-AUG-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 860098.413C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 756 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-338-462-9

Query Match          100.0%; Score 151; DB 14; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSRPMGRKQGGLDDLE 30
Db 535 ERMALQTDIVDLQSRPMGRKQGGLDDLE 564
```

```
RESULT 8
US-10-408-636-4
; Sequence 4, Application US/10408636
; Publication No. US20030215879A1
; GENERAL INFORMATION:
; APPLICANT: Glaxo Wellcome KK
; APPLICANT: Takemoto, Yoshihiro
; APPLICANT: Sakai, Yutaka
; APPLICANT: Hashimoto, Yasuhiro
; TITLE OF INVENTION: IKK3 Kinase
; FILE REFERENCE: PJ3630US2
; CURRENT APPLICATION NUMBER: US/10/408,636
; CURRENT FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: GB 9828704.8
; PRIOR FILING DATE: 1998-12-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-636-4

Query Match      100.0%; Score 151; DB 15; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLE 564

RESULT 9
US-10-394-322A-33
; Sequence 33, Application US/10394322A
; Publication No. US2003023291A1
; GENERAL INFORMATION:
; APPLICANT: SUNESIS PHARMACEUTICALS, INC.
; APPLICANT: Prescott, John C.
; TITLE OF INVENTION: IDENTIFICATION OF KINASE INHIBITORS
; FILE REFERENCE: 39750-0006 US
; CURRENT APPLICATION NUMBER: US/10/394,322A
; CURRENT FILING DATE: 2003-03-20
; PRIOR APPLICATION NUMBER: US 60/366,892
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 756
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-394-322A-33

Query Match      100.0%; Score 151; DB 15; Length 756;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 535 ERMALQTDIVDLQSPMGKKGGLDLE 564

RESULT 10
US-10-087-192-1758
; Sequence 1758, Application US/10087192
; Publication No. US20020182586A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David W.
; APPLICANT: Engelhard, Eric K.
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 529452000122

; CURRENT APPLICATION NUMBER: US/10/087,192
; CURRENT FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 09/747,377
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 09/798,586
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 2059
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1758
; LENGTH: 769
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-087-192-1758

Query Match      100.0%; Score 151; DB 12; Length 769;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 548 ERMALQTDIVDLQSPMGKKGGLDLE 577

RESULT 11
US-09-796-872-2
; Sequence 2, Application US/09796872
; Patent No. US20020045235A1
; GENERAL INFORMATION:
; APPLICANT: Karin, Michael
; APPLICANT: DiDonato, Joseph A.
; APPLICANT: Rothwarf, David M.
; APPLICANT: Hayakawa, Makio
; APPLICANT: Zandi, Ebrahim
; TITLE OF INVENTION: IxB Kinase, Subunits Thereof, and Methods of Using Same
; FILE REFERENCE: P-UD 3295
; CURRENT APPLICATION NUMBER: US/09/796,872
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/168,629
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/061,470
; PRIOR FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-796-872-2

Query Match      52.3%; Score 79; DB 9; Length 745;
Best Local Similarity 43.3%; Pred. No. 0.0023;
Matches 13; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKKGGLDLE 30
DB 532 DQIMSLHAEIMELQSPYGRGQGLMESLE 561

RESULT 12
US-09-844-908-10
; Sequence 10, Application US/09844908
; Patent No. US20020151021A1
; GENERAL INFORMATION:
; APPLICANT: Mercurio, Frank
; APPLICANT: Zhu, Hengyi
; APPLICANT: Barbosa, Miguel
; APPLICANT: Li, Gian
; APPLICANT: Murray, Brion W.
; TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSSEE: SEED and BERRY LLP
```

STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/844,908
FILING DATE: 27-Apr-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/910,820
FILING DATE: 12-AUG-1997
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.413C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 745 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-844-908-10

Query Match 52.3%; Score 79; DB 9; Length 745;
Best Local Similarity 43.3%; Pred. No. 0.0023;
Matches 13; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVLQSPMGRKQGGLDLE 30
Db 532 DQIMSLHAEIMELQSPYGRRGDLMESLE 561

RESULT 13
US-09-844-988-10
Sequence 10, Application US/09844988
Patent No. US200201587641
GENERAL INFORMATION:
APPLICANT: Mercurio, Frank
Zhu, Hengyi
Barbosa, Miguel
Li, Gnan
Murray, Brion W.
TITLE OF INVENTION: STIMULUS-INDUCIBLE PROTEIN KINASE
COMPLEX AND METHODS OF USE THEREFOR
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: SED and BERY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/844,988
FILING DATE: 26-Apr-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/910,820

FILING DATE: 1997-08-13
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.413C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 745 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-844-988-10

Query Match 52.3%; Score 79; DB 9; Length 745;
Best Local Similarity 43.3%; Pred. No. 0.0023;
Matches 13; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

Qy 1 ERMALQTDIVLQSPMGRKQGGLDLE 30
Db 532 DQIMSLHAEIMELQSPYGRRGDLMESLE 561

RESULT 14
US-10-060-065-14
Sequence 14, Application US/10060065
Publication No. US20030017480A1
GENERAL INFORMATION:
APPLICANT: Toshio Ota
APPLICANT: Takao Isogai
APPLICANT: Tetsuo Nishikawa
APPLICANT: Koji Hayashi
APPLICANT: Kaoru Otsuka
APPLICANT: Jun-Ichi Yamamoto
APPLICANT: Shizuko Ishii
APPLICANT: Tomoyasu Sugiyama
APPLICANT: Ai Wakamatsu
APPLICANT: Keiichi Nagai
APPLICANT: Tetsuji Otsuki
APPLICANT: Shin-Ichi Funahashi
APPLICANT: Chiaki Senoo
APPLICANT: Jun-Ichi Nezu
TITLE OF INVENTION: NOVEL GENES ENCODING PROTEIN KINASE/PROTEIN PHOSPHATASE
FILE REFERENCE: 06501-099002
CURRENT APPLICATION NUMBER: US/10/060,065
CURRENT FILING DATE: 2002-01-29
PRIOR APPLICATION NUMBER: PCT/JF00/05061
PRIOR FILING DATE: 2000-07-28
PRIOR APPLICATION NUMBER: US 60/159,590
PRIOR FILING DATE: 1999-10-18
PRIOR APPLICATION NUMBER: US 60/183,322
PRIOR FILING DATE: 2000-02-17
PRIOR APPLICATION NUMBER: JP 11-248036
PRIOR FILING DATE: 1999-07-29
PRIOR APPLICATION NUMBER: JP 2000-118776
PRIOR FILING DATE: 2000-01-11
PRIOR APPLICATION NUMBER: JP 2000-183767
PRIOR FILING DATE: 2000-05-02
PRIOR APPLICATION NUMBER: JP 2000-241899
PRIOR FILING DATE: 2000-06-09
NUMBER OF SEQ ID NOS: 43
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 14
LENGTH: 745
TYPE: PRT
ORGANISM: Homo sapiens
US-10-060-065-14

Query Match 52.3%; Score 79; DB 12; Length 745;
Best Local Similarity 43.3%; Pred. No. 0.0023;

Matches 13; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
DB 532 DQIMSLHAEIMELQSPYGRQGLMESLE 561

RESULT 15

US-10-243-408-4
; Sequence 4, Application US/10243408
; Publication No. US2003007683A1
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; Cao, Zhaodan
; R gnier, Catherine
; TITLE OF INVENTION: IKK- Proteins, Nucleic Acids and Methods
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 268 BUSH STREET, SUITE 3200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/243,408
; FILING DATE: 13-Sep-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/109,986
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/890,854
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T97-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 343-4341
; TELEFAX: (415) 343-4342
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 745 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-243-408-4

Query Match 52.3%; Score 79; DB 14; Length 745;
Best Local Similarity 43.3%; Pred. No. 0.0023;
Matches 13; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

QY 1 ERMALQTDIVDLQSPMGKQGGTLDLLE 30
DB 532 DQIMSLHAEIMELQSPYGRQGLMESLE 561

Search completed: September 24, 2004, 09:57:09
Job time : 128 secs